

## CURRICULUM VITAE

### TAHSEEN MOZAFFAR

Revised: January 15, 2023

#### Office Address:

The University of California, Irvine  
School of Medicine  
Department of Neurology  
UC Irvine-MDA ALS and Neuromuscular Center  
200 South Manchester Ave., Ste. 206  
Orange, CA 92868-4281

Phone: (714) 456-2238  
Fax: (714) 456-5997  
E-mail: [mozaffar@hs.uci.edu](mailto:mozaffar@hs.uci.edu)  
Website: <http://www.ucihealth.com/als>

#### Present Appointments

2017 – present Professor of Pathology and Laboratory Medicine  
2011 – present Professor of Clinical Neurology (Step VI)  
2000 – 2021 Founding Director, UC Irvine Neuromuscular Program  
2021 – present Director, Division of Neuromuscular Disorders  
2021 – present Associate Director, Institute for Clinical and Translational Science (ICTS)  
2016 – present Director Trials Innovation Center, ICTS  
2017 – present Institutional Hub Liaison to the Trials Innovation Network, National Center for Advancement of Translational Sciences (NCATS)  
2007 – present Director, UC Irvine-MDA ALS and Neuromuscular Center  
2007 – present Chair, Institutional Review Board, Committee A

#### Education:

1984 – 1989 M.B., B.S. (Bachelor of Medicine, Bachelor of Surgery)  
The Aga Khan University  
Karachi, Pakistan  
1981 – 1983 H.Sc (Biology)  
Adamjee Govt. Science College,  
Karachi, Pakistan

#### Postdoctoral Training:

1995 – 1997 Clinical and Research Fellow in Neuromuscular Disorders  
Washington University in St. Louis, St. Louis, Missouri  
1995 – 1995 Research Assistant (Professor C.D. Marsden)  
National Hospital for Neurology and Neurosurgery  
Institute of Neurology, London, UK  
1992 – 1995 Resident in Neurology  
Barnes Hospital, St. Louis, Missouri  
1991 – 1992 Intern in Medicine  
St. Luke's Hospital, Chesterfield, Missouri  
1989 – 1990 Rotating Intern, Medicine and Surgery

The Aga Khan University Hospital, Karachi, Pakistan

**Academic Appointments:**

2011 – present Professor of Clinical Neurology (Clinical X series)  
2017 – present Professor of Pathology and Laboratory Medicine  
2000 – present Director, Neuromuscular Division, Department of Neurology  
2020 – 2021 Vice Chair for Research, Department of Neurology  
2017 – 2021 Associate Program Director, UC Irvine Neurology Residency Training Program  
2017 – 2020 Interim Chair, Department of Neurology  
2017 – 2020 Dr. Stanley van den Noort Endowed Chair in Neurology  
2011 – 2020 Professor of Clinical Orthopaedic Surgery  
2010 – 2017 Vice Chair, Educational Affairs, Department of Neurology  
2011 – 2017 Program Director, Neurology Residency Program  
2008 – 2011 Associate Professor of Clinical Orthopaedic Surgery  
2006 – 2011 Associate Professor of Clinical Neurology  
2002 – 2006 Assistant Professor of Clinical Neurology  
2001 – 2003 Assistant Clinical Professor, Pathology  
2000 – 2002 Assistant Clinical Professor, Neurology  
1997 – 2000 Assistant Professor and Attending Neurologist  
Department of Medicine  
The Aga Khan University, Karachi, Pakistan  
1997 – 2000 Assistant Professor and Attending Pathologist  
Department of Pathology  
The Aga Khan University, Karachi, Pakistan  
1995 – 1997 Instructor in Neurology  
Washington University, St. Louis, Missouri

**Affiliations:**

Faculty Member,  
[Peripheral Nerve Research Laboratory](#)  
Department of Orthopaedics  
University of California, Irvine

Affiliated Member Faculty  
[Institute of Memory Impairments in Neurological Disorders \(MIND\)](#)  
University of California, Irvine

Faculty Member,  
[Institute for Immunology](#)  
University of California, Irvine

Team Member,  
[UCI Brain Initiative](#)  
University of California, Irvine

Affiliate Faculty,  
[Sue and Bill Gross Stem Cell Center](#)  
University of California, Irvine

Associate Director  
[Institute for Clinical Translational Sciences](#)  
University of California, Irvine

Founding Member,  
UCI Muscle Biology and Disease Research Group  
University of California, Irvine

## Honors and Awards:

2022	Honorable Mention - 2022 School of Medicine Clinical Faculty Mentor of the Year Award - selected as one of the top three clinical faculty mentors in the School of Medicine
2017 – 2020	Dr. Stanley van den Noort Endowed Chair in Neurology
2015 – 2022	Elected, Best Doctors, Best Doctors, Inc
2008, 2010 – 2023	Elected, Physician of Excellence, Orange County Medical Association
2012-2013, 2017 – 2021	Listed in Top Doctors, US News in collaboration with Castle-Connolly
2012	Elected Fellow, American Neurological Association
2011	Accelerated Promotion to Professor, University of California, Irvine
2009 - 2010	Selected as one of “America’s Top Physicians”, Guide to America’s Top Physicians, Consumers’ Research Council of America
2007	Elected Member, American Neurological Association
2007	Faculty Teaching Award, Department of Neurology University of California, Irvine
2007	Elected Fellow, American Academy of Neurology
2006	Accelerated Promotion to Associate Professor, University of California, Irvine
2006	Elected President, Orange County Neurological Society
2006	Kappa Delta Award (joint awardee), American Association of Orthopaedic Surgeons
2005	Faculty Career Development Award, University of California, Irvine
2001 - 2003	Faculty Teaching Award, Department of Neurology University of California, Irvine
2003	Teacher Recognition Award, American Academy of Neurology
2001 – 2003	Clinical X Stipend, University of California, Irvine
1997	Sven Eliasson Faculty Award for Outstanding Teaching, Washington University, Department of Neurology
1988	Honors in Pediatrics, MBBS Part III exam of Neurology
1987 – 1989	Begum Shafiqua Zia Merit Award
1984 – 1989	Hoechst Merit Scholarship

## Teaching Activities:

Undergraduate Teaching: Freshman Seminar titled: Jinnah’s Pakistan (seminar #87906)  
UCI Winter quarter, 2002 (One unit: Total enrollees 18)

N117: Introduction to Neuroscience Clinical Trials  
Title: Clinical Trials in Neuromuscular Diseases: A Tale of Two Diseases  
UCI Fall Quarter, 2018 (80 minutes: Total enrollees 17)

Graduate Teaching: Topics in Medicine Course. Spinal Cord and Neuromuscular Disorders: General Principles. March 2004, 2005  
Medical Student Lecture. Muscle and Nerve Pathology: General Principles. October 2006-2009  
Medical Structure Lecture, Motor Neuron Disorders. May 2009, 2010, 2011

Postgraduate teaching: 1. Weekly Morning Report for neurology residents/medical students (12 total)  
2. Weekly Neuromuscular Clinic Conference (fellows/residents) (4 total)  
3. Bi-weekly Neuromuscular Lecture Series - 6 lectures a year (fellows/residents) (24 total)  
4. Weekly neuromuscular pathology reading (fellows/residents/attending physicians) (8 total on average)

- Course Director:
1. Annual UCI Neuromuscular Colloquium (annually since 2011, interrupted due to COVID pandemic in 2020 and 2021). This is an international meeting held in May or June every year and has over 170 participants. It is held in person
  2. Annual UCI Neuromuscular Pathology Colloquium (annually since 2016, interrupted due to COVID pandemic in 2020). This is an international meeting, and for the last two years held in a hybrid format. It had over 150 participants from the all over the world in 2021. This is the only meeting of its kind in the US.
  3. Course Director, Clinical Approach to Muscle Diseases I and II, American Academy of Neurology Annual Meetings (2016 – 2020)

**Medical and Other Professional Qualifications:**

- |                |  |
|----------------|--|
| 2015 – 2025    | Board Certification in Clinical Neuromuscular Pathology (Certificate # CNMP0024-15), United Council for Neurologic Subspecialties                |
| 2010 – 2016    | Certified IRB Professional (CIP), Council of Certified IRB Professionals, Certificate Number 2101849, allowed to expire                          |
| 2008 – 2028    | Board Certification in sub-specialty of Neuromuscular Medicine<br>Certificate Number 126<br>American Board of Psychiatry & Neurology             |
| 1999 – present | California State Physician’s License No. A70580  |
| 1998 – 2008    | Board Certification (Electrodiagnostic Medicine) – retired after 2008<br>Certificate Number 2415<br>American Board of Electrodiagnostic Medicine |
| 1996 – 2026    | Board Certification (Neurology)<br>Certificate Number 42881<br>American Board of Psychiatry and Neurology  |
| 1995 – 2003    | Missouri State Physicians’ License No. MD101271 (retired 2003)   |
| 1992           | State Board of Medicine, Commonwealth of Pennsylvania (FLEX)   |
| 1991           | Educational Council for Foreign Medical Graduate (ECFMG)   |
| 1989 – 2007    | Pakistan Medical & Dental Council, License No. (retired 2007)  |

**Clinical Activities:**

- |                |   |
|----------------|---|
| 2019 – present | Attending Pathologist (Muscle), University of California, Irvine  |
| 2010           | Locum Consultant Neurologist<br>King Faisal Specialist Hospital & Research Center, Jeddah, Saudi Arabia |
| 2005 – 2013    | Consultant Neurologist<br>Long Beach Memorial Medical Center, Long Beach, California                    |
| 2000 –         | Attending Neurologist<br>University of California-Irvine Medical Center, Orange, California             |
| 1997 – 2000    | Attending Neurologist<br>The Aga Khan University Hospital, Karachi, Pakistan                            |
| 1997 – 2000    | Attending Pathologist (Neuromuscular Pathology)<br>The Aga Khan University Hospital, Karachi, Pakistan  |
| 1995 – 1997    | Attending Neurologist<br>St. Louis Regional Hospital, St. Louis, Missouri                               |
| 1995 – 1997    | Attending Neurologist<br>Barnes-Jewish Hospital, St. Louis, Missouri                                    |

**Administrative Activities:**

- |                |  |
|----------------|--|
| 2021 – present | Associate Director, ICTS   |
| 2021 – 2026    | Principal Investigator, INSPIRE-IBM, an NIH funded study           |
| 2021 – 2021    | Chair, Institutional Review Board (IRB) – Compliance Committee “E” |

2021 – present Director, Division of Neuromuscular Disorders  
 2017 – 2021 Associate Program Director, UC Irvine Neurology Residency Training Program  
 2019 - 2023 Member, Campus Laboratory Safety Committee  
 2018 – present Principal Investigator, UCI-NEXT, a NeuroNEXT site  
 2017 – 2020 Member, CFLC, School of Medicine  
 2017 – 2020 Member, Council of Clinical Chairs, School of Medicine  
 2017 - 2020 Member, Council of Executive Leadership Council (CELC) – Ambulatory Operations Subcommittee  
 2017 – 2018 Member, Vice Chancellor’s Leadership Council  
 2017 – 2018 Member, University Physicians and Surgeons Board of Directors  
 2017 – 2020 Member, Medical Executive Committee  
 2017 – 2020 Interim Chair, Department of Neurology  
 2012 – 2014 Chair, Institutional Review Board (IRB) – Compliance Committee “E”  
 2011 – 2017 Program Director, Neurology Residency Program, University of California, Irvine  
 2010 - present Member, Office of Research Working Group (quarterly meetings)  
 2010 – 2017 Vice Chair, Educational Affairs, Department of Neurology  
 2009 – 2011 Chair and Member, Postgraduate Clinical Programs Committee, University of California, Irvine  
 2007 – present Director, UC Irvine-MDA ALS and Neuromuscular Center  
 2007 – present Chair, Institutional Review Board (IRB) – Biomedical Committee “A”  
 2006 – 2011 Faculty Advisor, College Student Interest Group in Neurology (Co-SIGN), American Academy of Neurology and University of California, Irvine  
 2005 – 2011 Faculty Advisor, Student Interest Group in Neurology (SIGN), American Academy of Neurology and University of California, Irvine  
 2002 – 2007 Co-Director, MDA-ALS Research and Clinical Center (UC, Irvine)  
 2012 - present Co-Director, UC Irvine Muscular Dystrophy Association Care Center  
 2001 – 2012 Director, MDA Clinics (UC, Irvine)  
 2000 – 2021 Founding Director, Neuromuscular Program (UC, Irvine)  
 1998 – 2000 Director, Fellowship in Clinical Neurophysiology (The Aga Khan Univ.)  
 1997 – 2000 Residency Director, Division of Neurology (The Aga Khan Univ.)

**Intramural Committee Service:**

2022 – 2023 Member, Clinical Research Council, School of Medicine,  
 2022 – 2023 Member Search Committee, Director, Early-Phase Clinical Trials & Precision Therapeutics, School of Medicine  
 2021 – 2022 Member and Chair, Advancement to Candidacy for Masters in Biomedical and Translational Sciences, Isela S. Hernandez, Department of Neurology, School of Medicine, Irvine, CA  
 2019 – 2023 Member, Campus Laboratory Safety Committee  
 2019 – present Member, Executive Advisory Board, Center for Clinical Research  
 2018 – 2019 Member and Chair, Advancement to Candidacy for Masters in Biomedical and Translational Sciences, Veena Mathew, Department of Neurology, School of Medicine, Irvine, CA  
 2016 – 2018 Member, Clinical Translational Sciences Enterprise, ICTS  
 2017 – 2018 Member, Laboratory Testing Utilization Committee  
 2017 – 2020 Member, Council of Clinical Chairs, School of Medicine, UC Irvine  
 2017 – 2018 Member, Council of Chairs, University of California, School of Medicine  
 2017 – 2020 Member, Medical Executive Council, University of California, Irvine  
 2016 – 2017 Member, Enhance Clinical Trial Support, Strategic Planning Team, University of California, Irvine Health (Richard van Etten, MD PhD, Chair)  
 2016 – present Institutional Liaison to the Trial Innovation Centers (TIC), Clinical and Translational Science Awards (CTSA) Program, National Center for Advancing Translational Sciences (NCATS)  
 2016 – present Specialty Advisor, University of California, Irvine School of Medicine

2016 – 2017 Member, CTSE Clinical Trial Compliance Acceleration Task Force, Clinical and Translational Science Enterprise, University of California, Irvine

2015 – 2017 Member, Working Group on Participant Clinical Interaction, Clinical and Translational Science Enterprise, University of California, Irvine

2015 – 2017 Co-Chair, Task Force on Reducing Regulatory Burden, Clinical and Translational Science Enterprise, University of California, Irvine

2013 – 2013 Co-Chair, 5-year Review Committee for Chair of Ophthalmology, School of Medicine, University of California, Irvine

2012 – 2012 Chair, Chair 5-year Review Committee for Chair of Radiological Sciences, School of Medicine, University of California, Irvine

2013 – 2013 Member, Chair 5-year Review Committee for Chair of Anesthesiology and Perioperative Medicine, School of Medicine, University of California, Irvine

2013 – 2013 Member, Chair 5-year Review Committee for Chair of Internal Medicine, School of Medicine, University of California, Irvine

2012 – 2012 Member, Planning, Budget and Finance Committee (offered Chair, but declined)

2012 – 2012 Member, Chair 5-year Review Committee for Chair of Emergency Medicine, School of Medicine, University of California, Irvine

2010 – 2012 Representative to the University-wide Assembly

2010 – 2012 Member, Divisional Senate Assembly

2009 – 2009 Representative the Office of the President, meeting with Senator Darrell Steinberg, Senate President *Pro Temp*, State of California re: California State Bills SB-1502 and SB-1503

2009 – 2011 Member, College of Health Sciences Executive Committee, University of California, Irvine

2009 – 2010 Member, Industry Relations Committee, University of California, Irvine

2008 – 2008 Member Reviewer, Committee for Internal Review for California Institute for Regenerative Medicine (CIRM) Early Translational Research Award proposals

2007 – 2011 Member, School of Medicine, Clinical X Committee

2006 – 2010 Member, School of Medicine Representative Assembly

2006 – 2010 Member, Advancement to Candidacy for Doctorate, Laura Rummeler, Department of Biomedical Engineering, Samueli School of Engineering, Irvine, CA

2005 – 2006 Member, Curriculum and Educational Policy Committee, School of Medicine, University of California, Irvine

2004 – present Member, Institutional Review Board (IRB)

2003 – 2005 Member, *ad hoc* Search Committee, Neuromuscular Neurologist, Department of Neurology, UC Irvine

2003 – 2005 Member, School of Medicine Representative Assembly

2002 – 2004 Member, Replacement Hospital Expanded Building Advisory Committee, UC Irvine

2001 – 2001 Webmaster, Department of Neurology Website

2000 – 2008 Member, Medical Student Interviews, UC Irvine

2000 – 2001 Member, Clinical Research Sub-Committee, Hospital Replacement Programming Committee, UC Irvine

1999 – 2007 Training site liaison, American Board of Electrodiagnostic Medicine, Self-Assessment Examination Program, (The Aga Khan University and UC Irvine)

1998 – 1999 Alma Mater Fund utilization Committee, The Aga Khan University

1998 – 1999 Member, Committee for development of terminal objectives for medical students, The Aga Khan University

1998 – 1999 Member, Alumni Recruitment Committee, The Aga Khan University

1998 – 2000 Member, PGME Committee for review of Pediatrics residency, The Aga Khan University

**Extramural Committee Service:**

- 2023 Invited Member, European Neuromuscular Center (ENMC) International Workshop, titled “Inclusion Body Myositis: 10 years of progress—revision of the “ENMC 2013 diagnostic criteria for IBM”, Hoofddorp, The Netherlands, June 2023
- 2022 Invited Member, 262nd European Neuromuscular Center (ENMC) International Workshop on Standard of Care for the Dysferlinopathies, Brussels, Belgium, July 2022
- 2021 – 2023 Member, External Advisory Board, The Clinical Research in ALS and related disorders for Therapeutic Development (**CReATe**) Consortium, an NIH funded rare disease clinical research network (RDCRN) (Michael Benatar, PI)
- 2022 – 2024 Member, Board of Directors, United Council for Neurological Sub-specialties (UCNS)
- 2021 – 2021 Co-Chair, CTSA Committee, NeuroNEXT
- 2021 – present Member, Trial Protocol Development Committee, LGMD-GRASP and ML Bio (Phase 3 Trial of Ribitol in LGMDR1-Calpain)
- 2021 – 2021 Member, Milestone Committee, Clinical Neuromuscular Pathology Certification, United Council for Neurologic Subspecialties
- 2021 – present Liaison to the Medical Advisory Board, Board of Directors, The Myositis Association
- 2020 Clinical Approach to Muscle Disease I and II, American Academy of Neurology Annual Meeting, Toronto, ON
- 2017 – present Member Board of Directors and Scientific Advisory Board, Neuromuscular Disease Foundation, Beverly Hill, CA
- 2019 Clinical Approach to Muscle Disease I and II, American Academy of Neurology Annual Meeting, Philadelphia, PA
- 2019 Topic Co-Chair (with Jaya Trivedi, MD), Neuromuscular Disorders and Clinical Neurophysiology, American Academy of Neurology Annual Meeting, Philadelphia, PA
- 2018 Chair, Clinical Approach to Muscle Disease I and II, American Academy of Neurology Annual Meeting, Los Angeles, CA
- 2018 Invited Member, 237<sup>th</sup> European Neuromuscular Center (ENMC) International Workshop: GNE Myopathies. Hoofddorp, The Netherlands
- 2018 Member, Junior Faculty Mentoring Committee (for Dr. Teerin Liewluck), Mayo Clinic, Rochester, MN
- 2017 Topic Co-Chair (with Jaya Trivedi, MD), Neuromuscular Disorders and Clinical Neurophysiology, American Academy of Neurology Annual Meeting, Los Angeles, CA
- 2017 – present Permanent Member, Special Emphasis Panel ZRG1 ETTN-11 (A/H), NINDS – 6 meetings
- 2016 – 2017 Member, Special Emphasis Panel ZNS1 SRB-A(12), NINDS
- 2017 Chair, Clinical Approach to Muscle Disease I and II, American Academy of Neurology Annual Meeting, Boston, MA
- 2017 Session Co-Chair, Best of Neuromuscular Therapeutics, American Academy of Neurology Annual Meeting, Boston, MA
- 2016 Invited Member, 224th European Neuromuscular Center (ENMC) International Workshop on Necrotizing Myopathies, Zandvoort, Netherlands
- 2016 – 2019 Member Executive Committee, Muscle Study Group, Kansas City, KS
- 2016 Clinical Approach to Muscle Disease I and II, American Academy of Neurology Annual Meeting, Boston, MA
- 2016 Topic Co-Chair (with Jaya Trivedi, MD), Neuromuscular Disorders and Clinical Neurophysiology, American Academy of Neurology Annual Meeting, Boston, MA
- 2016 Member, ALS Task Force, Muscular Dystrophy Association, Chicago, Illinois
- 2016 Co-Moderator, Session titled: “Clinical Trials and Experimental Therapies in Neuromuscular Disorders”, American Academy of Neurology Annual Meeting, Vancouver, BC, Canada

- 2016 Invited Ad hoc, National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) Board of Scientific Counselors meeting (April 5-6, 2016)
- 2015 – 2016 Member, Organizing Committee, 2<sup>nd</sup> International Myositis Conference, Washington, DC, USA
- 2015 Topic Co-Chair (with Margherita Milone, MD), Neuromuscular Disorders and Clinical Neurophysiology, American Academy of Neurology Annual Meeting, Vancouver, BC, Canada
- 2015 Invited Member, 215th<sup>1</sup> European Neuromuscular Center (ENMC) International Workshop on IBMPFD, Heemskerk, Netherlands
- 2015 Member, Special Emphasis Panel ZNS1, SRB-G-04, NINDS
- 2015 Member, MDA Venture Philanthropy (MVP) grant review program
- 2015 Member, Special Emphasis Panel ZNS1, SRB-G-03, NINDS
- 2015 - 2016 Member, Program Committee, International Congress on Neuromuscular Diseases 2016 (ICNMD 2016), Toronto, ON, Canada
- 2015 Co-Moderator, Session titled: “Highlights in Neuromuscular Disorders”, American Academy of Neurology Annual Meeting, Washington, DC
- 2015 Co-Chair, Integrated Neurosciences Session on ALS and other Motor Neuron Diseases, American Academy of Neurology Annual Meeting Washington, DC
- 2014 Chair, Neuromuscular Specialty Interest Group, American Neurological Association Annual Meeting, Baltimore, MD
- 2014 Member, Conference Planning Committee, Muscle Study Group Annual Meeting, Beaver Hollow, NY
- 2014 Co-Chair, Session on Anterior Horn Cells, American Academy of Neurology Annual Meeting Philadelphia, PA
- 2014 Co-Chair, Integrated Neurosciences Session on Peripheral Neuropathy, American Academy of Neurology Annual Meeting Philadelphia, PA
- 2013 Co-Chair, Neuromuscular Special Interest Group Session, American Neurological Association 2013 Annual Meeting, New Orleans, LA
- 2013 – 2014 Member, Conference Planning Committee, Muscular Dystrophy Association, Annual Clinical Conference, Chicago, IL
- 2013 – 2015 Chair, Neuromuscular Section, American Academy of Neurology
- 2013 – 2015 Chair, Medical Advisory Board, The Myositis Association, Washington, DC.
- 2013 – 2013 Vice Chair, Neuromuscular Section, American Academy of Neurology
- 2013 Program Faculty, 35<sup>th</sup> Annual Carrell-Krusen Neuromuscular Symposium, Dallas, TX
- 2013 – 2017 Member, Clinical Advisory Committee, Muscular Dystrophy Association
- 2012 Co-Chair, Neuromuscular Special Interest Group Session, American Neurological Association 2012 Annual Meeting, Boston, MA
- 2012 Program Faculty, 34<sup>th</sup> Annual Carrell-Krusen Neuromuscular Symposium, Dallas, TX
- 2011 – present Course Director, Annual UC Irvine Neuromuscular Colloquium, a National Academic Neuromuscular Conference
- 2011 Member, Special Emphasis Panel ZNS1 SRB-G 54, NINDS
- 2011 – 2012 Member, Special Emphasis Panel NSD-K, SRC-G-53, NINDS
- 2009 – 2012 Member, California ALS Standards of Care Committee (joint effort of the ALS Association, the Muscular Dystrophy Association and the California PAC-10 ALS Consortium).
- 2009 – 2010 Chair, California ALS Standards of Care Committee (joint effort of the ALS Association, the Muscular Dystrophy Association and the California PAC-10 ALS Consortium).
- 2009 – 2017 Member, Medical Advisory Board, The Myositis Association, Washington, DC.
- 2008 Member, Student Fellowship Committee (including Viets Fellowship), Myasthenia Gravis Foundation of America
- 2008 Co-Director, Myasthenia Gravis and other autoimmune neuromuscular disorders (symposium organized by the Myasthenia Gravis Foundation of California and UC Irvine Healthcare), Dana Point, CA

2007	Member, NINDS Human Gene Discovery Repository ALS panel design subcommittee, NIH/NINDS - Katrina Gwinn-Hardy, PhD (Chair)
2006 – 2008	President, Orange County Neurological Society
2006 – 2008	Medical Safety Monitor, double-blind, placebo-controlled safety and efficacy study of Ritonavir and Hydroxyurea in patients with Amyotrophic Lateral Sclerosis (ALS). Principal Investigator: Catherine Lomen-Hoerth (UCSF)
2006 – 2008	Member, Advisory Board, ALS Association (Orange County Chapter)
2005 – 2007	Member, Steering Committee, Combination Drug Selection Trial in ALS, a multicenter clinical trial (Funding: ALS Association)
2005, 2006	Abstract Reviewer, Annual Scientific Meeting, Myasthenia Gravis Foundation of America, San Diego, CA
2005 – 2006	Member, Committee on Neurophysiologic Methods in Animal Models, National ALS Research Group Neurophysiology Working Group
2005 – 2007	Member and Co-Chair, Education Committee, North American ALS Research Group (ALSRG)
2005 – 2006	Member, Young Physicians Committee, Association of Pakistani Physicians, North America
2008 – 2009	Member, Subcommittee for the Neurophysiology Criteria for Diagnosis, First International Primary Lateral Sclerosis Consensus Conference (Chaminade Conference), Santa Cruz, CA.
2004	Member, Subcommittee for the Neurophysiology Criteria for Diagnosis, First International Primary Lateral Sclerosis Consensus Conference (Chaminade Conference), Santa Cruz, CA.
2004 – 2005	Co-Chair, Young Physicians' Task Force, Association of Pakistani Physicians in North America
2002 – 2007	Member, Executive Council, Association of Pakistani Physicians in North America (Southern California Chapter)
2002 – 2008	Member, Professional and Public Information Committee, Myasthenia Gravis Foundation of America
2002 – present	Member, Medical/Scientific Advisory Board, Myasthenia Gravis Foundation of America
2002 – 2004	Member, Membership Committee, Association of Pakistani Physicians in North America (APPNA)
2002 – 2004	Member, Executive Council, Association of Pakistani Physicians in North America (APPNA)
2002 – 2004	President, The Aga Khan University Alumni Association, North American Chapter
2001	Invited to be member of the Education Committee, American Association of Electrodiagnostic Medicine (declined)
2000 – present	Member, Medical Advisory Board, Myasthenia Gravis Foundation of California
1998 – 2013	Member, Reviewer's network, Therapeutics and Technology Assessment Subcommittee, American Academy of Neurology
1998 – 2013	Member, Reviewer's network, Quality Standards Subcommittee, American Academy of Neurology
1997 – 1999	Member, Central Executive Committee, The Aga Khan University Alumni Association

#### **Faculty Mentors to**

2012 – 2017	Namita Goyal, MD, Assistant Professor (now Full Professor), Neurology, UCI, Orange, CA
2015 – 2019	John Ravits, MD, Professor of Clinical Neurology, UCSD, San Diego, CA
2016 – present	Megan Waldrop, MD, Assistant Professor of Pediatrics (Neurology), Nationwide Children's Hospital/The Ohio State University, Columbus, OH.
2017 – present	S. Armando Villalta, PhD, Assistant Professor, Physiology & Biophysics, UC Irvine, Irvine, CA
2017 – 2020	Ali Aamer Habib, MD, Associate Professor, Neurology, UC Irvine, Irvine, CA
2017 – present	Manisha Kak Korb, MD, Assistant Professor, Neurology, UC Irvine, Irvine, CA
2017 – present	Mari Perez-Rosendahl, MD, Assistant Professor, Pathology, UC Irvine, Orange, CA

- 2018 – 2020 Teerin Liewluck, MD, Assistant (now Associate) Professor, Neurology, Mayo Clinic, Rochester, MN
- 2020 – present Neelam Goyal, MD, Assistant (now Associate) Professor, Neurology, Stanford University, Palo Alto, CA
- 2022 – present Eleni Tiniakou, MD, Assistant Professor, Medicine (Rheumatology), The Johns Hopkins University School of Medicine, Baltimore, MD
- 2022 – present Changrui Xiao, MD, Assistant Professor, Neurology and Genetics, UC Irvine, Irvine, CA

#### **Steering Committee and Data and Safety Monitoring Board Membership**

- 2006 – 2008 Medical Safety Monitor, double-blind, placebo-controlled safety and efficacy study of Ritonavir and Hydroxyurea in patients with Amyotrophic Lateral Sclerosis (ALS). Principal Investigator: Catherine Lomen-Hoerth (UCSF)
- 2017 – 2020 Member Safety Review Team, ACE-083 Clinical Studies, Acceleron Pharmaceuticals
- 2019 – present Chair and Member, DSMB, S 48168 (ARM 210) for the Treatment of RYR-related Myopathies (RYR1-RM), National Institute of Neurological Disorders and Stroke (NINDS), National Institute for Health (NIH)
- 2019 – present Member DSMB, Gene Therapies for Duchenne Muscular Dystrophy, Parexel for Sarepta Therapeutics
- 2021 – present Member DSMB, ALS-SOD1 Gene Therapy Trial, Avexis, a Novartis Company
- 2022 – present Chair and Member DMC, Applied Therapeutics AT-007-1005 Trial
- 2022 – present Member, Tolebrutinib (SAR442168) Myasthenia Gravis Steering Committee (Carolina Barnett Tapia, Chair), Sanofi

#### **Editorial Board Membership**

- 2019 – present Journal of Neuromuscular Diseases
- 2020 – present RRNMF Neuromuscular Journal

#### **Editorial Services as *Ad hoc* Reviewer:**

American Journal of Pathology  
 American Journal of Physiology: Regulatory, Integrative and Comparative Physiology  
 Annals of Clinical and Translational Neurology  
 Annals of Epidemiology  
 Annals of Neurology  
 Arthritis & Rheumatology  
 Arthritis Research and Therapy  
 BioMed Central (BMC) Neurology  
 Brain  
 Brain Pathology  
 Case Reports in Neurology  
 Cells  
 Critical Care Medicine  
 Cureus  
 European Journal of Medical Genetics  
 European Journal of Neurology  
 Expert Opinion on Therapeutic Patents  
 Genes  
 Journal of Applied Physiology  
 Journal of Clinical Investigation  
 Journal of Clinical Neuromuscular Disease  
 Journal of Neural Transmission

Journal of Neurophysiology  
Journal of the Neurological Sciences  
Journal of Neurology, Neurosurgery and Psychiatry  
Journal of the Pakistan Medical Association  
Mayo Clinic Proceedings  
Molecular and Clinical Oncology  
Molecular Therapy- Nucleic Acids  
Muscle & Nerve  
Neurology  
Neurology: Neurogenetics  
Neurology: Neuroimmunology and Neuroinflammation  
Neuromuscular Disorders  
Neuropathology and Applied Neurobiology  
Neurotherapeutics  
PLOS One  
Quarterly Journal of Medicine  
RRNMF Neuromuscular Journal

**Research Grant (*Ad hoc*) Reviewer:**

AFM Telethon (France)  
Muscular Dystrophy Association  
Myasthenia Gravis Foundation of California  
Myasthenia Gravis Foundation of America  
National Institutes of Health  
Orphan Disease Center (University of Pennsylvania)  
Prinses Beatrix Spierfonds (The Netherlands)  
Spark Therapeutics Internal Research Grant Program  
The Myositis Association

**Scientific Abstract Reviewer:**

American Neurological Association  
American Academy of Neurology  
International Congress of Neuromuscular Disorders (2016)  
Myasthenia Gravis Foundation of America

**Advisory Board Membership**

Abbvie  
Alexion (now an Astra Zeneca company)  
Alnylam  
Amicus  
Argenx  
Arvinas  
aTyr  
Audentes (now an Astellas company)  
AvroBio  
Baxter  
Biogen idec  
Biomarin  
CSL Behring  
Genzyme (now Sanofi)  
Idera Pharmaceuticals  
Maze Therapeutics  
Modis Therapeutics/Zolgenix

MT Pharma  
Novartis Pharma AG  
Orphazyme  
PTC Therapeutics  
Ra Pharmaceuticals (now part of UCB)  
Questcor (now Mallinckrodt)  
Sanofi-Genzyme (Sanofi)  
Sarepta  
Spark  
Takeda  
UCB  
Ultragenyx

**Consulting Services:**

Alexion  
Allergan Inc.  
Anthem Blue Cross  
Audentes  
Avanir  
California Stem Cell Inc.  
Crescent Healthcare –Walgreens  
CSL Biotherapeutics  
Grifols (previously known as Talecris)  
NuFactor

**Memberships:**

2013 – present California Neurological Association  
2013 – present Society for Neuroscience  
2010 – present Member, Muscle Study Group  
2007 – present Member, American Neurological Association  
2006 – present Member, World Federation of Neurology (WFN), Section on ALS/MND  
2005 – present Member, Northeast ALS Consortium (NEALS)  
2004 – present Member, North American ALS Research Group (ALSRG)  
2004 – present Member, Western ALS Group (WALS)  
2003 – 2005 American Society for Investigational Pathology (Regular Member)  
2002 – 2018 New York Academy of Sciences (Active Member)  
2001 – 2009 Pakistan International Neurosciences Society (Active Member)  
2001 – 2012 Association of Pakistani Physicians in North America (Active)  
2000 – 2009 Orange County Neurological Society (Regular Member)  
1998 – present World Muscle Society (Active Member)  
1997 – 2012 American Association of Electrodiagnostic Medicine (Fellow)  
1992 – present American Academy of Neurology (Fellow Member)

- Member, Neuromuscular section
- Member, History of Neurology section

**Research Interests:**

1. Pathophysiology of neuromuscular disorders
  - a. Molecular and cellular characterization of muscle atrophy in various neuromuscular disorders
  - b. Influence of serological markers on phenotypic and muscle histologic features in autoimmune myositis
    - i. Inclusion Body Myositis
      1. Role of immunosenescent T cells and Treg cells in primary

- pathogenesis of IBM
        - a. In-vitro models of IBM
        - b. Single cell RNA sequencing and transcriptomic studies
        - c. Longitudinal studies of disease progression in IBM
        - d. Imaging studies in IBM
      - ii. Antibody associated Myositis
    - c. Natural History studies as well as validation of outcome measures in Rare and Orphan Myopathies
      - i. Sporadic Inclusion Body Myositis
      - ii. Multisystem Proteinopathy type I (VCP related)
      - iii. GNE myopathy
      - iv. Late Onset Pompe Disease
- 2. Clinical Experimental Trials in Rare and Orphan Neuromuscular Genetic Disorders
  - a. GNE myopathy
  - b. Oculopharyngeal Muscular Dystrophy
  - c. Late-Onset Pompe Disease
  - d. VCP associated Multisystem Proteinopathy
  - e. ALS
  - f. Limb-Girdle Muscular Dystrophies
- 3. Pathophysiology of nerve dysfunction in chronic compressive neuropathies:
  - a. Role of Schwann cells (PI: Ranjan Gupta)
  - b. Role of intrinsic muscle factors determining functional reinnervation after chronic nerve injury (PI: Ranjan Gupta)
- 4. History of Medicine
  - a. Leprosy in Islamic Medicine: Contribution of the Muslim Physicians (9<sup>th</sup> through 12<sup>th</sup> century AD)

## **ONGOING RESEARCH SUPPORT**

<b>UX53-CL101</b>	08/21 – 06/26	Effort 5%
Ultragenyx		\$399,640
A Phase 1/2 First-in-human, 2-part Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single Ascending Doses (Part 1: Open-label) and Repeat Doses (Part 2: Randomized, Double-blind, Placebo-controlled) of UX053 in Patients with GSD III		
Role: Site PI		
<b>R01 AR074457-01A1</b>	04/21 – 03/26	Effort 20%
NIH/NIAMS		\$3,021,766
“Influence of NT5c1A antibodies on disease progression, clinical phenotype and blood and muscle biomarkers in sporadic Inclusion Body Myositis - A prospective evaluation”		
Role: Lead Investigator		
<b>106142-00002</b>	08/20 – 08/22	Effort 2%
Cartesian Inc.		\$302,475
Autologous T-cells expressing a chimeric antigen receptor directed to B-cell maturation antigen (BCMA) in patients with generalized myasthenia gravis (MG)		
Role: Site PI		
<b>ARGX-113-1802</b>	12/20 -12/23	Effort 2%
Argenx BVBA		\$136,305
“A Phase 2 Trial to Investigate the Efficacy, Safety, and Tolerability of Efgartigimod PH20 SC in Adult Patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)”		

Role: Site PI

**UX053-CL001** 11/20 -11/21 Effort 2%  
Ultragenyx Pharmaceutical, Inc \$55,292  
“Clinical Survey Study to Evaluate Biomarkers and Clinical Manifestations in Individuals with Glycogen Storage Disease Type III (GSD III)”  
Role: Site PI

**PDY16744** 2021 – 2024 Effort 2%  
Sanofi US Services, Inc \$118,642  
“A Phase 2, multicenter, open-label, non-randomized, proof-of-concept study evaluating the efficacy, safety, and tolerability of BIVV020 in adults with chronic inflammatory demyelinating polyneuropathy (CIDP)”  
Role: Site PI

**ARGX-113-2001** 2021 – 2024 Effort 2%  
Argenx BVBA \$77,567  
“A Phase 3, Randomized, Open-Label, Parallel-Group Study to Compare the Pharmacodynamics, Pharmacokinetics, Efficacy, Safety, Tolerability, and Immunogenicity of Multiple Subcutaneous Injections of Efgartigimod PH20 SC with Multiple Intravenous Infusions of Efgartigimod in Patients with Generalized Myasthenia Gravis”  
Role: Site PI

**ALXN-MG-501** 10/20 – 10/21 Effort 2%  
Alexion Pharmaceuticals, Inc \$24,503  
“Long-Term, Observational, Registry of Patients With Generalized Myasthenia Gravis Who Have Received Treatment With Complement C5 Inhibition Therapies”  
Role: Site PI

**ARGX-113-1705** 09/20 -02/22 Effort 1%  
Argenx BVBA \$96,414  
“A Long-Term, Single Arm, Open-Label, Multicenter, Phase 3 Follow-on Trial of ARGEXN-113-1704 to Evaluate the Safety and Tolerability of ARGX-113 in Patients with Myasthenia Gravis having Generalized Muscle Weakness”  
Role: Site PI

**OBS15351** 09/20 -08/21 Effort 1%  
Sanofi Genzyme \$19,444  
“A Longitudinal, Observational Study to Examine the Measurement Characteristics of the Pompe Disease Symptom Scale and the Pompe Disease Impact Scale”  
Role: Site PI

**NS107210, Mozaffar (PI)** 07/20 – 06/22 Effort 20%  
NIH/NINDS \$247,200  
“UCI-NEXT, a NeuroNEXT site”  
Role: Site PI

**IBM-OLE** 06/20 – 06/22 Effort 2%  
University of Kansas Medical Center \$133,521  
“An open-label, non-randomized trial to investigate the efficacy and safety of early versus delayed start of arimoclomol in patients with sporadic inclusion body myositis who have completed the IBM4809 trial”  
Role: Site PI

**AT845-01** 05/20 – 05/25 Effort 4%  
Audentes Therapeutics, Inc \$1,051,140  
“A Phase 1/2, Open-Label, Ascending-Dose Clinical Study to Evaluate the Safety and Preliminary Efficacy of AT845, an AAV8-Delivered Gene Transfer Therapy in Patients with Late Onset Pompe Disease”

Role: Site PI

<b>NCU-5595397</b> Jain Foundation, Inc “An International Clinical Outcome Study of Dysferlinopathy” Role: Site PI	05/20 – 05/21	Effort 2% \$48,020
<b>FP00011655_SA007</b> ML Bio Solutions, Inc “Biomarker Development in LGMD 2i” Role: Site PI	04/20 – 11/22	Effort 2% \$125,268
<b>106230-00002</b> PRA/Ra Pharmaceuticals “A Phase 2, Multicenter, Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of Zilucoplan in Subjects with Immune-Mediated Necrotizing Myopathy” Role: Site PI	01/20 – 01/22	Effort 2% \$81,700
<b>AT100-01</b> Audentes Therapeutics, Inc “An AAV8 Neutralizing Antibody Seroprevalence Study in Subjects with Late Onset Pompe Disease” Role: Site PI	12/19 – 12/22	Effort 2% \$31,973
<b>ATB200-07</b> Amicus Therapeutics “A Phase 3 Open-Label Extension Study to Assess the Long-term Safety and Efficacy of Intravenous ATB200 co-administered with Oral AT2221 in Adult Subjects with Late-Onset Pompe Disease (ATB-200-07)” Role: Site PI	12/19 -12/24	Effort 2% \$578,754
<b>SPK-3006-101</b> Spark Therapeutics, Mozaffar (PI) “Phase 1/2, Dose-Escalation Study to Evaluate the Safety, Tolerability and Efficacy of a Single Intravenous Infusion of SPK-3006 in Adults with Late-Onset Pompe Disease” Role: Study-wide PI	12/19 – 12/22	Effort 2% \$235,805
<b>106214-00002</b> Cure Duchenne Foundation, Mozaffar (PI) “Preclinical Studies in Inherited and Acquired Myopathies” Role: Site PI	10/19 – 10/24	Effort 1% \$21,942
<b>105982-00002</b> Baxalta Innovations GMBH (Takeda) “A Phase III Study to Evaluate the Efficacy, Safety, and Tolerability of Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase (HYQVIA/HyQvia) and Immune Globulin Infusion (Human), 10% (GAMMAGARD LIQUID/KIOVIG) for the Treatment of Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)” Role: Site PI	10/19 – 10/22	Effort 2% \$81,588
<b>MDA-5575699</b> Muscular Dystrophy Association, Inc. “Muscular Dystrophy Association Neuromuscular Observational Research (MOVR) Data Hub Protocol” Role: Site PI	09/19 – 09/22	Effort 2% \$27,000
<b>UL1 TR0001414, Cooper (PI)</b>	07/19 – 06/24	Effort 25%

NIH/NCATS "Institute for Clinical and Translational Science" Role: Co-Investigator		\$49,250
<b>IM101-611</b> Bristol Myers Squibb Co "A Phase 3, Randomized, Double-Blind Clinical Trial to Evaluate the Efficacy and Safety of Abatacept SC with Standard Treatment Compared to Standard Treatment Alone in Improving Disease Activity in Adults with Active Idiopathic Inflammatory Myopathy (IIM)" Role: Principal Investigator	07/19 – 06/22	Effort 2% \$80,863
<b>SPK-GAA-100</b> Spark Pharmaceuticals "A Multi-Center, Low Interventional Study with a Retrospective Component in Participants with Late Onset Pompe Disease" Role: Principal Investigator	07/19 -01/22	Effort 1% \$78,636
<b>FP00008765, Johnson (PI)</b> Muscular Dystrophy Association, (Virginia Commonwealth University) "Limb Girdle Muscular Dystrophy Research Network" Role: Site PI	09/18 – 03/23	Effort 1% \$75,270
<b>IBM4809</b> Premier Research International, LLC (Orphazyme A/S) "Phase 2/3 Study of Arimoclomol in Inclusion Body Myositis (IBM)" Role: Principal Investigator	09/18 – 05/22	Effort 3% \$107,976
<b>Department/Unrestricted funds</b> "Preclinical Studies in Acquired and Inherited Myopathies" Role: Principal Investigator	10/17 – 09/23	
<b>EFC14028</b> Genzyme Corp (Genzyme Therapeutics) "A Phase 3, Randomized, Multicenter, Multinational, Double-Blinded Study Comparing the Efficacy and Safety of Repeated Biweekly Infusions of neoGAA (GZ402666) and Alglucosidase Alfa in Treatment-Naïve Patients with Late-onset Pompe Disease" Role: Principal Investigator	09/16 – 09/23	Effort 2% \$578,990

**PENDING RESEARCH SUPPORT**

None

<b><u>AWARDED BUT DID NOT ACCEPT</u></b> The Myositis Association Phenotypic, myopathologic and biomarker correlation with NT5c1A seropositivity in sIBM patients: a prospective multicenter natural history study. Role: Lead Researcher	01/17 – 12/18 \$100,000
--	----------------------------

**COMPLETED STUDIES/GRANTS**

<b>ARGX-113-1704</b> Argenx BVBA "A Randomized, Double Blind, Placebo Controlled Phase III Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of ARGX-113 in Patients with Myasthenia Gravis who have Generalized Muscle Weakness" Role: Principal Investigator	07/19 -09/20	Effort 1% \$91,855
--	--------------	-----------------------

<b>ATB200-03</b>	03/16 – 03/21	Effort 2%
Amicus Therapeutics, Inc. \$132,566		
“Phase 3 Double-blind Randomized Study to Assess the Efficacy and Safety of Intravenous ATB200 Co-administered With Oral AT2221 in Adult Subjects With Late-Onset Pompe Disease Compared With Alglucosidase Alfa”		
Role: Principal Investigator		
<b>ATB200-02</b>	03/16 – 03/21	Effort 2%
Amicus Therapeutics, Inc. \$188,522		
“An Open-Label, Ascending-Dose, First-In-Human Study to Assess the Safety, Tolerability, and Pharmacokinetics of Intravenous Infusions of ATB200 Alone and ATB200 Co-Administered with Oral AT2221 in Adult Subjects with Pompe Disease Who Were Previously Treated with Alglucosidase Alfa”		
Role: Principal Investigator		
<b>105449-00003</b>	01/18 – 12/18	Effort 2%
<b>The Myositis Association</b> \$49,886		
Phase I Study of Dalazatide in sporadic inclusion body myositis		
Role: Principal Investigator		
<b>UX001-CL203</b>	03/16 – 03/18	
Ultragenyx Pharmaceutical, Inc. \$54,900		
A Phase 2, Open-label Study to Evaluate the Safety of Aceneuramic Acid Extended Release (Ace-ER) Tablets in GNE Myopathy (GNEM) (also known as Hereditary Inclusion Body Myopathy (HIBM) Patients with Severe Ambulatory Impairment		
<i>The goal of this study is to continue collecting safety and efficacy data with open label use of an investigational product in GNE myopathy patients with loss of ambulation.</i>		
Role: Principal Investigator		
<b>ISIS 420915- CS2</b>	04/13-08/18	
Ionis Pharmaceuticals, Inc. (formerly Isis Pharmaceuticals, Inc.) \$605,858		
A Phase 2/3 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of ISIS 420915 in Patients with Familial Amyloid Polyneuropathy		
Role: Co-Researcher (Faculty Sponsor)		
<b>ATYR1940-C-004</b>	3/16-3/17	
aTyr Pharma, Inc. \$353,271		
An Open-Label, Inpatient Dose Escalation Study to Evaluate the Safety, Tolerability, Immunogenicity, and Biological Activity of ATYR1940 in Patients with Limb Girdle and Facioscapulohumeral Muscular Dystrophies		
Role: Principal Investigator		
<b>ATYR1940-C-006</b>	7/16-6/17	
aTyr Pharma, Inc. \$313,072		
An Open-Label Extension Study to Evaluate the Long-Term Safety, Tolerability, Biological Activity of ATYR1940 in Patients with Limb Girdle and Facioscapulohumeral Muscular Dystrophy		
<b>Idera 8400-211</b>	2/16-2/18	
Idera Pharmaceuticals, Inc. \$118,768		
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial of IMO-8400 in Patients with Dermatomyositis		
Role: Principal Investigator		
<b>MG002</b>	08/17 – 07/18	
UCB/Parexel \$133,837		
A multicenter, randomized, investigator- and subject blind, placebo-controlled, treatment sequence study		

evaluating the safety, tolerability, and efficacy of UCB7665 in subjects with moderate to severe myasthenia gravis.

Role: Site Principal Investigator

**ArgnX 113-1602**

6/17-6/18

Argenx BVBA

\$48,832

A Randomized, Double Blind, Placebo Controlled Phase II Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of ARGX-113 in Patients with Myasthenia Gravis who have Generalized Muscle Weakness

Role: Principal Investigator

**GC-200479**

03/15 – 03/18

Genzyme

\$1,482,623

Investigating Pompe Prevalence in Neuromuscular Medicine Academic Practices (IPANEMA Study)

Role: Principal Investigator

**UX001-CL301**

05/15 – 05/17

Ultragenyx

\$221,077

A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Sialic Acid-Extended Release Tablets in Patients with GNE Myopathy (GNEM) or Hereditary Inclusion Body Myopathy (HIBM)

Role: Principal Investigator

**GTI408**

10/15 – 10/16

Grifols

\$56,640

A Multi-center, Randomized, Double-blind Placebo-controlled Study to Evaluate the Efficacy and Safety of Immune Globulin (Human), 10% Caprylate/Chromatography Purified (IGIV-C) in Symptomatic Subjects with Generalized Myasthenia Gravis

Role: Principal Investigator

**ECU-MG-301**

04/14-04/17

Quintiles

\$95,933

A randomized, double-blind, placebo controlled, multi-center study to evaluate the safety and efficacy of eculizumab in subjects with refractory generalized myasthenia gravis (gMG). *This is a phase 3 trial of eculizumab, a complement inhibitor, in generalized myasthenia gravis (MG)*

Role: Principal Site Investigator

**ECU-MG-302**

12/14-12/17

Quintiles

\$444,161

A phase III, open-label, extension trial of ecu-mg-301 to evaluate the safety and efficacy of eculizumab in subjects with refractory generalized myasthenia gravis (gMG). *This is the open label extension of the randomized, blinded, placebo-controlled phase III trial of eculizumab in generalized MG.*

Role: Principal Site Investigator

**UX001-CL401**

07/13-07/16

Ultragenyx

\$51,043

Hereditary Inclusion Body Myopathy-Patient Monitoring Program (HIBM-PMP): A Registry and Prospective Observational Natural History Study to Assess HIBM Disease. *This is a natural history cohort study in parallel to the phase II study of efficacy of extended release sialic acid in HIBM.*

Role: Principal Site Investigator

**BVS857X2202**

4/15 – 9/16

Novartis

\$170,930

A two-part placebo-controlled study to evaluate the safety, tolerability and preliminary efficacy of BVS857 in patients with spinal and bulbar muscular atrophy (SBMA).  
Role: Principal Investigator

**BAF312X3306**

03/14 – 02/16

Novartis

\$75,073

A multi-centre, double-blind, placebo controlled, proof of concept study to evaluate the efficacy and tolerability of BAF312 in patients with polymyositis.

Role: Principal Investigator

**701-301**

09/14-09/19

Biomarin

\$743,151

A Phase 3 Switchover Study of the Efficacy and Safety of BMN 701 (GILT-tagged Recombinant Human GAA) and Long-Term Study for Extended Treatment in rhGAA Exposed Subjects with Late Onset Pompe Disease. *The goal of this phase 3 trial is to determine the efficacy of a new enzyme replacement therapy (ERT) in Pompe Disease*

Role: Principal Site Investigator

**QB859730**

09/13 – 08/16

University of Kansas

\$98,265

PHS/FDA –prime award #5R01FD003739-02 (Barohn)

Phase 2 Study of Rasagiline for Treatment of Amyotrophic Lateral Sclerosis. *This study examines the safety, tolerability and efficacy of Rasagiline in ALS*

Role: Principal Site Investigator

**FTY720I2201**

01/13 – 04/16

Novartis

\$181,338

A double-blind, randomized, multicenter, placebo-controlled parallel-group study to evaluate the efficacy and safety of fingolimod 0.5 mg administered orally once daily versus placebo in patients with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP)

Role: Principal Site Investigator

**BEL115123**

08/13-08/15

Glaxo Smith Kline

\$98,085

A Randomized, Placebo-controlled, double-blind study to evaluate the efficacy, safety, tolerability, and pharmacodynamics of Belimumab in Subjects with Generalized Myasthenia Gravis (MG). *The goal of this phase 2 study is to study the safety, tolerability and efficacy of a B-cell activating factor inhibitor in Myasthenia Gravis (MG)*

Role: Principal Site Investigator

**PS#222493**

(Goyal)

05/13-06/14

Massachusetts General Hospital

\$63,681

ALS Therapy Development Inst. – Prime Site PI: (Cudkowicz/Berry)

Phase IIa Double-Blind, Placebo-Controlled Study to Evaluate the Safety of Oral Fingolimod in Patients with Amyotrophic Lateral Sclerosis (ALS)

Role: Co-Researcher

**CY 4026**

(Shefner)

08/12 – 08/15

Cytokinetics

\$122,712

A Phase IIb, Multi-National, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate The Safety, Tolerability, and Efficacy of CK-2017357 in Patients with Amyotrophic Lateral Sclerosis (ALS). *The goal of this study is to evaluate the role of CK-2017357 in improving strength and fatigue in patients with ALS.*

Role: Primary Site Investigator

<b>NIH/5R01NS049203-10</b>	(Gupta)	08/04 – 12/14
NINDS/NIH		No Cost Extension
Schwann cell regulation of chronic nerve injury. <i>The goal of this study is to evaluate the role of Schwann cell in pathogenesis of chronic nerve compression.</i>		
Role: Co-investigator		
<b>NIH 1R01ES016348-03 subaward #6</b>		07/09 - 04/13
Columbia University		\$8,734
COSMOS: Multicenter ALS Cohort Study of Oxidative Stress and Disease Progression		
Role: Principal Site Investigator		
<b>MG-45665</b>		08/09 – 08/13
Myasthenia Gravis Foundation of California		\$25,000
Sleep Disturbances in Patients with Myasthenia Gravis: A Prospective Study		
Role: Site Co-Investigator		
<b>AGLU07310</b>		04/12 – 04/13
Genzyme Corp.		\$40,888
EMBASSY STUDY: A Phase 4 Prospective Exploratory Muscle Biopsy, Biomarker, and Imaging Assessment Study in Patients with Late-Onset Pompe Disease Treated with Alglucosidase Alfa		
Role: Principal Site Investigator		
<b>CY4026</b>		08/12 – 08/15
Cytokinetics, Inc.		\$122,712
A Phase IIb, Multi-National, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate The Safety, Tolerability, and Efficacy of CK-2017357 in Patients with Amyotrophic Lateral Sclerosis (ALS).		
Role: Principal Site Investigator		
<b>223AS304</b>		08/12 – 07/13
Biogen idec		\$165,497
An Open-Label, Multi-Center, Extension Study to Evaluate the Long-Term Safety and Efficacy of Dexamipexole (BIIB050) in Subjects with Amyotrophic Lateral Sclerosis		
Role: Principal Site Investigator		
<b>AT220-010</b>		04/12 – 12/13
Amicus Therapeutics, Inc.		\$48,782
An Open-Label, Multi-Center, International Study to Investigate Drug-Drug Interactions between AT220 and Alglucosidase alfa in patients with Pompe Disease		
Role: Principal Site Investigator		
<b>11-AVR-130</b>		05/12 – 05/14
Avanir Pharmaceuticals		\$77,699
A Phase 2a, Double-Blind, Randomized, Placebo-controlled, Four-arm, Multicenter, Dose-Finding Study to Assess the Safety and Efficacy of Three Dose Levels of AVP-923 (Dextromethorphan/Quinidine) in the Treatment of Central Neuropathic Pain in Relapsing-remitting Multiple Sclerosis		
Role: Principal Site Investigator		
<b>PSA-214300</b>		12/08 – 06/13
Massachusetts General Hospital		\$103,493
Clinical Trial of Ceftriaxone in Subject with ALS		
Role: Principal Site Investigator		
<b>223AS302</b>		06/11 – 06/13

Biogen idec	\$197,411
A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of the Safety and Efficacy of Dexpramipexole in Subjects With Amyotrophic Lateral Sclerosis	
Role: Principal Site Investigator	
<b>CY4025</b>	10/11 – 10/14
Cytokinetics	\$72,325
A Phase II, Multicenter, Double-Blind, Randomized, Placebo-Controlled Dose Titration Study to Evaluate the Safety, Tolerability, and Pharmacodynamic Effects of CK-2017357 in Patients with Amyotrophic Lateral Sclerosis (ALS)	
Role: Principal Site Investigator	
<b>IGPRO20_3003</b>	10/12 – 10/17
CSL Behring	\$54,437
Randomized, multicenter, double-blind, placebo-controlled, parallel-group phase III study to investigate the efficacy, safety, and tolerability of 2 different doses of IgPro20 (subcutaneous immunoglobulin) for the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP) the PATH study	
Role: Principal Site Investigator	
<b>CSL-54617</b>	07/12 – 04/13
CSL Behring	\$8,000
IVIg monotherapy to induce clinical remission in patients with CIDP and dermatomyositis	
Role: Principal Investigator	
<b>CY4023</b>	05/11 – 05/14
Cytokinetics	\$87,000
A Phase II, Double-Blind, Randomized, Three-Way Crossover, Placebo-Controlled, Pharmacodynamic Study of CK 2017357 in Patients with Generalized Myasthenia Gravis on Standard Therapy	
Role: Site Co-Investigator	
<b>PSA-215221</b>	07/09 – 06/13
MA General Hospital	\$27,485
Trial of High Fat/High Calorie Diet Versus Optimal Calorie Replacement in ALS	
Role: Principal Site Investigator	
<b>LMS-002</b>	08/11 – 08/13
BioMarin Pharmaceuticals	\$49,094
A Phase 3, Multicenter, Double-blind, Placebo-controlled Randomized Discontinuation Study Followed by an Open-label Extension Period to Evaluate the Efficacy and Safety of Amifampridine Phosphate (3,4-Diaminopyridine Phosphate) in Patients with Lambert-Eaton Myasthenic Syndrome (LEMS)	
Role: Site Co-Investigator	
<b>NP00-10-002</b>	05/11 – 11/12
Neuraltus	\$143,229
A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of NP001 in Subjects with Amyotrophic Lateral Sclerosis (ALS)	
Role: Principal Site Investigator	
<b>S381146</b>	04/10 – 07/12
Emory University	\$13,500
Randomized, Placebo-Controlled Trial of Arimoclomol in SOD1 Positive Familial Amyotrophic Lateral Sclerosis (ALS)	
Role: Principal Site Investigator	
<b>FX-R-001</b>	04/09 – 04/12
FoldRx Pharmaceuticals	\$5,700

A Global, Multi-Center, Longitudinal, Observational Survey of Patients with Documented Transthyretin (TTR)

Role: Site Co-Investigator

**H-47159**

06/09 – 06/11

Hologenix, LLC

\$19,200

Double blind, Placebo Controlled, Crossover Pilot Trial on the Effect of Optically Modified Polyethylene Terephthalate Fiber Mattress Covers on Sleep Disturbances in Patients with Chronic Back Pain

Role: Site Co-Investigator

**000240501-112**

10/05 – 10/12

NIH/NINDS (Subcontract through University of Alabama)

\$25,526

Thymectomy In Non-Thymomatous MG Patients on Prednisone

Role: Principal Site Investigator

**PSA-022108**

12/07 – 03/10

MA General Hospital

\$25,000

Validation of Metabolomic Biomarkers and Development of ALS Diagnostics (Bio-ALS 001)

Role: Principal Site Investigator

**CU-39416**

01/06 – 12/07

ALS Association through a subcontract with Columbia University

\$32,328

Combination Drug Selection Trial in ALS

Role: Member Central Steering Committee; Principal Site Investigator

**160604**

05/09 – 05/10

Baxter Healthcare Corp

\$96,730

A Randomized, Double-Blind, Placebo Controlled, Cross-Over Study of the Effectiveness of Immune Globulin Intravenous (Human) 10% (IGIV, 10%) for the Treatment of Multifocal Motor Neuropathy

Role: Principal Site Investigator

**2803197-V012**

12/05 – 06/07

CA Pacific Med Ctr

\$5,660

Administrative Supplement To Clinical Studies For Collection Of Blood Samples And Data For Repository Banking In Epilepsy, Parkinson's Disease And Stroke

Role: Principal Site Investigator

**CU-36570**

06/04 – 12/07

NIH (subcontract through Columbia University)

\$67,172

Phase III Multicenter Clinical Trial of Minocycline in ALS

Role: Principal Site Investigator

**CU-47164**

04/07 – 03/10

Columbia University (NIH)

\$752

Longitudinal Data Collection Associated with the ALS Biomaterial Banking Study

Role: Principal Site Investigator

**60407**

03/06 – 06/07

TGen, Phoenix, AZ

\$7,500

Resequencing the variable human genome in sporadic ALS: a necessary prelude to diagnostics and drug development

Role: Principal Site Investigator

**09503**

07/05 – 06/06

University of California, Irvine

\$3,000

Faculty Career Development Award Project: Economic Burden from the Use of Complementary and Alternative Methods of Treatment in Amyotrophic Lateral Sclerosis  
Role: Principal Site Investigator

**189671** 10/04 – 07/10  
NIH \$110,640  
A Phase I/II Randomized, Placebo-controlled Trial to Assess the Safety and Efficacy of Intravenous Immunoglobulin G (Omr-IgG-am™ IV) Containing High Anti-West Nile virus Antibody Titers in Patients With, or at High Risk for Progression to West Nile Virus Encephalitis and/or Myelitis (CASG 210).  
Role: Site Co-Investigator

**1200763** 07/03 – 12/07  
Glaxo-Smith-Kline \$569,733  
Randomized, Placebo-controlled, Double-blind Pilot Trial to Evaluate the Safety and Efficacy of Ropinirole in Motor Recovery after Stroke.  
Role: Site Co-Investigator

**Trainees:**

Doctoral Students

2006-2008 Laura Rummler, BS  
Department of Biomedical Engineering, Samueli School of Engineering  
University of California, Irvine  
Dissertation title:  
Role: Committee Member

Graduate Students

2021 – 2023 Isela Hernandez, BS  
Candidate for Master of Science in Biomedical and Translational Sciences  
University of California, Irvine  
Thesis title: TBD  
Role: Faculty Advisor and Committee Chair

2017 – 2019 Veena Mathew, BS  
Candidate for Master of Science in Biomedical and Translational Sciences  
University of California, Irvine  
Thesis Title: Understanding Disease Heterogeneity and Patient Characteristics in Patients with Amyotrophic Lateral Sclerosis (ALS)  
Role: Faculty Advisor and Committee Chair

Postdoctoral Fellows

Trainee: Karen Halldorsdottir, MD  
Position: Neuromuscular Medicine Fellow  
Dates: 2022 – 2023  
Current Position: In training

Trainee: Melody Badii  
Position: Neuromuscular Medicine Fellow  
Dates: 2022 – 2023  
Current Position: In training

Trainee: Khalid Alrasheed, MD  
 Position: Advanced Neuromuscular Medicine Fellow  
 Dates: 2022 – 2023  
 Current Position: In training

Trainee: Sahar Sheikhabahaei, MD  
 Position: Advanced Neuromuscular Medicine Fellow  
 Dates: 2021 – 2022  
 Current Position: Private Practice in Pasadena, CA

Trainee: David Stevens, MD  
 Position: Neuromuscular Medicine Fellow  
 Dates: 2021 – 2022  
 Current Position: Private Practice in Anaheim, CA

Trainee: Khalid Alrasheed, MD  
 Position: Neuromuscular Medicine Fellow  
 Dates: 2021 – 2022  
 Current Position: In training

Trainee: Shadi Milani-Nejad, DO  
 Position: Neuromuscular Medicine Fellow  
 Dates: 2020 – 2021  
 Current Position: Assistant Professor (Neurology), UC Irvine

Trainee: Jeffrey Mullen, MD  
 Position: Neuromuscular Medicine Fellow  
 Dates: 2020-2021  
 Current Position: Assistant Professor (Neurology), UC Irvine

Trainee: Neil Manering, MD  
 Position: Neuromuscular Medicine Fellow  
 Dates: 2019 – 2020  
 Current Position: Attending Neuromuscular Neurology, Presbyterian Intercommunity Hospital, Whittier, CA

Trainee: Michael Hunter, MD  
 Position: Neuromuscular Medicine Fellow  
 Dates: 2019 – 2020  
 Current Position: Attending Neurologist, Intermountain Healthcare, Salt Lake City, UT

Trainee: Jonathan Cauchi, MD  
 Position: Advanced Neuromuscular Medicine Fellow  
 Dates: 2019 – 2020  
 Current Position: Assistant Professor, University of New Mexico, Albuquerque, NM

Trainee: Afra Janarious, MD MBA  
 Position: Neuromuscular Medicine Fellow  
 Dates: 2018 – 2020 (break due to maternity leave)  
 Current Position: Attending Physician, Osceola Regional Medical Center, Assistant Professor, University of Central Florida, Orlando, FL

Trainee: Jonathan Cauchi, MD  
 Position: Neuromuscular Medicine Fellow  
 Dates: 2018 – 2019  
 Current Position: Fellow

Trainee: Sarita Said-Said, MD  
 Position: Advanced Neuromuscular Medicine Fellow  
 Dates: 2018 – 2019  
 Current Position: Attending Neurologist, Palouse Specialty Physicians, Moscow, ID

Trainee: Sarita Said-Said, MD  
 Position: Neuromuscular Medicine Fellow  
 Dates: 2017 – 2018  
 Current Position: Fellow

Trainee: Tim T. Lai, MD  
 Position: Neuromuscular Medicine Fellow  
 Dates: 2016 – 2017  
 Current Position: Private Practice, Fountain Valley, CA

Trainee: Monica Lavian, DO  
 Position: Neuromuscular Medicine Fellow  
 Dates: 2016 – 2017  
 Current Position: Private Practice, Torrance, CA

Trainee: Caroline Peyronnard, MD  
 Position: Neuromuscular Medicine Fellow  
 Dates: 2015 – 2016  
 Current Position: Attending Neurologist, Hôpital du Sacré-Cœur de Montréal, Université de Montréal, Montreal, Quebec, Canada

Trainee: Sonia Nayyar, MD  
 Position: Neuromuscular Medicine Fellow  
 Dates: 2015 – 2016  
 Current Position: Fellow

Trainee: Farzin Pedouim, MD  
 Position: Neuromuscular Medicine Fellow  
 Dates: 2014 (July – September 2014)  
 Current Position: Movement Disorders Fellow, Loma Linda University, CA

Trainee: Gulmohor “Gena” Roy, MD  
 Position: Neuromuscular Medicine Fellow and Clinical Neurophysiology Fellow  
 Dates: 2013 – 2015  
 Current Position: Attending Neurologist, Sutter Medical Center, Berkeley, CA

Trainee: Tiyonnoh Cash, MD  
 Position: Neuromuscular Medicine Fellow and Clinical Neurophysiology Fellow  
 Dates: 2012 – 2014  
 Current Position: Locum Tenens

Trainee: Hitesh Patel, MD  
 Position: Clinical Neurophysiology Fellow  
 Dates: 2012 – 2013  
 Current Position: Attending Neurologist, Memorial Care Hospital, San Clemente, CA

Trainee: Sheila Santhappa, MD  
 Position: Neuromuscular Medicine Fellow  
 Dates: 2011 – 2012  
 Current Position: Private Practice, Clearwater, FL

Trainee: Catherine Mamah, MD  
 Position: Clinical Neurophysiology Fellow  
 Dates: 2011 – 2012  
 Current Position: Charcot Marie Tooth Association Fellow, Univ. of Pennsylvania

Trainee: Sharon Kim, MD  
 Position: Clinical Neurophysiology Fellow  
 Dates: 2010 – 2011  
 Current Position: Attending Neurologist, Children’s Hospital of Orange County, Orange CA  
 Assistant Professor of Pediatrics, UC Irvine

Trainee: Jonathan McKinnon, MD  
 Position: Neuromuscle Medicine Fellow  
 Dates: 2010 – 2011  
 Current Position: Private Practice, Las Vegas, NV

Trainee: Kaveh Saremi, MD  
 Position: Clinical Neurophysiology Fellow  
 Dates: 2009 – 2010  
 Current Position: Attending Neurologist, Hoag Hospital, Newport Beach, CA

Trainee: Kwasi Adzotor, MD  
 Position: Clinical Neurophysiology Fellow  
 Dates: 2008 – 2009  
 Current Position: Private Practice, Texas

Trainee: Vinh Q. Dang, MD  
 Position: Clinical Neurophysiology Fellow  
 Dates: 2007 - 2009  
 Current Position: Attending Neurologist, Kaiser Permanente Medical Center, Fontana, CA

Trainee: Ronnie Karayan, MD  
 Position: Clinical Neurophysiology Fellow  
 Dates: 2006 - 2007  
 Current Position: Private Practice, Glendale, CA

Trainee: Karen Alice Lee (nee Dumars), MD  
 Position: Clinical Neurophysiology Fellow  
 Dates: 2005 – 2006  
 Current Position: Private Practice, Long Beach, CA

Trainee: Kristin L. Lueck, MD  
 Position: Clinical Neurophysiology Fellow  
 Dates: 2004 – 2005  
 Current Position: Attending Neurologist, Kaiser Permanente Medical Group, Orange County, CA

Trainee: Ying Peng, MD PhD  
 Position: Clinical Neurophysiology Fellow  
 Dates: 2003-2004  
 Current Position: Private Practice, Mission Viejo, CA

Trainee: Neelantha Menaka De Silva, MD  
 Position: Neuromuscular Medicine Fellow  
 Dates: 2002-2003  
 Current Position: Private Practice, Orange, CA

Trainee: Peter K. Kim, MD  
Position: Clinical Neurophysiology Fellow  
Dates: 2002-2003  
Current Position: Private Practice, Northridge, CA

Trainee: Edward B. Markus, DO  
Position: Clinical Neurophysiology Fellow  
Dates: 2001-2002  
Current Position: Attending Neurologist, Kaiser Permanente Medical Group, Orange County, CA

Trainee: Feroza Saleem, MD  
Position: Clinical Neurophysiology Fellow  
Dates: 1999-2000  
Current Position: Attending Neurologist, Liaquat Postgraduate Medical Center, Karachi, Pakistan.

## Publications

Citation Statistics (as of December 03, 2022)

Google Scholar <a href="#">h-index</a>	46
<a href="#">i10-index</a>	100
Scopus H-index	42
ORCID Profile	



### Peer-reviewed original articles

1. Bhutta ZA, Naqvi SH, **Mozaffar T** (spelled as Muzaffar T), Farooqui BJ. Neonatal sepsis in Pakistan. Presentation and Pathogens. *Acta Paediatr Scand* 1991; 80:596-601. [PubMed](#)
2. Levin MI, **Mozaffar T**, Al-Lozi MT, Pestronk A. Paraneoplastic Necrotizing Myopathies: Clinical and pathological features. *Neurology* 1998; 50: 764-767. [PubMed](#)
3. **Mozaffar T**, Lopate G, Pestronk A. Clinical correlates of granulomas in muscle. *Journal of Neurology* 1998; 245:519-524. [PubMed](#)
4. Shah U, Arshad M, **Mozaffar T**. Dysphagia in Hereditary Sensory Autonomic Neuropathy (HSAN) Type IV. *J Pak Med Assoc* 1999; 49:121-123. [PubMed](#)
5. Saleem F, **Mozaffar T**. Neuralgic Amyotrophic (Parsonage-Turner Syndrome): An often Misdiagnosed Diagnosis. *J Pak Med Assoc* 1999; 49:101-103. [PubMed](#)
6. Khealani B, **Mozaffar T**. Chronic subdural hematoma presenting as transient ischemic attack: A case report. *Ann Acad Med Singapore* 1999; 28:861-862. [PubMed](#)
7. **Mozaffar T**, Pestronk A. Myopathy with anti-Jo-1 antibodies. Pathology in perimysium and neighboring muscle fibers. *J Neurol Neurosurg Psychiatry* 2000; 68:472-478 [PubMed](#)
8. Khealani B, Farhat Z, **Mozaffar T**. Primary Intraventricular Hemorrhage related to Factor XI deficiency. *South Med J* 2000; 93: 1917-1918. [PubMed](#)
9. Lodi S, **Mozaffar T**, Sarwari AR. Gram Negative Meningitis Resulting From Rupture Of A Spinal Epidural Abscess Into The Subarachnoid Space. *J Pak Med Assoc* 2000; 50:393-394. [PubMed](#)
10. Akhtar N, Jafri W, **Mozaffar T**. Cerebral Artery Air Embolism Following an Esophagogastrosocopy: A Case Report. *Neurology* 2001; 56:136-137. [PubMed](#)
11. Habib AA, **Mozaffar T**. Brain Abscess. History of Neurology: Seminal Citations series. *Arch Neurol* 2001;58:1302-1304. [PubMed](#)
12. Habib AA, **Mozaffar T**. Neuropathology of Leprosy. History of Neurology: Seminal Citations series. *Arch Neurol* 2002;59:138-140. [PubMed](#)
13. Qureshi HU, Habib AA, Siddiqui AA, **Mozaffar T**, Sarwari AR. Predictors of Mortality in Brain Abscess. *J Pak Med Assoc* 2002;52(3):111-116. [PubMed](#)
14. Gupta R, Lin YM, Bui P, Chao T, Preston C, **Mozaffar T**. Macrophage recruitment follows the pattern of inducible nitric oxide synthase expression in a model for carpal tunnel syndrome. *J Neurotrauma* 2003;20:671-680. [PubMed](#)
15. Donaldson MR, Jensen JL, Tristani-Firouzi M, Tawil R, Bendahhou S, Suarez WA, Cobo AM, Poza JJ, Behr E, Wagstaff J, Szepietowski P, Pereira S, **Mozaffar T**, Escolar DM, Fu Y-H, Ptáček LJ. PIP<sub>2</sub> binding residues of Kir2.1 are common targets of mutations causing Andersen syndrome. *Neurology* 2003;60:1811-1816. [PubMed](#)
16. Syed NA, Khealani BA, Ali S, Hasan A, Akhtar N, Brohi H, **Mozaffar T**, Ahmed N, Hameed A, Baig SM, Wasay M. Ischemic stroke subtypes in Pakistan: The Aga Khan University Stroke Data Bank. *J Pak Med Assoc* 2003;53:584-588. [PubMed](#)
17. Gupta R, Rowshan K, Chao T, **Mozaffar T**, Steward O. Chronic Nerve Compression Induces Local Demyelination and Re-Myelination in a Rat Model of Carpal Tunnel Syndrome. *Exp Neurol* 2004;187:500-508. [PubMed](#)
18. Gupta R, Gray M, Chao T, Bear D, Modafferi E, **Mozaffar T**. Schwann cells up-regulate vascular endothelial growth factor secondary to chronic nerve compression injury. *Muscle Nerve* 2005;31:452-60. [PubMed](#)

19. Khealani BA, Hameed B, **Mozaffar T (misspelled as Mozzafar T)**, Wasay M. Primary intraventricular hemorrhage: A review of 15 cases. *J Pak Med Assoc* 2005;55:315-317. [PubMed](#)
20. Choi J, Kong K, **Mozaffar T**, Holcombe RF. Delayed Oxaliplatin-associated neurotoxicity following adjuvant chemotherapy for stage III colon cancer. *Anti Cancer Drugs* 2006;17:103-105. [PubMed](#)
21. Gupta R, Rummmler LS, Palispis W, Truong L, Chao T, Rowshan K, **Mozaffar T**, Steward O. Local down-regulation of myelin-associated glycoprotein permits axonal sprouting with chronic nerve compression injury. *Exp Neurol* 2006; 200:418-429. [PubMed](#)
22. **Mozaffar T**, Gordon PH. Minocycline-induced skin and dental pigmentations. *Neurology* 2006;67:2185. [PubMed](#)
23. **Mozaffar T**, Zeng M, Haddad F, Adams GR, Baldwin KM. Molecular and cellular defects in skeletal muscle in acute quadriplegic myopathy. *Muscle Nerve* 2007;35:55-65. [PubMed](#)
24. Duncley T, Craig DW, Huentelman MJ, Pearson JV, Szelinger S, Joshipura K, Halperin RF, Stamper C, Jensen KR, Letizia D, Hesterlee SE, Pestronk A, Levine T, Bertorini T, Graves MC, **Mozaffar T**, Jackson CE, Bosch P, McVey A, Dick A, Barohn R, Lomen-Hoerth C, Rosenfeld J, O'Connor DT, Zhang K, Crook RC, Ryberg H, Hutton M, Katz J, Mitsumoto H, Bowser R, Miller RG, Simpson EP, Appel SH, Stephan D. Molecular therapeutic targets for sporadic ALS. *N Engl J Med* 2007;357:775-788. [PubMed](#)
25. Lee SU, Grigorian A, Pawling J, Chen IJ, Gao G, **Mozaffar T**, McKerlie C, Demetriou M. N-glycan processing deficiency promotes spontaneous inflammatory demyelination and neurodegeneration. *J Biol Chem* 2007;282:33725-33734. [PubMed](#)
26. Gordon PH, Moore DH, Miller RG, Florence JM, Verheijde JL, Doorish C, Hilton JF, Spitalny M, MacArthur RB, Mitsumoto H, Neville H, Boylan K, **Mozaffar T**, Belsh JM, Ravits J, Bedlack R, Graves M, McCluskey L, Barohn RJ, Tandan R. Minocycline is not effective for amyotrophic lateral sclerosis: A phase III randomized control trial. *Lancet Neurol* 2007;6:1045-1053. [PubMed](#)
27. Gwinn K, Corriveau RA, Mitsumoto H, Bednarz K, Brown RH Jr, Cudkowicz M, Gordon PH, Hardy J, Kasarskis EJ, Kaufmann P, Miller R, Sorenson E, Tandan R, Traynor BJ, Nash J, Sherman A, Mailman MD, Ostell J, Buijijn L, Cwik V, Rich SS, Singleton A, Refolo L, Andrews J, Zhang R, Conwit R, Keller MA; **ALS Research Group**. Amyotrophic lateral sclerosis: an emerging era of collaborative gene discovery. *PLoS ONE* 2007;2:e1254. [PubMed](#)
28. Bannwarth S, Procaccio V, Rouzier C, Fragaki K, Poole J, Chabrol B, Desnuelle C, Pouget J, Azulay JP, Attarian S, Pellissier JF, Gargus JJ, Abdenur J, **Mozaffar T**, Calvas P, Labauge P, Pages M, Wallace DC, Lambert JC, Paquis-Flucklinger V. Rapid identification of mitochondrial DNA (mt DNA) mutations in neuromuscular disorders by using Surveyor strategy. *Mitochondrion* 2008;8:136-145. [PubMed](#)
29. Sharfuddin AA, Fatima H, Jilani SM, Mozaffar FH, **Mozaffar T**. The spectrum of neurological complications in Pakistani patients with malignancies. *J Pak Med Assoc* 2008;58:160-164. [PubMed](#)
30. Ringman JM, **Mozaffar T**. Myopathy associated with chronic orlistat consumption: A case report. *Neuromuscul Disord* 2008;18:410-412. [PubMed](#)
31. Gordon PH, Cheung KC, Levin B, Andrews H, Doorish C, Macarthur RB, Montes J, Bednarz K, Florence J, Rowin J, Boylan K, **Mozaffar T**, Tandan R, Mitsumoto H, Kelvin EA, Chapin J, Bedlack R, Rivner M, McCluskey LF, Pestronk A, Graves M, Sorenson EJ, Barohn RJ, Belsh JM, Lou JS, Levine T, Saperstein D, Miller RG, Scelsa SN, and the Combination Drug Selection Trial Study Group\*. A novel, efficient, randomized, selection trial comparing combinations of drug therapy in ALS. *Amyotrophic Lateral Scler* 2008;9:212-222. [PubMed](#)
32. **Mozaffar T**, Strandberg E, Kazuko A, Hilgenberg L, Smith M, Gupta R. Neuromuscular Junction Integrity after Chronic Nerve Compression Injury. *J Orthop Res* 2009;27:114-119. [PubMed](#)
33. Cudkowicz ME, Shefner JM, Simpson E, Grasso D, Yu H, Zhang H, Shui A, Schoenfeld D, Brown RH, Weiland S, Barber JR, and **the Northeast ALS Consortium**. Arimoclomol at Dosages up to 300 mg/day is well tolerated and safe in amyotrophic lateral sclerosis. *Muscle Nerve* 2008;38:837-844. [PubMed](#)

34. **American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM).** Diagnostic criteria for late-onset (childhood and adult) Pompe disease. *Muscle Nerve* 2009;40:149-160. [PubMed](#)
35. **ALSUntangled Group.** ALSUntangled update 1: investigating a bug (Lyme Disease) and a drug (Iplex) on behalf of people with ALS. *Amyotrophic Lateral Scler* 2009;10:248-50. [PubMed](#)
36. Pasnoor M, Wolfe GI, Nations S, Trivedi S, Barohn RJ, Herbelin L, McVey A, Dimachkie M, Kissel J, Walsh R, Amato A, **Mozaffar T**, Hungs M, Chui L, Goldstein J, Novella S, Burns T, Phillips L, Claussen G, Young A, Bertorini T, Oh S. Clinical findings in MuSK-antibody positive myasthenia gravis: A U.S. experience. *Muscle Nerve* 2010;41:370-374. [PubMed](#)
37. Burns TM, Grouse CK, Conaway MR, Sanders DB and **mg composite and mg-qol15 study group.** Construct and concurrent validation of the MG-QOL15 in the practice setting. *Muscle Nerve* 2010;41:219-226. [PubMed](#)
38. **ALSUntangled Group.** ALSUntangled update 2: investigating the Hickey Wellness Center. *Amyotrophic Lateral Scler* 2009;10:490-491. [PubMed](#)
39. **ALSUntangled Group.** ALSUntangled Update 3: Investigating stem cell transplants at the Hospital San Jose Tecnologico de Monterrey. *Amyotrophic Lateral Scler* 2009;11:248-249. [PubMed](#)
40. Burns TM, Conaway MR, Sanders DB, **MG Composite and MG-QOL15 Study Group.** The MG Composite: A valid and reliable outcome measure for the care of patients with myasthenia gravis. *Neurology* 2010;74:1434-40. [PubMed](#)
41. **ALSUntangled Group.** ALSUntangled update 4: investigating the XCell-Center. *Amyotrophic Lateral Scler* 2010;11:337-338. [PubMed](#)
42. **ALSUntangled Group.** ALSUntangled update 5: Investigating the Stowe/Morales ALS Protocol. *Amyotrophic Lateral Scler* 2010;11:414-416. [PubMed](#)
43. **ALSUntangled Group.** ALSUntangled update 6: Investigating Marty Murray's method. *Amyotrophic Lateral Scler* 2010;11:494-496. [PubMed](#)
44. Pioro EP, Brooks BR, Cummings J, Schiffer R, Thisted RA, Wynn D, Hepner A, Kaye R; **for the Safety, Tolerability, and Efficacy Results Trial of AVP-923 in PBA Investigators.** Dextromethorphan Plus Ultra Low-Dose Quinidine Reduces Pseudobulbar Affect. *Ann Neurol* 2010;68:693-702. [PubMed](#)
45. Maselli RA, Arredondo J, Cagney O, **Mozaffar T**, Skinner S, Yousif S, Davis RR, Gregg JP, Sivak M, Konia TH, Thomas K, Wollmann RL. Congenital myasthenic syndrome associated with epidermolysis bullosa caused by homozygous mutations in *PLEC1* and *CHRNE*. *Clin Genet* 2010;80:444-451. [PubMed](#)
46. **ALSUntangled Group.** ALSUntangled update 7: Investigating hyperimmune goat serum (Aimspiro) for ALS. *Amyotrophic Lateral Scler* 2010;11:571-573. [PubMed](#)
47. **ALSUntangled Group.** ALSUntangled update 8: Low dose naltrexone for ALS. *Amyotrophic Lateral Scler* 2011;12:76-78. [PubMed](#)
48. Burns TM, Grouse CK, Wolfe GI, Conaway MR, Sanders DB; **MG Composite and MG-OL15 Study Group.** The MG-QOL15 for following the health-related quality of life of patients with myasthenia gravis. *Muscle Nerve* 2011;43:14-18. [PubMed](#)
49. **ALSUntangled Group.** ALSUntangled update 9: Blue-green algae (Spirulina) as a treatment for ALS. *Amyotrophic Lateral Scler* 2011;12:153-155. [PubMed](#)
50. **ALSUntangled Group.** ALSUntangled No. 10: Luteolin and Lutimax. *Amyotrophic Lateral Scler* 2011;12:235-237. [PubMed](#)
51. Miller RG, Moore DH, Forshew DA, Katz JS, Barohn RJ, Valan M, Bromberg MB, Goslin KL, Graves MC, McCluskey LF, McVey AL, **Mozaffar T**, Florence JM, Pestronk A, Ross M, Simpson EP, Appel SH; On behalf of the WALs Study Group. Phase II screening trial of lithium carbonate in amyotrophic lateral sclerosis: Examining a more efficient trial design. *Neurology* 2011; 77:973-979. [PubMed](#)
52. **ALSUntangled Group.** ALSUntangled No. 11: Nu Tech Mediworld. *Amyotrophic Lateral Scler* 2011;12:309-311. [PubMed](#)
53. Muppidi S, Wolfe GI, Conaway M, Burns TM; **MG COMPOSITE AND MG-QOL15 STUDY GROUP.** MG-ADL: still a relevant outcome measure. *Muscle Nerve.* 2011;44:727-731. [PubMed](#)

54. **ALSUntangled Group.** ALSUntangled No. 12: Dean Kraft, Energy Healer. *Amyotrophic Lateral Scler* 2011;12:389-391. [PubMed](#)
55. **ALSUntangled Group.** ALSUntangled No. 13: Bee Venom. *Amyotrophic Lateral Scler* 2011;12:471-472. [PubMed](#)
56. Chan N, Le C, Shieh P, **Mozaffar T**, Khare M, Bronstein J, Kimonis V. Valsolin-containing protein mutation and Parkinson's disease. *Parkinsonism Relat Disord* 2012;18:107-109. [PubMed](#)
57. Gupta R, Nassiri N, Bathen M, Hazel A, Palispis W, **Mozaffar T**. Cajal Band Reorganization and the disruption Schwann cell dystrophin related complex in a novel mouse model of carpal tunnel syndrome. *Muscle Nerve* 2012;45:231-242 [PubMed](#)
58. **ALSUntangled Group.** ALSUntangled No. 14: Mototab. *Amyotrophic Lateral Scler* 2012;13:161-164. [PubMed](#)
59. **ALSUntangled Group.** ALSUntangled No. 15: Coconut Oil. *Amyotrophic Lateral Scler* 2012;13:328-330. [Reprint](#)
60. Sadjadi R, Conway M, Cutter G, Sanders DB, Burns TM, **MG Composite and MG-QOL15 Study Group.** Psychometric evaluation of the myasthenia gravis composite (MGC) using rasch analysis. *Muscle Nerve* 2012;45:820-825. [PubMed](#)
61. **ALSUntangled Group.** ALSUntangled No. 16: Cannabis. *Amyotrophic Lateral Scler* 2012;13:400-404. [Reprint](#)
62. Lin MY, Frieboes LS, Forootan M, Palispis WA, **Mozaffar T**, Jafari M, Steward O, Gall CM, Gupta R. Biophysical stimulation induces Schwann cell proliferation in an integrin-dependent mechanism in an in-vitro model of chronic nerve compression. *Ann Neurol* 2012;72:112-123. [PubMed](#)
63. Yin HZ, Nalbandian A, Hsu C, Li S, Llewellyn KJ, **Mozaffar T**, Kimonis VE, Weiss JH. Slow Development of ALS-Like Spinal Cord Pathology in Mutant Valosin-Containing Protein (VCP) Gene Knock in Mice. *Cell Death Dis* 2012;16:e374. [PubMed](#)
64. Nalbandian A, Llewellyn KJ, Badadani M, Yin HZ, Nguyen C, Mukherjee J, Vesa J, Watts G, Caiozzo V, **Mozaffar T**, Weiss JH and Virginia E. Kimonis VE. A Progressive Translational Mouse Model of Human VCP Disease: The VCP<sup>R155H/+</sup> Mouse. *Muscle Nerve* 2012;47:260-270. [PubMed](#)
65. Mehta SG, Khare M, Ramani R, Watts GD, Simon M, Osann KE, Donkervoort S, Dec E, Nalbandian A, Platt J, Pasquali M, Wang A, **Mozaffar T**, Smith CD, Kimonis VE. Genotype-Phenotype studies of VCP-associated Inclusion Body Myopathy with Paget Disease of Bone and/or Frontotemporal Dementia. *Clin Genet* 2013;83:422-431 (doi 10.1111/cge.12000). [PubMed](#)
66. Nalbandian A, Llewellyn KJ, Kitazawa M, Yin H, Edwards R, Nguyen C, Mukherjee J, **Mozaffar T**, Watts G, Weiss J, Kimonis VE. The Homozygous VCP<sup>R155H/R155H</sup> Mouse Model Exhibits Accelerated Human VCP Disease-Associated Pathology. *PLoS ONE* 2012;7:e46308. [PubMed](#)
67. **ALSUntangled Group.** ALSUntangled No. 17: "When ALS is Lyme". *Amyotrophic Lateral Scler* 2012;13:487-491. [Full Text](#)
68. Chao T, Frump D, Caiozzo VJ, **Mozaffar T**, Steward O, Gupta R. Mmp-3 Inhibition Leads To Prolonged Preservation of Denervated Motor Endplates After Traumatic Nerve Injury. *Ann Neurol* 2013;73:210-223. [PubMed](#)
69. **ALSUntangled Group.** ALSUntangled No. 18: apoequorin (Prevagen). *Amyotrophic Lateral Scler Frontotemporal Degener* 2013;14:78-79. [PubMed](#)
70. No D, Valles-Ayoub Y, Carbajo R, Khokher Z, Sandoval L, Stein B, Tarnopolsky MA, **Mozaffar T**, Darvish B, Pietruszka M, Darvish D. Novel gene mutations in autosomal recessive hereditary inclusion body myopathy patients. *Genet Test Mol Biomarkers* 2013;17:376-382. [PubMed](#)
71. **ALSUntangled Group.** ALSUntangled No. 19: sodium chlorite. *Amyotrophic Lateral Scler Frontotemporal Degener* 2013;14:236-238. [PubMed](#)
72. Howard JF Jr, Barohn RJ, Cutter GR, Freimer M, Juel VC, **Mozaffar T**, Mellion ML, Benatar MG, Farrugia ME, Wang JJ, Malhotra SS, Kissel JT; MG Study Group. A Randomized, double-blind, placebo-controlled Phase II study of eculizumab in patients with refractory generalized myasthenia gravis. *Muscle Nerve.* 2013;48:76-84. [PubMed](#)

73. Gupta R, Rafijah G, Bowen A, Dolores C, Vitali R, **Mozaffar T**. The use of fibrin glue to augment nerve repairs does not impede neural regeneration in an animal model for segmental nerve defects. *J Hand Surg* 2013;38:847-855. [PubMed](#)
74. ALSUntangled Group, Fournier C, Bedlack B, Hardiman O, Heiman-Patterson T, Gutmann L, Bromberg M, Ostrow L, Carter G, Kabashi E, Bertorini T, **Mozaffar T**, Andersen P, Dietz J, Gamez J, Dimachkie M, Wang Y, Wicks P, Heywood J, Novella S, Rowland LP, Piro E, Kinsley L, Mitchell K, Glass J, Sathornsumetee S, Kwiecinski H, Baker J, Atassi N, Forshew D, Ravits J, Conwit R, Jackson C, Sherman A, Dalton K, Tindall K, Gonzalez G, Robertson J, Phillips L, Benatar M, Sorenson E, Shoesmith C, Nash S, Maragakis N, Moore D, Caress J, Boylan K, Armon C, Grosso M, Gerecke B, Wymer J, Oskarsson B, Bowser R, Drory V, Shefner J, Lechtzin N, Leitner M, Miller R, Mitsumoto H, Levine T, Russell J, Sharma K, Saperstein D, McClusky L, MacGowan D, Licht J, Verma A, Strong M, Lomen-Hoerth C, Tandan R, Rivner M, Kolb S, Polak M, Rudnicki S, Kittrell P, Quereshi M, Sachs G, Pattee G, Weiss M, Kissel J, Goldstein J, Rothstein J, Pastula D, Gleb L, Ogino M, Rosenfeld J, Carmi E, Oster C, Barkhaus P, Valor E. ALSUntangled 20: the Deanna protocol. *Amyotroph Lateral Scler Frontotemporal Degener*. 2013;14:319-323. [PubMed](#)
75. **ALSUntangled Group**. ALSUntangled 21: Fecal transplants. *Amyotroph Lateral Scler Frontotemporal Degener*. 2013;14:482-485. [PubMed](#)
76. Dimachkie MM, Muzyka IM, Katz JS, Jackson C, Wang Y, McVey AL, Dick A, Pasnoor M, **Mozaffar T** (misspelled as Mozaffar MT), Xiao-Song Z, Kissel JT, Ensrud E, Rosenfeld J, Barohn RJ. Leg Amyotrophic Diplegia: Prevalence and pattern of weakness at US neuromuscular centers. *J Clin Neuromuscul Dis*. 2013;5:7-12. [PubMed](#)
77. Cudkowicz ME, van den Berg LH, Shefner JM, Mitsumoto H, Mora JS, Ludolph A, Hardiman O, Bozik ME, Ingersoll EW, Archibald D, Meyers AL, Dong Y, Farwell WR, Kerr DA; **for the EMPOWER investigators**. Dexamipexole versus placebo for patients with amyotrophic lateral sclerosis (EMPOWER): a randomised, double-blind, phase 3 trial. *Lancet Neurol* 2013;12:1059-1067. [PubMed](#) (name listed erroneously as Mozaff T.)
78. Shefner JM, Watson ML, Meng L, Wolff AA; **NEALS/Cytokinetics STUDY Team**. A study to evaluate safety and tolerability of repeated doses of tirasemtiv in patients with amyotrophic lateral sclerosis. *Amyotroph Lateral Scler Frontotemporal Degener*. 2013;14:574-581. [PubMed](#)
79. **ALSUntangled Group**. ALSUntangled 22: Propofol. *Amyotroph Lateral Scler Frontotemporal Degener*. 2013;14:640-642. [PubMed](#)
80. Llewellyn K, Nalbandian A, Kwang-Mook, J, Nguyen C, Avanesian A, **Mozaffar T**, Piomelli D, Kimonis V. Lipid-enriched diet rescues lethality and slows down progression in a murine model of VCP-associated disease. *Hum Mol Genet*. 2014;23:1333-1344. [PubMed](#)
81. **ALSUntangled Group**. ALSUntangled 23: the Rife machine and retroviruses. *Amyotroph Lateral Scler Frontotemporal Degener*. 2014;15:157-159. [PubMed](#)
82. Mitsumoto H, Factor-Litvak P, Andrews H, Goetz RR, Andrews L, Rabkin JG, McElhiney M, Nieves J, Santella RM, Murphy J, Hupf J, Singleton J, Merle D, Kilty M, Heitzman D, Bedlack RS, Miller RG, Katz JS, Forshew D, Barohn RJ, Sorenson EJ, Oskarsson B, Fernandes Filho JA, Kasarskis EJ, Lomen-Hoerth C, **Mozaffar T**, Rollins YD, Nations SP, Swenson AJ, Shefner JM, Andrews JA, Koczon-Jaremko BA; The ALS Cosmos Study Group. ALS Multicenter Cohort Study of Oxidative Stress (ALS COSMOS): Study methodology, recruitment, and baseline demographic and disease characteristics. *Amyotroph Lateral Scler Frontotemporal Degener*. 2014;15:192-203. [PubMed](#)
83. Willis A-M, Hubbard J, Macklin EA, Glass J, Tandan R, Simpson EP, Brooks B, Gelinis D, Mitsumoto H, **Mozaffar T**, Hanes GP, Ladha SS, Heiman-Patterson T, Katz J, Lou J-S, Mahoney K, Grasso D, Lawson R, Yu H, Cudkowicz M for the MDA Clinical Research Network<sup>16</sup>. Hyperalimentation in Amyotrophic Lateral Sclerosis: a randomized double-blind placebo-controlled trial. *Lancet* 2014;383:2065-2072. [PubMed](#)
84. **ALSUntangled Group**. ALSUntangled 24: Vitamin D. *Amyotroph Lateral Scler Frontotemporal Degener*. 2014;15:318-320. [PubMed](#)
85. Naderi N, Masoomi H, Mozaffar T, Malik S. Patient characteristics and comorbidities associated with cerebrovascular accident following acute myocardial infarction in the United States. *Int J Cardiol* 2014;175:323-327. [PubMed](#)

86. Jung J, Hahn P, Choi B, **Mozaffar T**, Gupta R. Early surgical decompression restores neurovascular blood flow and ischemic parameters in an in-vivo animal model of nerve compression injury. *J Bone Joint Surg* 2014;96:897-906. [PubMed](#)
87. **ALSUntangled Group**. ALSUntangled 25: Ursodiol. *Amyotroph Lateral Scler Frontotemporal Degener.* 2014;15:475-478. [PubMed](#)
88. Lawton KA, Brown MV, Alexander D, Li Z, Wulff JE, Lawson R, Jaffa M, Milburn MV, Ryals JA, Bowser R, Cudkowicz ME, Berry JD; **Northeast ALS Consortium**. Plasma metabolomics biomarker panel to distinguish patients with amyotrophic lateral sclerosis from disease mimics. *Amyotroph Lateral Scler Frontotemporal Degener.* 2014;15:362-370. PMID: 24984169
89. Kirk K, Gennings C, Hupf JC, Tadesse S, D'Aurelio M, Kawamata H, Valsecchi F, Mitsumoto H; **ALS/PLS COSMOS Study Groups**, Manfredi G. Bioenergetic markers in skin fibroblasts of sporadic amyotrophic lateral sclerosis and progressive lateral sclerosis patients. *Ann Neurol* 2014;76:620-624. PMID: 25090982
90. **ALSUntangled Group**. ALSUntangled 26: Lunasin. *Amyotroph Lateral Scler Frontotemporal Degener.* 2014;15:622-626. PMID: 25245186
91. Cudkowicz ME, Titus S, Kearney M, Yu H, Sherman A, Schoenfeld D, Hayden D, Shui A, Brooks B, Conwit R, Felsenstein D, Greenblatt DJ, Keroack M, Kissel JT, Miller R, Rosenfeld J, Rothstein JD, Simpson E, Tolckoff-Rubin N, Zinman L, Shefner JM; **Ceftriaxone Study Investigators**. Safety and efficacy of ceftriaxone for amyotrophic lateral sclerosis: a multistage, randomized, double-blinded, placebo-controlled trial. *Lancet Neurol* 2014;13:1083-1091. PMID: 25297012
92. **ALSUntangled Group**. ALSUntangled: Introducing the Table of Evidence. *Amyotroph Lateral Scler Frontotemporal Degener.* 2015;16:142-145. PMID: 25544643
93. Schwarzkopf R, Dang P, Luu M, **Mozaffar T**, Gupta R. Topical tranexamic acid does not affect electrophysiologic or neurovascular sciatic nerve markers in an animal model. *Clin Orthop Relat Res* 2015;473:1074-1082. PMID: 25560955.
94. Sanders DB, Rosenfeld J, Dimachkie MM, Meng L, Malik FI for the **Tirasemtiv in Myasthenia Gravis Study Group**. A Double-Blinded, Randomized, Placebo-Controlled Trial to Evaluate Efficacy, Safety, and Tolerability of Single Doses of Tirasemtiv in Patients with Acetylcholine Receptor-Binding Antibody-Positive Myasthenia Gravis. *Neurotherapeutics* 2015;12:445-460. PMID: 25742919.
95. Kurimoto S, Jung J, Tapadia M, Lengfeld J, Agalliu D, Waterman M, **Mozaffar T**, Gupta R. Activation of the wnt/ $\beta$ -catenin signaling cascade after traumatic nerve injury. *Neuroscience* 2015;294:101-108. PMID: 25743255
96. **ALSUntangled Group**. ALSUntangled No 27: Precision Stem Cell. *Amyotroph Lateral Scler Frontotemporal Degener.* 2015;16:282-285. PMID: 25807846
97. Goyal NA, Cash TM, Alam U, Enam S, Tierney P, Araujo N, Mozaffar FH, Pestronk A, **Mozaffar T**. Seropositivity for NT5c1A antibody in sporadic inclusion body myositis predicts more severe motor, bulbar and respiratory involvement. *J Neurol Neurosurg Psychiatry* 2016;87:373-378. PMID: 25857661
98. Miller RG, Block G, Katz JS, Barohn RJ, Gopalakrishnan V, Cudkowicz M, Zhang JR, McGrath MS, Ludington E, Appel SH, Azhir A; **Phase 2 Trial NP001 Investigators**. Randomized Phase 2 trial of NP001- a novel immune regulator: Safety and early efficacy in ALS. *Neurol Neuroimmunol Neuroinflamm* 2015;2:e100. PMID: 25884010
99. Jung JS, Frump D, Su J, Wang W, **Mozaffar T**, Gupta R. Desert Hedgehog is a Mediator of Demyelination in Compression Neuropathies. *Exp Neurol* 2015;271:84-94. PMID: 25936873
100. **ALSUntangled Group**. ALSUntangled No 28: Acupuncture. *Amyotroph Lateral Scler Frontotemporal Degener.* 2015;16:286-289. PMID: 25960084
101. Goyal NA, **Mozaffar T**. Tongue Atrophy and Fasciculations in Transthyretin Familial Amyloid Neuropathy: An ALS Mimicker. *Neurol Genet* 2015;1:e18. PMID: 27066555
102. Jensen BS, Willer T, Saade DN, Cox MO, **Mozaffar T**, Scavina M, Stefans VA, Winder TL, Campbell KP, Moore SA, Matthews KD. GMPPB-Associated Dystroglycanopathy: Emerging Common Variants with Phenotype Correlation. *Hum Mutation* 2015; 36:1159-1163. PMID: 26310427. PMID: 26310427

103. **ALSUntangled Group**. ALSUntangled No 29: MitoQ. *Amyotroph Lateral Scler Frontotemporal Degener*. 2015;16:427-429. PMID: 26090901
104. **ALSUntangled Group**. ALSUntangled No 30: Methylcobalamin. *Amyotroph Lateral Scler Frontotemporal Degener*. 2015;16:536-539. PMID: 26203660
105. Narayanaswami P, Geisbush T, Jones L, Weiss M, **Mozaffar T**, Gronseth G, Rutkove, SB. Critically re-evaluating a common technique: Accuracy, reliability and confirmation bias of EMG. *Neurology* 2016;86:218-223. PMID: 26701380
106. Bedlack R, Quinn C, Karam C, **et al**. ALSUntangled No. 31: Protandim. *Amyotroph Lateral Scler Frontotemporal Degener* 2016;17:154-6.
107. Bedlack R, Quinn C, Karam C, **et al**. ALSUntangled No. 32: Gluten-free diet. *Amyotroph Lateral Scler Frontotemporal Degener* 2016;17:307-9.
108. Johnson EM, Roberts M, **Mozaffar T**, Young P, Quartel A, Berger KI. Pulmonary function tests (maximal inspiratory pressure, maximum expiratory pressure, vital capacity, forced vital capacity) predict ventilator and wheelchair use in late-onset Pompe Disease. *Neuromuscul Disord* 2016; 26:136-145. PMID: 26794303
109. Bedlack R, Quinn C, Karam C, **et al**. ALS Untangled No.33 Endotherapia. *Amyotroph Lateral Scler Frontotemporal Degener* 2016;17:461-5.
110. Murphy J, Factor-Litvak P, Goetz R, Lomen-Hoerth C, Nagy PL, Hupf J, Singleton J, Woolley S, Andrews H, Heitzman D, Bedlack RS, Katz JS, Barohn RJ, Sorenson EJ, Oskarsson B, Fernandes Filho JA, Kasarskis EJ, **Mozaffar T**, Rollins YD, Nations SP, Swenson AJ, Koczon-Jaremko BA, Mitsumoto H; ALS COSMOS. Cognitive-behavioral screening reveals prevalent impairment in a large multicenter ALS cohort. *Neurology* 2016; 86:813-820. PMID: 26802094
111. Bedlack R, Quinn C, Karam C, **et al**. ALSUntangled No. 34: GM604. *Amyotroph Lateral Scler Frontotemporal Degener* 2016;17:617-21.
112. Price MA, Barghout V, Benveniste O, Christopher-Stine L, Corbett A, de Visser M, Hilton-Jones D, Kissel JT, Lloyd TE, Lundberg IE, Mastaglia F, **Mozaffar T**, Needham M, Schmidt J, Sivakumar K, DeMuro C, Tseng B. Mortality and causes of death in patients with sporadic inclusion body myositis: survey study based on the clinical experience of specialists in Australia, Europe and the USA. *J Neuromuscul Dis* 2016; 3:67-75. PMID: 27854208
113. Pasnoor M, He J, Herbelin L, Burns TM, Nations S, Bril V, Wang AK, Elsheikh BH, Kissel JT, Saperstein DS, Shaibani A, Jackson C, Swenson AJ, Howard, Jr. JF, Goyal N, David WS, Wicklund MP, Pulley MT, Becker M, **Mozaffar T**, Benatar M, Pascuzzi RM, Simpson EP, Rosenfeld J, Dimachkie MM, Statland JM, Barohn RJ. A Randomized Controlled Trial of Methotrexate for Patients with Generalized Myasthenia Gravis. *Neurology* 2016;87:57-64. PMID: 27306628
114. Shefner JM; Wolff AA; Meng L; Bian A; Lee J; Barragan D; Andrews JA; on behalf of the **Benefit-ALS Study Group**. A randomized, placebo-controlled, double-blind phase IIb trial evaluating the safety and efficacy of tirasemtiv in patients with amyotrophic lateral sclerosis. *Amyotroph Lateral Scler Frontotemporal Degener* 2016 Jul-Aug;17:426-35. PMID: 23952636
115. Bali T, Self W, Liu J, Siddique T, Wang LH, Bird TD, Ratti E, Atassi N, Boylan KB, Glass JD, Maragakis NJ, Caress JB, McCluskey LF, Appel SH, Wymer JP, Gibson S, Zinman L, **Mozaffar T**, Callaghan B, McVey AL, Jockel-Balsarotti J, Allred P, Fisher ER, Lopate G, Pestronk A, Cudkowicz ME, Miller TM. Defining SOD1 ALS natural history to guide therapeutic clinical trial design. *J Neurol Neurosurg Psychiatry* 2017;88:99-105. PMID: 27261500
116. Evangelista T, Wehl CC, Kimonis V, Lochmüller H; **VCP related diseases Consortium**. 215th ENMC International Workshop VCP-related multi-system proteinopathy (IBMPFD) 13-15 November 2015, Heemskerk, The Netherlands. *Neuromuscul Disord* 2016;26:535-547. PMID: 27312024
117. van der Ploeg A, Carlier PG, Carlier R-Y, Kissel RT, Schoser B, Wenninger S, Pestronk A, Barohn RJ, Dimachkie MM, Goker-Alpan O, **Mozaffar T**, Pena LDM, Simmons Z, Straub V, Guglieri M, Young P, Boentert M, Baudin P-Y, Wens S, Shafi R, Bjartmar C, Thurberg BL. Prospective exploratory muscle biopsy, imaging, and functional assessment in patients with

- late-onset Pompe disease treated with alglucosidase alfa: The EMBASSY Study. *Mol Genet Metab* 2016;119:115-123. PMID: 27473031
118. Wolfe GI, Kamniski HJ, Aban IB, Minisman G, Kuo H-C, Marx A, Strobel P, Mazia C, Oger J, Cea JG, Heckmann JM, Evoli A, Nix W, Ciafaloni E, Antonini G, Witoonpanich R, King JO, Beydoun SR, Chalk CH, Barboi AC, Amato AA, Shaibani AI, Katirji B, Lecky BRF, Buckley C, Vincent A, Dias-Tosta E, Yoshikawa H, Waddington-Cruz M, Pulley MT, Rivner MH, Kostera-Pruszezyk, Pascuzzi RM, Jackson CE, Ramos GSG, Verschuuren JJGM, Massey JM, Kissel JT, Werneck LC, Benatar M, Barohn RJ, Tandan R, **Mozaffar T**, Conwit R, Odenkirchen J, Sonet JR, Jaretzki A, Newsom-Davis J, Cutter GR on behalf of the MGTX Study Group\*. Randomized Trial of Thymectomy in Myasthenia Gravis. *N Engl J Med* 2016;375:511-522. PMID: 27509100
  119. Fixsen E, Bedlack R, Quinn C, **et al**. ALSUntangled No. 35: Hyperbaric Oxygen Therapy. *Amyotroph Lateral Scler Frontotemporal Degener* 2016;17:622-624.
  120. Lavian M, Goyal NA, **Mozaffar T**. Sporadic inclusion body myositis misdiagnosed as idiopathic granulomatous myositis. *Neuromuscul Disord* 2016;26:741-743. PMID: 27692540
  121. Kishnani P, Tarnopolsky M, Sivakumar K, Roberts M, Dasouki M, Dimachkie M, Finanger E, Goker-Alpan O, Guter K, **Mozaffar T**, Pervaiz MA, Laforet P, Levine T, Adera M, Lazauskas R, Sitaraman S, Khanna R, Benjamin E, Feng J, Flanagan J, Barth J, Barlow C, Lockhart D, Valenzano K, Boudes P, Johnson F, Byrne B. Duvoglustat HCl Increases Systemic and Tissue Exposure of Active Acid  $\alpha$ -Glucosidase in Pompe Patients when Coadministered with Alglucosidase Alfa. *Molecular Therapy* 2017;25:1199-1208. PMID: 28341561
  122. Bedlack R, Fixsen E, Quinn C, **et al**. ALSUntangled No. 36: Accilion. *Amyotroph Lateral Scler Frontotemporal Degener* 2017;18:142-147.
  123. Peschansky V, Bedlack R, Quinn C, **et al**. ALSUntangled 38: L-serine. *Amyotroph Lateral Scler Frontotemporal Degener* 2017;18:148-153.
  124. Al-Obeidi E, Al-Tahan S, Surampalli A, Goyal N, Wang A, Hermann A, Omizu M, Smith C, **Mozaffar T**, Kimonis V. Genotype-phenotype study in patients with valosin-containing protein mutations associated with multisystem proteinopathy. *Clin Genet* 2018;93:119-125. PMID: 28692196
  125. Howard JF Jr, Utsugisawa K, Benatar M, Murai H, Barohn RJ, Illa I, Jacob S, Vissing J, Burns TM, Kissel JT, Muppidi S, Nowak RJ, O'Brien F, Wang JJ, Mantegazza R; **REGAIN Study Group**. Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study. *Lancet Neurol* 2017;16:976-986. PMID: 29066163
  126. Allenbach Y, Mammen AL, Benveniste O, Stenzel W; **Immune-Mediated Necrotizing Myopathies Working Group**. 224<sup>th</sup> ENMC International Workshop: Clinico-seropathological classification of immune-mediated necrotizing myopathies Zandvoort, The Netherlands, 14-16 October 2016. *Neuromuscul Disord* 2018;28:87-99. PMID: 29221629
  127. Oskarsson B, Moore D, **Mozaffar T**, Ravits J, Wiedau-Pazos M, Parziale N, Joyce NC, Mandeville R, Goyal N, Cudkowicz ME, Weiss M, Miller RG, McDonald CM. Mexilitene for Muscle Cramps in ALS: A Randomized Double-Blind Crossover Trial. *Muscle Nerve* 2018;58:42-48. PMID: 29510461
  128. Hewett K, Sanders DB, Grove RA, Broderick CL, Rudo TJ, Bassiri A, Zvartau-Hind M, Brill V; **BEL115123 Study Group**. Randomized study of adjunctive belimumab in participants with generalized myasthenia gravis. *Neurology* 2018;90:e1425-e1434. PMID: 29661905
  129. Plewa J, Surampalli A, Wencel M, Milad M, Donkervoort S, Caiozzo VJ, Goyal N, **Mozaffar T**, Kimonis V. A cross-sectional analysis of clinical evaluation in 35 individuals with mutations of the valosin-containing protein gene. *Neuromuscul Disord* 2018;28:788-786. PMID: 30097247
  130. Statland JM, Moore D, Wang Y, Walsh M, **Mozaffar T**, Elman L, Nations S, Mitsumoto H, Fernandes JA, Saperstein D, Hayat G, Herbelin L, Karam C, Katz J, Wilkins HM, Agbas A, Swerdlow RH, Santella RM, Dimachkie MM, Barohn RJ; Rasagiline Investigators of the Muscle Study Group and Western ALS Consortium. Rasagiline for Amyotrophic Lateral

- Sclerosis: a Randomized Controlled Trial. *Muscle Nerve* 2018; doi: 10.1002/mus.26335. PMID: 30192007
131. Grunseich C, Miller R, Swan T, Glass DJ, Mouelhi ME, Fornaro M, Petricoul O, Vostiar I, Roubenoff R, Meriggioli MN, Kokkinis A, Guber RD, Budron MS, Vissing J, Soraru G, **Mozaffar T**, Ludolph A, Kissel JT, Fischbeck KH; BVS857 Study Group. Safety, tolerability, and preliminary efficacy of an IGF-1 mimetic in patients with spinal and bulbar muscular atrophy: a randomized, placebo-controlled trial. *Lancet Neurol* 2108;17:1043-1052. PMID: 30337273
  132. Woolley S, Goetz R, Factor-Litvak P, Murphy J, Hupf J, Lomen-Hoerth C, Andrews H, Heitzman D, Bedlack R, Katz J, Barohn R, Sorenson E, Oskarsson B, Filho AF, Kasarskis E, **Mozaffar T**, Nations S, Swenson A, Koczon-Jaremko A, Christodoulou G, Mitsumoto H. Longitudinal screening detects cognitive stability and behavioral deterioration in ALS patients. *Behav Neurol* 2018;2018:5969137. PMID: 30515252
  133. Levine TD, Katz JS, Barohn R, Vaughan LJ, Dimachkie MM, Saperstein DS, **Mozaffar T**, Wolfe G, Mayo MS, Badger G, Katzin L, Ritt E, Greer M, DiStefano J, Schmidt PM. The Neuropathy Reviewal Process for IVIg Treatment: Lessons Learned from the INSIGHTS Study. *Neurology: Clinical Practice* 2018;8:429-436. PMID: 30564497
  134. Nallamilli BRR, Chakravorty S, Kesari A, Tanner A, Ankala A, Schneider T, da Silva C, Beadling R, Alexander JJ, Askree SH, Whitt Z, Bean L, Collins C, Khadilkar S, Gaitonde P, Dastur R, Wicklund M, **Mozaffar T**, Harms M, Rufibach L, Mittal P, Hegde M. Genetic landscape and novel disease mechanisms from a large LGMD cohort of 4656 patients. *Ann Clin Transl Neurol* 2018;5:1574-1587. PMID: 3056463
  135. Palmio J, Leonard-Louis S, Sacconi S, Savarese M, Pentillä, Semmler AL, Bach JE, Kress W, **Mozaffar T**, Lai T, Stojkovic T, Berardo A, Reisin R, Attarian S, Urtizberea A, Esteban AMC, Maggi L, Kurbatov, S, Nikitin S, Milisenda JC, Fatehi F, Raimondi M, Silveira F, Rego R, Hackman P, Claeys KG, Udd B. Expanding the importance of HMERF titinopathy: new mutations and clinical aspects. *J Neurol* 2019;266:680-690. PMID:30666435
  136. Lochmuller H, Behin A, Caraco Y, Lau H, Mirabella M, Tournev I, Tarnopolsky M, Pogorvelova O, Woods C, Lai A, Shah J, Koutsoukos T, Skrinar A, Mansbach H, Kakkis E, **Mozaffar T**. A phase 3 randomized study evaluating Sialic Acid Extended-Release for GNE Myopathy. *Neurology* 2019;92:1-9. PMID: 31036580
  137. Wolfe G.I., Kaminski H.J., Aban I.B., Minisman G., Kuo H.-C., Marx A., Ströbel P., Mazia C., Oger J., Cea J.G., Heckmann, J.M., Evoli A., Nix W., Ciafaloni E., Antonini G., Witoonpanich R., King J.O., Beydoun S.R., Chalk, C.H., Barboi A.C., Amato A.A., Shaibani A.I., Katirji B., Lecky B.R.F., Buckley C., Vincent A., Dias-Tosta E., Yoshikawa H., Waddington-Cruz M., Pulley M.T., Rivner M.H., Kostera-Pruszyk A., Pascuzzi R.M., Jackson C.E., Verschuuren J.J.G.M., Massey J.M., Kissel J.T., Werneck L.C., Benatar M., Barohn R.J., Tandan R., **Mozaffar T**, Silvestri N.J., Conwit R., Sonett, J.R., Jaretzki III A., Newsom-Davis J., Cutter G.R., on behalf of the MGTX Study Group. Long-term effect of thymectomy in patients with non-thymomatous myasthenia gravis treated with prednisone: 2-year extension of the MGTX randomised trial. *Lancet Neurology* 2019;18:259-268. PMID: 30692052
  138. Parker J, **Mozaffar T**, Messmore A, Deignan JL, Kimonis VE, Ringman JM. Homozygosity for the A431E mutation in PSEN1 presenting with a relatively aggressive phenotype. *Neurosci Lett* 2019;699:195-198. PMID: 30716424
  139. Muppidi S, Utsugisawa K, Benatar M, Murai H, Barohn RJ, Illa I, Jacob S, Vissing J, Burns TM, Kissel JT, Nowak RJ, Andersen H, Casasnovas C, De Bleecker JL, Vu TH, Mantegazza R, O'Brien FL, Wang JJ, Fujita KP, Howard JF Jr, **REGAIN Study Group**. Long-term safety and efficacy of eculizumab in generalized myasthenia gravis. *Muscle Nerve* 2019;60:14-24. PMID: 30767274
  140. Andersen H, Mantegazza R, Wang JJ, O'Brien F, Patra K, Howard JF Jr; **REGAIN Study Group**. Eculizumab improves fatigue in refractory generalized myasthenia gravis. *Qual Life Res* 2019;28:2247-2254. PMID: 30905021
  141. Pogoryelova O, Urtizberea JA, Argov Z, Nishino I, Lochmüller H; **ENMC workshop study group**. 237th ENMC International Workshop: GNE myopathy - current and future research

- Hoofddorp, The Netherlands, 14-16 September 2018. *Neuromuscul Disord* 2019;29:401-410. PMID: 30956020
142. Lemmers RJLF, van der Stoep N, van der Vliet PJ, Moore SA, Granado DSL, Johnson K, Topf A, Evangelista T, Straub V, **Mozaffar T**, Kimonis V, Scotton C, Ferlini A, Tapscott S, Voermans N, van Engelen B, Sacconi S, Tawil R, Lamers MH, van der Maarel SM. SMCHD1 mutation spectrum for facioscapulohumeral muscular dystrophy type 2 (FSHD2) and *Bosma arhinia* microphthalmia syndrome (BAMS) reveals disease-specific localization of variants in the ATPase domain. *J Med Genet* 2019;56:693-700. PMID: 31243061
  143. Howard JF Jr, Bril V, Burns TM, Mantegazza R, Bilinska M, Szczudlik A, Beydoun S, Garrido FJRR, Piehl F, Rottoli M, Van Damme P, Vu T, Evoli A, Freimer M, **Mozaffar T**, Ward ES, Dreier T, Ulrichs P, Verschueren K, Guglietta A, de Haard H, Leupin N, Verschuur JGM; Efgartigimod MG Study Group. Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis. *Neurology* 2019;92:e2661-e2673. PMID: 31118245
  144. Hunter M, Heatwole C, Wicklund M, Wehl CC, **Mozaffar T**, Statland JM, Johnson NE. Limb-girdle muscular dystrophy: A perspective adult patients on what matters most. *Muscle Nerve* 2019;60:419-424. PMID: 31298728
  145. Alandy-Dy J, Wencel M, Hall K, Simon J, Chen Y, Valenti E, Yang J, Bali D, Lakatos A, Goyal N, **Mozaffar T**, Kimonis V. Variable clinical features and genotype-phenotype correlations in 18 patients with late-onset Pompe disease. *Ann Transl Med* 2019;7:276. PMID: 31392188
  146. Al-Tahan S, Weiss L, Yu H, Tang S, Saporta M, Vihola A, Mozaffar T, Udd B, Kimonis V. A new family with HSPB8 associated autosomal dominant rimmed vacuolar myopathy. *Neurol Genet* 2019;5:e349. PMID: 31403083
  147. Cocanougher BT, Flynn L, Yun P, Jain M, Waite M, Vasavada R, Wittenbach JD, de Chastonay S, Chhibber S, Innes AM, MacLaren L, **Mozaffar T**, Arai AE, Donkervoort S, Bonnemann CG, Foley AR. Adult *MTM1*-related Myopathy Carriers: Classification Based on Deep Phenotyping. *Neurology* 2019;93:e1535-e1542. PMID: 31541013
  148. Murai H, Uzawa A, Suzuki Y, Imai T, Shiraishi H, Suzuki H, Okumura M, O'Brien F, Wang JJ, Fujita KP, Utsugisawa K; **REGAIN Study Group**. Long-term efficacy and safety of eculizumab in Japanese patients with generalized myasthenia gravis: A subgroup analysis of the REGAIN open-label extension study. *J Neurol Sci* 2019;407:116419. PMID 31698177
  149. Goyal NA, **Mozaffar T**, Chui LA. Oculopharyngeal Muscular Dystrophy, an Often Misdiagnosed Neuromuscular Disorder: A Southern California Experience. *J Clin Neuromuscul Dis* 2019;21:61-68. PMID: 31743248
  150. Chan JP, Clune J, Shah SB, Ward SR, Kocsis JD, **Mozaffar T**, Steward O, Gupta R. Examination of the Human Motor Endplate after Brachial Plexus Injury with Two-Photon Microscopy. *Muscle Nerve* 2019;61:390-395. PMID: 31820462
  151. Kastenschmidt JM, Ellefsen KL, Mannaa AH, Giebel JJ, Yahia R, Ayer RE, Pham P, Rios R, Vetrone SA, **Mozaffar T**, Villalta. QuantiMus SA: a machine learning-based approach for high precision analysis of skeletal muscle morphology. *Front Physiol* 2019;10:1416. PMID: 31849692
  152. Howard JF Jr, Nowak RJ, Wolfe GI, Freimer ML, Vu TH, Hinton JL, Benatar M, Duda PW, MacDougall JE, Farzaneh-Far R, Kaminski HJ; and the Zilucoplan MG Study Group, Barohn R, Dimachkie M, Pasnoor M, Farmakidis C, Liu T, Colgan S, Benatar MG, Bertorini T, Pillai R, Henegar R, Bromberg M, Gibson S, Janecki T, Freimer M, Elsheikh B, Matisak P, Genge A, Guidon A, David W, Habib AA, Mathew V, **Mozaffar T**, Hinton JL, Hewitt W, Barnett D, Sullivan P, Ho D, Howard JF Jr, Traub RE, Chopra M, Kaminski HJ, Aly R, Bayat E, Abu-Rub M, Khan S, Lange D, Holzberg S, Khatrib B, Lindman E, Olapo T, Sershon LM, Lisak RP, Bernitsas E, Jia K, Malik R, Lewis-Collins TD, Nicolle M, Nowak RJ, Sharma A, Roy B, Nye J, Pulley M, Berger A, Shabbir Y, Sachdev A, Patterson K, Siddiqi Z, Sivak M, Bratton J, Small G, Kohli A, Fetter M, Vu T, Lam L, Harvey B, Wolfe GI, Silvestri N, Patrick K, Zakalik K, Duda PW, MacDougall J, Farzaneh-Far R, Pontius A, Hoarty M. Clinical Effects of the Self-administered Subcutaneous Complement Inhibitor Zilucoplan in Patients With Moderate to Severe Generalized Myasthenia Gravis Results of a Phase 2 Randomized,

- Double-Blind, Placebo-Controlled, Multicenter Clinical Trial. *JAMA Neurol* 2020;77:582-592. PMID: 32065623
153. Lee I, Kuo H-C, Aban IB, Cutter GR, McPherson T, Kaminski HJ, Sussman J, Ströbel P, Oger J, Cea G, Heckmann J, Evioli A, Nix W, Ciafaloni E, Antonini G, Witoonpanich R, King JO, Beydoun SR, Chalk C, Barboi AC, Amato AA, Shaibani AI, Katirji B, Lecky BRF, Buckley C, Vincent A, Dias-Tosta E, Yoshikawa H, Cruz MW, Pulley MT, Rivner MH, Kostera-Pruszczyk A, Pascuzzi RM, Jackson CE, Verschuuren JJ, Massey JM, Kissel JT, Werneck LC, Benatar M, Barohn RJ, Tandan R, **Mozaffar T**, Conwit R, Minisman G, Sonett JR, Wolfe GI. Minimal manifestation status and prednisone withdrawal in the MGTX trial. *Neurology* 2020;95:E755-E766. PMID: 32611638
  154. Vissing J, Jacob S, Fujita KP, O'Brien F, Howard JF, **REGAIN study group**. 'Minimal symptom expression' in patients with acetylcholine receptor antibody-positive refractory generalized myasthenia gravis treated with eculizumab. *J Neurol* 2020; 267:1991-2001. PMID: 32189108
  155. Mitsumoto H, Garofalo DC, Santella RM, Sorenson EJ, Oskarsson B, Fernandes JAM Jr, Andrews H, Hupf J, Gilmore M, Heitzman D, Bedlack RS, Katz JS, Barohn RJ, Kasarskis EJ, Lomen-Hoerth C, **Mozaffar T**, Nations SP, Swenson AJ, Factor-Litvak P. Plasma creatinine and oxidative stress biomarkers in amyotrophic lateral sclerosis. *Amyotroph Lateral Scler Frontotemporal Degener* 2020;21:263-272. PMID: 32276554
  156. Mantegazza R, O'Brien FL, Yountz M, Howard JF Jr; **REGAIN study group**. Consistent improvement with eculizumab across muscle groups in myasthenia gravis. *Ann Clin Transl Neurol* 2020;7:1327-1339. PMID: 32700461
  157. Kim YJ, Schioppa E, Dankó K, **Mozaffar T**, Chunduru S, Lees K, Goyal N, Sarazin J, Fiorentino DF, Sarin KY. A phase 2 double-blinded, placebo-controlled trial of toll-like receptor 7,8,9 antagonist, IMO-8400, in dermatomyositis. *J Am Acad Dermatol* 2021;84:1160-1162. PMID: 32781178.
  158. Bril V, Benatar M, Andersen H, Vissing J, Brock M, Greve B, Kiessling P, Woltering F, Griffin L, Van den Bergh P; **MG0002 Investigators**. *Neurology* 2021;96:e853-e865. PMID: 33219142
  159. Mantegazza R, Wolfe GI, Muppidi S, Wiendl H, Fujita KP, O'Brien FL, Booth HDE, Howard JF Jr; **REGAIN Study Group**. Post-intervention status in patients with refractory myasthenia gravis treated with eculizumab. *Neurology* 2021;96:e610-e618. PMID:33229455
  160. Lochmüller H, Behin A, Tournev I, Tarnopolsky M, Horváth R, Pogoryelova O, Shah J, Koutsoukos T, Skrinar A, Kakkis E, Bedrosian CL, **Mozaffar T**. Results from a 3-year non-interventional, observational disease monitoring program in adults with GNE myopathy. *J Neuromuscul Dis* 2021;8:571-578. PMID: 33459658
  161. Ikenaga C, Findlay AR, Goyal NA, Robinson S, Cauchi J, Hussain Y, Wang LH, Kershen JC, Beson BA, Wallendorf M, Bucelli RC, **Mozaffar T**, Pestronk A, Wehl CC. Clinical utility of anti-cytosolic 5'-nucleotidase 1A antibody in idiopathic inflammatory myopathies. *Ann Clin Transl Neurol* 2021;8:571-579. PMID: 33556224
  162. Amato AA, Hanna MG, Machado PM, Badrising UA, Chinoy H, Benveniste O, Karanam AK, Wu M, Tankó LB, Schubert-Tennigkeit AA, Papanicolaou DA, Lloyd TE, Needham M, Liang C, Reardon KA, de Visser M, Ascherman DP, Barohn RJ, Dimachkie MM, Miller JAL, Kissel JT, Oskarsson B, Joyce NC, Van den Bergh P, Baets J, De Bleecker JL, Karam C, David WS, Mirabella M, Nations SP, Jung HH, Pegoraro E, Maggi L, Rodolico C, Filosto M, Shaibani AI, Sivakumar K, Goyal NA, Mori-Yoshimura M, Yamashita S, Suzuki N, Aoki M, Katsuno M, Morihata H, Murata K, Nodera H, Nishino I, Romano CD, Williams VSL, Vissing J, Zhang Auberson L; **RESILIENT Study Extension Group**. Efficacy and safety of bimagrumab in sporadic inclusion body myositis. Long term extension of RESILIENT. *Neurology*. 2021 Mar 23;96(12):e1595-e1607. PMID: 33597289
  163. Kastenschmidt JM, Coulis G, Farahat PK, Pham P, Rios R, Cristal T, Mannaa AH, Ayer RE, Yahia R, Deshpande AA, Hughes BS, Savage AK, Giesige CR, Harper SQ, Locksley RM, **Mozaffar T**, Villalta SA. A stromal progenitor and ILC2 niche promotes muscle eosinophilia and fibrosis-associated gene. *Cell Reports* 2021;35:108997. PMID: 33852849

164. Howard JF, Karam C, Yountz M, O'Brien FL, **Mozaffar T**, for the REGAIN Study Group. Long-term efficacy of eculizumab in refractory generalized myasthenia gravis: responder analyses. *Ann Clin Transl Neurol* 2021;8:1398-1407. PMID: 34043280
165. Howard JF Jr, Bril V, Vu T, Karam C, Peric S, Margania T, Murai H, Bilinska M, Shakarishvili R, Smilowski M, Guglietta A, Ulrichs P, Vangeneugden T, Utsugisawa K, Verschuuren J, Mantegazza R; **ADAPT Investigator Study Group**. Safety, efficacy, and tolerability of efgartigimod in patients with generalized myasthenia gravis (ADAPT): a multicentrem, randomized, placebo-controlled, phase 3 trial. *Lancet Neurol* 2021;20:526-536. PMID: 34146511
166. Diaz-Manera J, Kishnani PS, Kushlaf H, Ladha S, **Mozaffar T**, Straub V, Toscano A, van der Ploeg AT, Berger KI, Clemens PR, Chien Y-H, Day JW, Illarioshkin S, Roberts M, Attarian S, Borges JL, Bouhour F, Choi YC, Erdem-Ozdamar S, Goker-Alpan O, Kostera-Pruszczyk A, Haack KA, Hug C, Huynh-Ba O, Johnson J, Thibault N, Zhou T, Dimachkie M, Schoser B. Initial Results of the AVALGLUCOSIDASE ALFA Phase 3 COMET Trial in Late-Onset Pompe Disease Patients. *Lancet Neurol* 2021;20:1012-1026. PMID: 34800399
167. Wencil M, Shaibani A, Goyal NA, Dimachkie MM, Trivedi J, Johnson N, Gutmann L, Wicklund M, Bandyopadhyay S, Genge A, Freimer M, Goyal N, Pestronk A, Florence J, Karam C, Ralph J, Rasheed Z, Hayes M, Hopkins S, **Mozaffar T**, on behalf of The IPANEMA Study Group. Investigating Late-Onset Pompe Prevalence in Neuromuscular Medicine Academic Practice (The IPaNeMA Study). *Neurol Genet* 2021;7:e623.
168. Schoser B, Roberts M, Byrne BJ, Sitaraman S, Jiang H, Laforet P, Toscano A, Castelli J, Diaz-Manera J, Goldman M, van der Ploeg AT, Bratkovic D, Kuchipudi S, **Mozaffar T\***, Kishnani PS\* (\*co-senior authors), on behalf of the PROPEL STUDY GROUP. Safety and efficacy of ciplaglusidase alfa/miglustat versus alglucosidase alfa/placebo in late-onset Pompe disease: Results from an international double-blind, randomised phase 3 trial (PROPEL). *Lancet Neurol* 2021;20:1027-1037. PMID: 34800400
169. Siddiqi Z, Nowak R, **Mozaffar T**, O'Brien F, Yountz M, Patti F. Eculizumab in refractory generalized myasthenia gravis treated with prior rituximab: subgroup analysis of REGAIN and its extension study. *Muscle Nerve* 2021;64:662-669. PMID: 34590717
170. Avelar JB, Wencil M, Chumakova A, **Mozaffar T**. COVID-19 Infection in Patients with Late-Onset Pompe Disease. *Muscle Nerve* 2021;65:334-336. PMID: 34952985
171. Kovalchick LV, Bates K, Statland J, Wehl CC, Kang PB, Lowes LP, **Mozaffar T**, Straub V, Wicklund M, Heatwole C, Johnson NE. Patient reported quality of life in Limb-Girdle Muscular Dystrophy. *Neuromuscul Disord* 2021;32:57-64. PMID: 34961728
172. Cudkovic MD, Lindborg SR, Goyal NA, Miller RG, Burford MJ, Berry JD, Nicholson KA, **Mozaffar T**, Katz JS, Jenkins LJ, Baloh RH, Lewis RA, Staff NP, Owegi MA, Berry DA, Gothelf Y, Levy YS, Aricha R, Kern RJ, Windebank AJ, Brown RH. A randomized placebo-controlled phase 3 study of mesenchymal stem cells induced to secrete high levels of neurotrophic factors in amyotrophic lateral sclerosis. *Muscle Nerve* 2021;65:291-302. PMID: 34890069
173. Britton KA, Ling JP, Braunstein KE, Montagne JM, Kastenschmidt JM, Wilson A, Ikenaga C, Tsao W, Pinal-Fernandez I, Russell KA, Reed N, **Mozaffar T**, Wagner KR, Ostrow LW, Corse AM, Mammen AL, Villalta SA, Larman HB, Wong PC, Lloyd TE. Loss of TDP-43 function and rimmed vacuoles persist after T cell depletion in a xenograft model of sporadic inclusion body myositis. *Sci Transl Med* 2022;14:eabi9196. PMID: 35044790
174. Korb M, Peck A, Alfano LN, Berger KI, James MK, Ghoshal N, Healzer E, Henchcliffe C, Khan S, Mammen PA, Patel S, Pfeffer G, Ralson SH, Roy B, Seeley WW, Swenson A, **Mozaffar T**, Wehl C, Kimonis V, on behalf of the VCP Standards of Care Working Group. Development of a standard of care for patients with valosin-containing protein associated multisystem proteinopathy. *Orphanet J Rare Dis* 2022;17:23. PMID: 35093159
175. Gidaro T, Gasnier E, Annoussamy M, Vissing J, Attarian S, **Mozaffar T**, Iyadurai S, Wagner K, Vissier D, Walker G, Shukla S, Servais L. Home-based gait analysis as an exploratory endpoint during a multicenter phase 1 trial in limb girdle muscular dystrophy type R2 and facioscapulohumeral muscular dystrophy. *Muscle Nerve* 2022;65:237-242. PMID: 34687225
176. Goyal NA, Coulis G, Duarte J, Farahat PK, Mannaa AH, Cauchi J, Irani T, Araujo N, Wang L, Wencil M, Li V, Zhang L, Greenberg SA, **Mozaffar T\***, Villalta SA (co-senior authors)\*.

- Immunophenotyping of Inclusion Body Myositis Blood T and NK Cells. *Neurology* 2022;7:1212. PMID: 35131904
177. Khachatryan T, **Mozaffar T**, Mnatsakanyan L. Utility of video-fundoscopy and prospects of portable stereo-photography of the ocular fundus in neurological patients. *BMC Neurol* 2022;22:61. PMID: 35183131
178. Johnson MA, Klickstein JA, Khanna R, Gou Y, **Cure VCP Disease Research Consortium**, Raman M. The Cure VCP Scientific Conference 2021: Molecular and clinical insights into neurodegeneration and myopathy linked to multisystem proteinopathy-1 (MSP-1). *Neurobiol Dis* 2022;69:105722. doi.org/10.1016/j.nbd.2022.105722. PMID: 35405261
179. Goyal NA, Greenberg SA, Cauchi J, Araujo N, Li V, Wencel M, Irani T, Wang LH, Palma A, Villalta SA, **Mozaffar T**. Correlations of Disease Severity Outcome Measures in Inclusion Body Myositis. *Neuromuscul Disord* 2022;32:800-805. PMID: 36050251
180. Bruss DM, Venkataraman P, **Mozaffar T**. Facial Onset Sensory Motor Neuronopathy-Like Syndrome: A Case Report. *J Clin Neuromuscul Dis*. 2022;24:55-58. doi: 10.1097/CND.0000000000000402. PMID: 36005474
181. Bril V, Szczudlik A, Vaitkus A, Rozsa C, Kostera-Pruszczyk A, Hon P, Bednarik J, Tyblova M, Köhler W, Toomsoo T, Nowak RJ, **Mozaffar T**, Freimer ML, Nicolle MW, Magnus T, Pulley MT, Rivner M, Dimachkie MM, Distad BJ, Pascuzzi RM, Babiar D, Lin J, Coll MQ, Griffin R, Mondu E. A Randomized, Double-Blind, Placebo-Controlled Trial of the Corticosteroid-sparing Effects of Immunoglobulin in Myasthenia Gravis. *Neurology* 2022 (in press)

#### **Book Chapters**

1. Yamada K, **Mozaffar T**, Awadalla S. *Neurologic emergencies*. In: Carey CF, Lee HH, Woeltje KF, eds. *The Washington Manual of Medical Therapeutics* (29<sup>th</sup> edition). Philadelphia: Lippincott - Raven 1998: 475-493.
2. **Mozaffar T**, Pestronk A. Cancer-related muscle diseases. In: Karpati G: *Structural and Molecular Basis of Skeletal Muscle Diseases*. ISN Neuropath Press, Basel 2002, pp 266-269.
3. Solbrig MV, **Mozaffar T**, Kim RC. Pediatric Leprosy. In: Jones HR, Darras BT, De Vivo DC (eds.). *Neuromuscular disease of infancy, childhood and adolescence: A clinician's approach*. Butterworth-Heinemann, Boston 2003, pp 505-518.
4. **Mozaffar T**. Diseases of Muscle. In: Shuaib A, Shafiqat S (Eds.). *Neurology: A Concise Text for Medical Students and House Officers*. Higher Education Commission of Pakistan, Islamabad, 2006 (in press).
5. Gupta R, **Mozaffar T**. Peripheral Nerve Physiology, Anatomy, and Pathology. In: Buckwalter JA, Einhorn TA, O'Keefe RJ (eds). *Orthopedic Basic Science: Biology and Biomechanics of the Musculoskeletal System*. 3<sup>rd</sup> Ed (chapter 23), pp 427-443. American Academy of Orthopedic Surgeons, Rosemont, Illinois, 2007.
6. Gupta R, **Mozaffar T**. Form and Function of the Spinal Cord and Peripheral Nerves. In: Buckwalter JA, Einhorn TA, O'Keefe RJ (eds). *Orthopedic Basic Science: Biology and Biomechanics of the Musculoskeletal System*. 3<sup>rd</sup> Ed (Chapter 13), pp 245-258. American Academy of Orthopedic Surgeons, Rosemont, Illinois, 2007.
7. Chui LA, **Mozaffar T**. Oculopharyngeal muscular dystrophy. In: Lisak RP, Truong DD, Carroll W, Bhidayasiri R (eds). *International Neurology: a clinical approach*. Wiley-Blackwell Publishing, Oxford, United Kingdom, 2009;231-232.
8. Karayan R and **Mozaffar T**. Emery-Dreifuss muscular dystrophy. In: Lisak RP, Truong DD, Carroll W, Bhidayasiri R (eds). *International Neurology: a clinical approach*. Wiley-Blackwell Publishing, Oxford, United Kingdom, 2009;233-234.
9. **Mozaffar T** and Gupta R. Neurological Disorders. In Fischgrund, **J (ed)**. *Orthopaedic Knowledge Update 10*. American Academy of Orthopaedic Surgeons, Rosemont, Illinois, 2011;225-238.
10. **Mozaffar T**. Endocrine and Toxic Myopathies (on line update). In: Karpati G, Hilton-Jones D, Bushby K and Griggs RC (eds). *Disorders of Voluntary Muscle*, 8<sup>th</sup> edition. Cambridge University Press, 2010 [Weblink](#)

11. Chui LA, **Mozaffar T**, Goyal NA. Oculopharyngeal muscular dystrophy. In: Lisak RP, Truong DD, Carroll WM, Bhidayasiri R (eds). *International Neurology: a clinical approach*. Wiley-Blackwell Publishing, Oxford, United Kingdom, 2016;476-478.

#### **Invited Reviews**

1. **Mozaffar T**, Haque-Mozaffar, F. Critical Care Myopathy: An Emerging Medical Catastrophe. *JPMA (Journal of the Pakistan Medical Association)* 2003;53:608-611. [PubMed](#)
2. Strandberg EJ, **Mozaffar T**, Gupta R. The role of neurodiagnostic studies in nerve injuries and other orthopedic disorders. *J Hand Surg [Am]*. 2007;32:1280-90. [PubMed](#)
3. Tipadia M, **Mozaffar T**, Gupta R. Compression Neuropathies of Upper Extremity: Update on Pathophysiology, Classification and Electrodiagnostic Findings. *Journal of Hand Surgery (American)*, 2010;35:668-677. [PubMed](#)
4. Chang E, Ghosh N, Yanni D, Lee S, Alexandru D, **Mozaffar T**. A review of spasticity treatments: Pharmacologic and interventional approaches. *Crit Rev Phys Rehabil Med*. 2013;25:11-22. PMID: 25750484.
5. Goyal NA, **Mozaffar T**. Respiratory and nutritional support in amyotrophic lateral sclerosis. *Curr Treat Options Neurol*. 2014;16:210. PMID: 24390801
6. Goyal NA, **Mozaffar T**. Experimental Trials in Amyotrophic Lateral Sclerosis: A Review of Recently Completed, Ongoing and Planned Trials Using Existing and Novel Drugs. *Expert Opin Investig Drugs* 2014;26:1-11. PMID: 24965719
7. Findlay AR, Goyal NA, **Mozaffar T**. An Overview of Polymyositis and Dermatomyositis. *Muscle Nerve* 2015;51:638-656. PMID: 25641317
8. Goyal NA, **Mozaffar T**. Novel Therapeutic Options in Treatment of Idiopathic Inflammatory Myopathies. *Curr Treat Options Neurol* 2018;20:37. PMID: 30033499
9. Habib AA, Jazi GA, **Mozaffar T**. Update on immune-mediated therapies for myasthenia gravis. *Muscle Nerve* 2020;62:579-592. PMID: 32462710
10. Korb MK, Kimonis VE, **Mozaffar T**. Multisystem proteinopathy: where myopathy and motor neuron disease converge. *Muscle Nerve* 2021;63:442-454. PMID: 33145792
11. Goyal NA, **Mozaffar T**. Dysphagia in Inclusion Body Myositis, A Disease of the Elderly. *OBM Geriatrics* 2021;5(1):13; doi:10.21926/obm.geriatr.2101154.
12. Alfano LN, **Mozaffar T**. Random forest: random results or meaningful insights for patients with FSH muscular dystrophy? *Brain* 2021;144:3288-3290 (invited scientific commentary). PMID:34636841
13. Wolfe GI, Ward ES, de Haard H, Ulrichs P, **Mozaffar T**, Pasnoor M, Vidarsson G. IgG regulation through FcRn blocking: A novel mechanism for the treatment of myasthenia gravis. *J Neurol Sci* 2021;430:118074. PMID:34563918
14. Stevens D, Milani-Nejad S, **Mozaffar T**. Pompe Disease: A clinical, diagnostic, and therapeutic overview. *Curr Treat Options Neurol* 2022;24, 573–588 DOI 10.1007/s11940-022-00736-1
15. Perez-Rosendahl M, **Mozaffar T**. Inclusion Body Myositis: Evolving Concepts. *Curr Opin Neurol* 2022; 35:604-610 DOI:10.1097/WCO.0000000000001095
16. Mullen J, Alrasheed K, **Mozaffar T**. GNE Myopathy: History, Etiology, and Treatment Trials. *Front Neurol* 2022;13:1002310
17. Goyal NA, **Mozaffar T**, Dimachkie MM. Imaging Beyond Muscle MRI in Inclusion Body Myositis. *Clin Exp Rheumatol* 2022 (in press)

#### **Letters**

1. **Mozaffar T**. Critical illness myopathy. *Muscle Nerve* 2001;24:973. [PubMed](#)
2. **Mozaffar T**. Case 21-1997: Paraneoplastic cerebellar degeneration and Hodgkin's disease. *N Engl J Med* 1998; 338: 66. [PubMed](#)
3. Bedlack RS, Genge A, Amato AA, Shaibani A, Jackson CE, Kissel JT, Wall C, King WM, Cupler E, Lou JS, Ensrud E, Tan E, Goldstein JM, Katz J, Dimachkie MM, Barohn RJ, **Mozaffar T**. Correspondence regarding: TDP-43 Proteinopathy and Motor Neuron Disease in Chronic Traumatic Encephalopathy. *J Neuropath Exp Neurol* 2011;70:96-97. [PubMed](#)

4. Gupta R, **Mozaffar T**. Reply: About Chronic nerve compression alters Schwann cell myelin architecture in a murine model by Gupta et al, *Muscle Nerve*, 2012;45-2: 231-241.
5. Lai TT, **Mozaffar T**. Diagnostic Value of MRI in Inflammatory Myositis. *Neurol Neuroimmunol Neuroinflamm* 2015;2:e128. PMID: 26185775
6. Burns TM, Smith GA, Allen JA, Amato AA, Arnold WD, Barohn R, Benatar M, Bird SJ, Bromberg M, Chahin N, Ciafaloni E, Cohen JA, Corse A, Crum BA, David WS, Dimberg E, Sousa EA, Donofrio PD, Dyck PJ, Engel AG, Ensrud ER, Ferrante M, Freimer M, Gable KL, Gibson S, Gilchrist JM, Goldstein JM, Gooch CL, Goodman BP, Gorelov D, Gospe SM Jr, Goyal NA, Guidon AC, Guptill JT, Gutmann L, Gutmann L, Gwathmey K, Harati Y, Harper CM Jr, Hehir MK, Hobson-Webb LD, Howard JF Jr, Jackson CE, Johnson N, Jones SM, Juel VC, Kaminski HJ, Karam C, Kennelly KD, Khella S, Khoury J, Kincaid JC, Kissel JT, Kolb N, Lacomis D, Ladha S, Larriviere D, Lewis RA, Li Y, Litchy WJ, Logigian E, Lou JS, MacGowen DJ, Maselli R, Massey JM, Mauermann ML, Mathews KD, Meriggioli MN, Miller RG, Moon JS, **Mozaffar T**, Nations SP, Nowak RJ, Ostrow LW, Pascuzzi RM, Peltier A, Ruzhansky K, Richman DP, Ross MA, Rubin DI, Russell JA, Sachs GM, Salajegheh MK, Saperstein DS, Scelsa S, Selcen D, Shaibani A, Shieh PB, Silvestri NJ, Singleton JR, Smith BE, So YT, Solorzano G, Sorenson EJ, Srinivasen J, Tavee J, Tawil R, Thaisetthawatkul P, Thornton C, Trivedi J, Vernino S, Wang AK, Webb TA, Weiss MD, Windebank AJ, Wolfe GI. Editorial by concerned physicians: Unintended effect of the orphan drug act on the potential cost of 3,4-diaminopyridine. *Muscle Nerve* 2016;53:165-168. PMID: 26662952
7. Charles JA, Souayah N, Narayanaswami P, Jones L, Weiss M, **Mozaffar T**, Rutkove SB. Critically re-evaluating a common technique: Accuracy, reliability, and confirmation bias of EMG. *Neurology* 2016;87:645. PMID: 27502964
8. Robbins NM, **Mozaffar T**, Mammen AL, Liewluck T, Guidon A, Lawson VH. Pearls & Oysters: Pembrolizumab-induced myasthenia gravis. *Neurology* 2019;93:183-184. PMID: 31332091
9. Mathew V, Wencel M, Habib AA, Goyal NA, Needham M, **Mozaffar T**. Attitudes Towards Non-Interventional Observational Studies in US and Australian Patients with Sporadic Inclusion Body Myositis. *J Clin Neuromuscul Dis* 2020;21:246-247. PMID: 32453104

### **Syllabi**

1. Lai T, Goyal NA, Mozaffar T. Acquired Myotonia with Atypical Features. In: Unusual Diagnostic and Management Problems in Neuromuscular Disorders (Connolly AM, Dyck PJ, Al-Lozi MT – course directors), American Academy of Neurology, Annual Meeting, Boston, MA, April 2017.
2. Lavian M, Goyal NA, **Mozaffar T**. Hereditary Myopathy with Early Respiratory Failure in a young Afghan woman. In: Unusual Diagnostic and Management Problems in Neuromuscular Disorders (Connolly AM, Dyck PJ, Al-Lozi MT – course directors), American Academy of Neurology, Annual Meeting, Boston, MA, April 2017.
3. Peyronnard, Goyal NA, **Mozaffar T**. Late onset ocular and proximal myopathy associated with myosin heavy chain 2 gene mutations. In: Unusual Diagnostic and Management Problems in Neuromuscular Disorders (Connolly AM, Dyck PJ, Al-Lozi MT – course directors), American Academy of Neurology, Annual Meeting, Vancouver, BC (Canada), April 2016.
4. Nayyar S, **Mozaffar T**, Goyal NA. Hemibody weakness and hemibody atrophy in late onset myosin heavy chain 7 gene mutations. In: Unusual Diagnostic and Management Problems in Neuromuscular Disorders (Connolly AM, Dyck PJ, Al-Lozi MT – course directors), American Academy of Neurology, Annual Meeting, Vancouver, BC (Canada), April 2016.
5. Doan V, Goyal NA, **Mozaffar T**. Adult onset LGMD with mutation in GMPBB gene. In: Unusual Diagnostic and Management Problems in Neuromuscular Disorders (Connolly AM, Dyck PJ, Amato AA – course directors), American Academy of Neurology, Annual Meeting, Washington DC, April 2015.
6. Roy G, Goyal NA, **Mozaffar T**. Allgrove Syndrome. In: Unusual Diagnostic and Management Problems in Neuromuscular Disorders (Connolly AM, Dyck PJ, Amato AA –

- course directors), American Academy of Neurology, Annual Meeting, Washington DC, April 2015.
7. Roy G, Goyal NA, **Mozaffar T**. Mitochondrial Depletion Syndrome. In: Unusual Diagnostic and Management Problems in Neuromuscular Disorders (Connolly AM, Dyck PJ, Amato AA – course directors), American Academy of Neurology, Annual Meeting, Philadelphia, PA, May 2014.
  8. Cash TM, Goyal NA, **Mozaffar T**. Myofibrillar Myopathy in a 5-year-old boy. In: Unusual Diagnostic and Management Problems in Neuromuscular Disorders (Connolly AM, Dyck PJ, Amato AA – course directors), American Academy of Neurology, Annual Meeting, Philadelphia, PA, May 2014.
  9. Santhappa S, **Mozaffar T**. Neurolymphomatosis. In: Unusual Diagnostic and Management Problems in Neuromuscular Disorders (Meriggioli M, Dyck PJ, Amato AA – course directors), American Academy of Neurology, Annual Meeting, New Orleans, April 2012.
  10. **Mozaffar T**, Wang AK. HIBM-2/Nonaka Myopathy. In: Unusual Diagnostic and Management Problems in Neuromuscular Disorders (Meriggioli M, Dyck PJ, Amato AA – course directors), American Academy of Neurology, Annual Meeting, Honolulu, April 2011.
  11. Adzotor K, **Mozaffar T**. X-linked myotubular myopathy in manifesting carriers. In: Unusual Diagnostic and Management Problems in Neuromuscular Disorders (Kissel JT, Jackson CE, Harati Y – course directors), American Academy of Neurology, Annual Meeting, Seattle, April 2009.
  12. Lueck KL, **Mozaffar T**. Cervical Radiculopathy in Multiple Sclerosis. In: Unusual Diagnostic and Management Problems in Neuromuscular Disease (Kissel JT, Jackson CE, Rosenfeld J – course directors), Academy of Neurology, Annual Meeting, San Diego, April 2006.
  13. Lee KA, **Mozaffar T**. Adrenomyeloneuropathy. In: Unusual Diagnostic and Management Problems in Neuromuscular Disease (Kissel JT, Jackson CE, Rosenfeld J – course directors), Academy of Neurology, Annual Meeting, San Diego, CA, April 2006.
  14. **Mozaffar T**. Hereditary neuropathy with liability towards pressure palsies. In: Unusual Diagnostic and Management Problems in Neuromuscular Disease (Kissel JT, Jackson CE, Harati Y – course directors), Academy of Neurology, Annual Meeting, Miami Beach, FL, April 2005.
  15. **Mozaffar T**. Neuromuscular Complications of Malnutrition: Hansen’s Disease (Leprosy), Osteomalacic Myopathy and Lathyrism. In: Tropical Neurology (Joseph Zunt, MD, Director). American Academy of Neurology Annual Meeting, Honolulu, HI, March 31, 2003.

### ***Manuscripts Being Prepared for Submission***

1. Lueck KL, Gehret D, **Mozaffar T**. Cervical radiculopathy in multiple sclerosis.
2. Karayan R, Afghani E, Kawas CH, **Mozaffar T**. Economic burden from the use of complementary and alternative methods of treatment in amyotrophic lateral sclerosis.
3. **Mozaffar T**, Habib AA. The Norwegian Contributions to Leprous Neuropathy: The Works of Danielssen, Hansen and Monrad-Krohn. (Being submitted: *Neurology*)
4. **Mozaffar T**, Madden K. Anti-Ganglioside antibodies in ALS: An illustrative case report.
5. **Mozaffar T**, Ansari SA. Status of Lepers and Leprosy during the early Islamic Period (12<sup>th</sup> and 13<sup>th</sup> century AD). (Manuscript being submitted to the *Journal of History of Medicine and Allied Sciences*).
6. **Mozaffar T**, Lee K. Myasthenia gravis as a manifestation of the immune reconstitution inflammatory syndrome.

### ***Abstracts***

1. Wolfe G., Kaminski H., Aban I., Cutter G., **MGTX Study Group**. Results from the MGTX Extension Study of thymectomy in myasthenia gravis. *Muscle Nerve* 2018; 58:S105.
2. Wencel M, Goyal N, Shaibani A, Dimachkie M, Johnson N, Trivedi J, Gutmann L, Wicklund M, Bandyopadhyay S, Genge A, Freimer M, Pestronk A, Florence J, Karam C, Ralph J,

- Mozaffar, T.** Results of an Investigator-Initiated Multi-Site Late Onset Pompe Disease Screening Study. *Ann Neurol* 2018;84:S116-116.
3. Wencel M, Araujo N, Medina E, Zhang LS, Nguyen D, **Mozaffar T**, Goyal N. Feasibility and validation of modified Oculobulbar facial respiratory score (mOBFRS) in sporadic inclusion body myositis. *Ann Neurol* 2018;84:S217-218.
  4. Wencel M, Araujo N, Medina E, Zhang LS, Nguyen D, **Mozaffar T**, Goyal N. Feasibility and validation of modified Oculobulbar facial respiratory score (mOBFRS) in amyotrophic lateral sclerosis. *Ann Neurol* 2018;84:S220-220.
  5. Mathew V, Wencel M, Goyal N, Habib AA, Needham M, **Mozaffar T**. Willingness to participate in natural history studies amongst patients with sporadic inclusion body myositis (sIBM): A comparison between the United States and Australia. *Muscle Nerve* 2018;58:S19-20.
  6. **Mozaffar T**, Bratkovic D, Byrne BJ, Clemens P, Geberhiwot T, Goker-Alpan O, Kishnani P, Ming X, Roberts M, Schwenkreis P, Sivakumar K, van der Ploeg AT, Wright J, Johnson FK, Sitaraman S, Barth JA, Sathe S, Schoser B. First in-human study of AT-GAA (ATB200/AT2221) in patients with Pompe Disease: Preliminary results from the ATB200-02 trial. *Muscle Nerve* 2018;58:S1-1
  7. Wencel M, Goyal N, Shaibani A, Dimachkie M, Johnson N, Trivedi J, Gutmann L, Wicklund M, Bandyopadhyay S, Genge A, Freimer M, Pestronk A, Florence J, Karam C, Ralph J, **Mozaffar, T.** Results of an Investigator-Initiated Multi-Site Late Onset Pompe Disease Screening Study. *Muscle Nerve* 2018;58:S20-20.
  8. **Mozaffar T**, Wencel M, Goyal NA, Phillips CW, Olsen C. Dalazatide, an Inhibitor of the Kv1.3 Channel on Chronically Activated Effector Memory T Cells, Has Immunotherapy Potential Against Sporadic Inclusion Body Myositis. *Ann Neurol* 2017;82:S23.
  9. Behin A, **Mozaffar T**, Tarnopolsky M, et al. GNE-myopathy (HIBM): Upper and lower extremity muscle strength declines over time in a prospective. *Neuromuscul Disord* 2017;27:S149-S50.
  10. Gidaro T, Moraux A, Grelet M, et al. ActiMyo home monitoring in adult patients with limb girdle muscular dystrophy type 2B and facioscapulohumeral muscular dystrophy in study ATYR 1940-C-004. *Neuromuscul Disord* 2017;27:S226-S.
  11. Lochmuller H, Behin A, Caraco Y, et al. A phase 3 randomized, double blind, placebo-controlled study to evaluate the efficacy and safety of sialic acid extended-release tablets in patients with GNE myopathy (GNEM). *Neuromuscul Disord* 2017;27:S150-S.
  12. **Mozaffar T**, Wencel M, Goyal N, Philips C, Olsen C. Kv1.3 expression on effector memory T cells in sporadic inclusion body myositis: potential for targeted immunotherapy with dalazatide. *Neuromuscul Disord* 2017;27:S158-S.
  13. Palmio J, Leonard S, Sacconi S, et al. Expanding importance of HMERF titinopathy: new mutations and clinical aspects. *Neuromuscul Disord* 2017;27:S237-S.
  14. Vissing J, Attarian S, Gidaro T, et al. Results of a Phase 1b/2 Study of ATYR1940 in Adult Patients with Limb Girdle Muscular Dystrophy Type 2B (LGMD2B) and Facioscapulohumeral Muscular Dystrophy (FSHD) (ATYR1940-C-004). *Neurology* 2017;89:E101-E.
  15. Wencel M, Araujo N, **Mozaffar T**, Goyal N. Feasibility and validation of modified oculobulbar facial respiratory score (mOBFRS) in amyotrophic lateral sclerosis (ALS) and sporadic inclusion body myositis (sIBM). *Neuromuscul Disord* 2017;27:S225-S.
  16. Wencel M, Araujo N, **Mozaffar T**, Goyal N. FEASIBILITY AND VALIDATION OF MODIFIED OCULOBULBAR FACIAL RESPIRATORY SCORE (mOBFRS) IN AMYOTROPHIC LATERAL SCLEROSIS (ALS) AND SPORADIC INCLUSION BODY MYOSITIS (sIBM). *Muscle Nerve* 2017;56:S6-S.
  17. Wencel M, Goyal N, **Mozaffar T**. Interim analysis of an investigator-initiated multi-site late-onset Pompe disease screening study. *Neuromuscul Disord* 2017;27:S160-S.
  18. Wencel M, Goyal N, Shaibani A, et al. CHALLENGES AND FEASIBILITY OF AN INVESTIGATOR-INITIATED MULTI-SITE POMPE DISEASE SCREENING STUDY. *Muscle Nerve* 2017;56:S16-S.
  19. Goyal N, Nayyar S, **Mozaffar T**. Distal myopathy with associated hemiatrophy. *Neuromuscul Disord* 2016;26:S173-S.

20. Levine T, Katz J, Barohn R, **et al.** Response to IVIG in Patients with CIDP: The INSIGHTS Quality Improvement Project. *Ann Neurol* 2016;80:S163-S.
21. Levine T, Katz J, Barohn R, **et al.** RESPONSE TO INTRAVENOUS IMMUNOGLOBULIN IN PATIENTS WITH CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY: THE INSIGHTS QUALITY IMPROVEMENT PROJECT. *Muscle Nerve* 2016;54:526-.
22. Levine T, Saperstein D, Vaughan L, **et al.** INSIGHTS: ANALYSIS OF IVIG RESPONSIVENESS IN PATIENTS WITH MYASTHENIA GRAVIS. *Muscle Nerve* 2016;54:646-.
23. Levine T, Vaughan L, Badger G, **et al.** INSIGHTS: Analysis of IVIG Responsiveness in Patients with Myasthenia Gravis. *Ann Neurol* 2016;80:S190-S1.
24. Levine T, Vaughan L, Badger G, **et al.** INSIGHTS: ANALYSIS OF INTRAVENOUS IMMUNOGLOBULIN RESPONSIVENESS IN PATIENTS WITH MYASTHENIA GRAVIS. *Muscle Nerve* 2016;54:621-.
25. Tarnopolsky M, **Mozaffar T**, Behin A, et al. Upper and lower extremity muscle strength decline over 1 year in a prospective, observational GNE-myopathy natural history study. *Neuromuscul Disord* 2016;26:S169-S70.
26. Wencil M, Farooque R, Rai SR, **et al.** Utility of routine respiratory function testing in a tertiary neuromuscular clinic: A 10-year experience. *Mol Genet Metabol* 2016;117:S120-S1.
27. Wencil MA, Shambaugh C, Goyal NA, Kimonis VE, **Mozaffar T**. Treatment Related Effects of Anti-GAA Antibodies in Late Onset Pompe Disease. *Ann Neurol* 2016;80:S232-S.
28. Roberts M, **Mozaffar T**, Young P, Johnson E, Quartel A, Berger K. Lung function tests (MIP, MEP, FVC, VC) predict ventilation and wheelchair use in late-onset Pompe disease. *Neuromuscul Disord* 2015;25:S191.
29. **Mozaffar T**, Lavian M, Goyal N. Sporadic inclusion body myositis misdiagnosed as granulomatous myositis. *Neuromuscul Disord* 2015;25:S239.
30. Mathews K, Jensen B, Saade D, Willer T, Cox M, **Mozaffar T**, Scavina M, Winder T, Campbell K, Moore S. Clinical summary of eight unrelated individuals with GMPPB mutations. *Neuromuscul Disord* 2015;25:S268-269.
31. **Mozaffar T**, Goyal N, Cash T, Rai S, Wang A, Chui L. Utility of respiratory database in a tertiary neuromuscular clinic: A 10 year experience. *Neuromuscul Disord* 2015;25:S270-271.
32. Goyal N, Waldrop M, **Mozaffar T**. Unique myopathy presenting in adulthood with proximal muscle weakness and respiratory insufficiency. *Neuromuscul Disord* 2015;25:S282.
33. Schoser B, Byrne B, Eyskens F, Hiwot T, Hughes D, Kissel J, Mengel E, **Mozaffar T**, Pestronk A, Roberts M, Sivakumar K, Statland J, Young P, Heusner C, Dummer W. An international, phase 3, switchover study of reveglucosidase alfa (BMN 701) in subjects with late-onset Pompe disease. *Neuromuscul Disord* 2015;25:S189.
34. Levine T, Katz J, Barohn R, et al. Clinical Response of Neuromuscular Patients to Ivig: An Interim Analysis of the Insights Registry. *Muscle Nerve* 2015;52:S1-S1.
35. **Mozaffar T**, Amato AA, Wyant N, Monaghan C, Hurtt M. Design of a Randomized, Double-Blind, Pla-Cebo-Controlled Phase 2 Clinical Trial of the Toll-Like Receptor Antagonist Imo-8400 in Patients with Dermatomyositis. *Muscle Nerve* 2015;52:S8-S9.
36. Ayer G, Christopher-Stine L, Ladha S, **Mozaffar T**, So YE, Silvestri N. Validation of Patient Reported Outcomes in Obtained in the Home Infusion Setting in the Management of Patients with Neuromuscular Disease. *Muscle Nerve* 2014;50:674-674.
37. Ayer G, Christopher-Stine L, Ladha S, **Mozaffar T**, So YT, Silvestri N. Validation of Patient Reported Outcomes Measures (Proms) in a Home Infusion Model. *Muscle Nerve* 2014;50:S5-S5.
38. Jensen B, Saade D, Willer T, et al. Dystroglycanopathy due to GMPPB mutations: case series and review of the literature. *Journal of Neuropathology and Experimental Neurology* 2015;74:617-617.
39. Kimonis V, Wencil M, Surampalli A, et al. Variable Clinical Features in 13 Patients with Pompe Disease. *Mol Genet Metabol* 2014;111:298-299.
40. Levine T, Katz J, Barohn R, et al. Ig Treatment Outcomes Assessment: Preliminary Findings from the INSIGHTS Database. *Ann Neurol* 2014;76:S64-S65.
41. Levine T, Katz J, Barohn R, et al. Immunoglobulin Treatment Outcomes Assessment and Clinical Guidelines Study (the "Insights Study"): Preliminary Findings on Scope of Practice from the Insights Database. *Muscle Nerve* 2014;50:666-666.

42. Levine T, Katz J, Barohn R, et al. Ig TREATMENT OUTCOMES ASSESSMENT AND CLINICAL GUIDELINES STUDY (THE "INSIGHTS STUDY"): PRELIMINARY FINDINGS AND SCOPE OF PRACTICE FROM THE INSIGHTS DATABASE. *Muscle Nerve* 2014;50:S8-S8.
43. Thurberg BL, Carlier P, Kissel JT, et al. A phase 4 prospective study in patients with adult Pompe disease treated with alglucosidase alfa. *Mol Genet Metabol* 2015;114:S113-S114.
44. Thurberg BL, van der Ploeg A, Kissel JT, et al. Alglucosidase alfa reduces lysosomal glycogen in skeletal muscle biopsies of patients with late-onset Pompe disease (LOPD). *Neuromuscul Disord* 2014;24:871-872.
45. Goyal NA, **Mozaffar T**. Tongue atrophy and fasciculations in Familial Amyloid Polyneuropathy (PS3-356#195). Presented at the 13<sup>th</sup> International Congress on Neuromuscular Diseases, Nice, France, July 9, 2014.
46. Goyal NA, Cash TC, Alam U, Enam S, Mozaffar FH, **Mozaffar T**. Clinical Patterns In NT5C1A Antibody Positive Sporadic Inclusion Body Myositis Patients Compared To Seronegative Patients (PS3-#194). Presented at the 13<sup>th</sup> International Congress on Neuromuscular Diseases, Nice, France, July 9, 2014.
47. **Mozaffar T**, Jung J, Frump D, Su J, Gupta R. Schwann Cell-Derived Desert Hedgehog provides a neuroprotective effect against the mechanical stimuli from compressive neuropathies. *Neurology* 2014;82:S6.007.
48. Goyal NA, Cash TC, Alam U, Enam S, Mozaffar FH, **Mozaffar T**. Clinical Patterns In NT5C1A Antibody Positive Sporadic Inclusion Body Myositis Patients Compared To Seronegative Patients (S26.007). *Neurology* 2014;82:S26.007.
49. Pasnoor M, Herbelin L, He J, Dimachkie M, Nations S, Bril V, Wang A, Kissel J, Burns T, Saperstein D, Rosenfeld J, Shaibani A, Jackson C, Swenson A, Howard J, Goyal N, Wicklund M, Miller J, Barohn R and **MSG Methotrexate Study MG Group**. Phase II trial of methotrexate in myasthenia gravis (S16.002). *Neurology* 2014;82:S16.002.
50. Levine T, Katz J, Barohn J, **Mozaffar T**, Wolfe G, Saperstein D, Katzin L, Dimachkie M, Ritt E, Vaughan L, Greer M. Ig treatment outcomes assessment and clinical guidelines study (the "INSIGHTS Study"): Preliminary findings on scope of practice from the INSIGHTS database (P7.099). *Neurology* 2014;82:P7.099.
51. Ayer G, Christopher-Stine L, Ladha S, **Mozaffar T**, So Y, Hehir M, Silvestri N. Validation of disease-specific patient reported outcomes in the home environment (P7.108). *Neurology* 2014;82:P7.108.
52. Jung J, Frump D, Waterman M, **Mozaffar T**, Gupta R. The role of the wnt/beta catenin signaling pathway at the motor endplate following traumatic nerve injury. Society for Neuroscience Annual Meeting, November 2013, San Diego, CA.
53. Jung J, Frump D, **Mozaffar T**, Gupta R. Desert Hedgehog has a neuroprotective effect against mechanical stimuli. Society for Neuroscience Annual Meeting, November 2013, San Diego, CA.
54. Xu, SQ, Vu, NHT, Chao, E, Simon, M, Zoleikhaecian, M, Kimonis, V, Huang, TS, Mozaffar T, Wallace DC. Summary of the Mitochondrial findings in a series of 300 cases. *Mitochondrion* 2013; 14:936-937.
55. Katz J, Levine T, Barohn R, **Mozaffar T**, Wolfe G, Saperstein D, Katzin L, Ritt E, Vaughan L, Greer M. Immunoglobulin treatment outcomes assessment and clinical guidelines study (The "INSIGHTS" Study). Preliminary findings on scope of practice from the Insights database. *Muscle Nerve* 2013;48:675.
56. Jung J, Frump D, Waterman M, Gupta R, **Mozaffar T**. The role of the wnt/beta catenin signaling pathway at the motor endplate following traumatic nerve injury. *Ann Neurol* 2013;74:S100.
57. Jung J, Frump D, Gupta R, **Mozaffar T**. Desert hedgehog deficiency accentuates peripheral nerve demyelination. *Ann Neurol* 2013;74:S96.
58. Katz J, Levine T, Barohn R, **Mozaffar T**, Wolfe G, Saperstein D, Katzin L, Ritt E, Vaughan L, Greer M. Ig treatment outcomes assessment and clinical guidelines study (The "INSIGHTS" Study). Preliminary findings from the Insights database. *Ann Neurol* 2013;74:S24.
59. Pedouim FP, Enam S, Goyal N, **Mozaffar T**. Seropositive inclusion body myositis: The clinical spectrum. *Ann Neurol* 2013;74:S104-S105
60. Lee, CJ, **Mozaffar T**. An Alternative Regimen of Intravenous Immunoglobulin Monotherapy in Patients with Chronic Inflammatory Demyelinating Polyneuropathy and Dermatomyositis. *Neurology* 2013;

61. Katz J, Levine T, Barohn R, **Mozaffar T**, Wolfe G, Saperstein D, Katzin L, Ritt E, Vaughan L, Greer M. Understanding IVIg Prescribing Habits through INSIGHTS (Immunological and Neurological Study of Immune Globulin Habits Treatments and Standards). *Neurology* 2013;
62. Naderi N, Abcede H, Al-Khoury L, **Mozaffar T**, Jain V. Predictive Risk Factors of In-Hospital Mortality Following Acute Stroke in the United States: Data from the Nationwide Inpatient Database, 2006-2010. *Neurology* 2013;
63. Kim S, **Mozaffar T**. Acute respiratory failure secondary to myofibrillar myopathy in a 6-years-old. *Neurology* 2013;
64. Kishnani P, Tarnopolsky M, Sivakumar K, Roberts M, Byrne B, Goker-Alpan O, Guter K, Pervaiz MA, Dasouki M, **Mozaffar T**, Finanger E, Johnson F, Boudes P. A phase 2a study to investigate drug-drug interactions between escalating doses of AT2220 (duvoglustat hydrochloride) and acid alfa-glucosidase in subjects with Pompe disease. *Mol Genet Metab* 2013;108: S54.
65. Lank K, Llewellyn K, Nalbandian A, Nguyen C, **Mozaffar T**, Kimonis V. Valosin Containing Protein Associated Disease Progression And Lethality Improves With An Increased-Fat Diet In A Mouse Model. *J Inv Med* 2013;61: 166.
66. Howard J, Barohn R, Freimer M, Juel V, **Mozaffar T**, Mellion M, Benatar M, Farrugia M, Kissel J. Randomized, Double-Blind, Placebo-Controlled, Crossover, Multicenter, Phase II Study of Eculizumab in Patients with Refractory Generalized Myasthenia Gravis (gMG). *Neurology* 2012;78: S35004.
67. Naderi N, Masoomi H, **Mozaffar T**, Malik S. Predictive Factors of In-Hospital Cerebrovascular Accident Following Acute Myocardial Infarction: Data from the Nationwide Inpatient Sample, 2006-2008. *Neurology* 2012;78: P06242.
68. Shefner J, Andrews J, Bedlack R, Berry J, Goslin K, Jackson C, Kissel J, Lange D, Licht J, **Mozaffar T**, Pestronk A, Rosenfeld J, Wolff A, Lee J, Masonek J, Jones D, Meng L, Cedarbaum J. A Study To Evaluate Safety and Tolerability of CK-2017357 (CK-357) in Patients with Amyotrophic Lateral Sclerosis Using a Twice-Daily, Dose-Titration Regimen. *Neurology* 2012;78:P04155.
69. Yin HZ, **Mozaffar T**, Kimonis VE, Weiss JH. ALS-like spinal cord pathology in transgenic mice with a mutation in the Valsolin-Containing Protein gene. *Ann Neurol* 2011;70:S36-S37.
70. Howard JF, Barohn R, Cutter G, Freimer M, Juel V, **Mozaffar T**, Mellion M, Benatar M, Farrugia M, Pulley M, Gorson K, Chaudry V, Pascuzzi R, Siddiqi Z, Kissell JT. Randomized, double-blind, placebo-controlled, crossover, multicenter, phase II study of eculizumab in patients with refractory generalized myasthenia gravis (gMG). *Muscle Nerve* 2011;44:689-690.
71. Vitali RS, Bowen A, Rafijah N, Dolores C, **Mozaffar T**, Rafijah GH, Gupta R. The use of fibrin glue with nerve repairs does not hinder recovery. *J Periph Nerv Syst* 2011;16:S145-S146.
72. Kang JR, Wang W, Nassiri N, **Mozaffar T**, Gupta R. Does neural wound healing help to explain the pathogenesis of compressive neuropathies? *J Periph Nerv Syst* 2011;16:S63-S63.
73. **Mozaffar T**, Chen H, Preston WG, Wang AK. Use of pulse intravenous cyclophosphamide in refractory chronic inflammatory demyelinating polyneuropathy (CIDP). *J Periph Nerv Syst* 2011;16:S91-91.
74. **Mozaffar T**, McKinnon JH, Pirsaheli R, Wang AK. Paraproteinemic neuropathies associated with antibodies to trisulfated heparin disaccharide (TS-HDS). *J Periph Nerv Syst* 2011;16:S91-91.
75. Wang A, Donkervoort S, Quan DN, **Mozaffar T**, Kimonis V. ALS in a patient with VCP associated Inclusion Body Myopathy. *Neurology* 2011;76:A516-A516.
76. Katz J, Saperstein D, **Mozaffar T**, Greer M. "Real World" Use of IVIG in CIDP: Assessment of Utilization Across the Spectrum of Practice. *Neurology* 2010;74:A527.
77. Miller R, Forshew D, Katz J, Moore D, Spitalny M, Valan M, Barohn R, Bromberg M, Goslin K, Graves M, McCluskey L, McVey A, **Mozaffar T**, Pestronk A, Ross M, Simpson E. Phase II Controlled Trial of Lithium Carbonate in Patients with Amyotrophic Lateral Sclerosis. *Neurology* 2010;74:A200-201.
78. Wang AK, Simon MT, Wallace D, **Mozaffar T**. Maternally Inherited Limb-Girdle Myopathy with Neck Extensor and Cardiopulmonary Involvement Resulting from a Mitochondrial tRNA Leu<sup>3302</sup> Point Mutation. *Neurology* 2010;74:A181-182.
79. Muzyka IM, Dimachkie MM, Barohn RJ, Katz JS, Jackson CE, Wang Y, McVey A, Pasnoor M, **Mozaffar T**, Dick A, Rosenfeld J. Lower Extremity Amyotrophic Diplegia (LAD): Prevalence and Pattern of Weakness. *Neurology* 2010;74:A467.

80. Saremi K, Wang A, **Mozaffar T**. Calf hypertrophy in Spinal Muscular Atrophy: A case report. *J Clin Neuromusc Dis* 2010;11:S7.
81. Wang AK, **Mozaffar T**. Inherited myopathy masked by toxic myopathy. *J Clin Neuromusc Dis* 2010;11:S8.
82. Muzyka IM, Dimachkie MM, Barohn RJ, Katz JS, Jackson C, Wang Y, McVey A, Dick A, Pasnoor M, **Mozaffar T**, Rosenfeld J. Lower extremity amyotrophic diplegia (LAD): Prevalence and pattern of weakness. *J Clin Neuromusc Dis* 2010;11:S14.
83. **Mozaffar T**, Hazel A, Bathen ME, Gupta R. Understanding the etiology of acquired compression neuropathy. *Ann Neurol* 2009;66:S25.
84. Hazel A, Bathen ME, Palispis W, Rummler LS, Strandberg E, **Mozaffar T**, Gupta R. A novel murine model of primary demyelinating neuropathy. *J Invest Med* 2009;51:220-220.
85. **Mozaffar T**, Strandberg EJ, Abe K, Cahill K, Hilgenberg LG, Smith MA, Gupta R. Atrogin-1 levels and axonal integrity and maintained after chronic nerve compression-induced sprouting. *Ann Neurol* 2007;62:S8.
86. **Mozaffar T**, Strandberg EJ, Abe K, Cahill K, Hilgenberg LG, Smith MA, Gupta R. Atrogin-1 levels and axonal integrity and maintained after chronic nerve compression-induced sprouting. *J Periph Nerv Syst* 12: 60-60 Suppl. 1 JUL 2007
87. Pasnoor M, Wolfe G, Nations S, Trivedi J, Barohn R, Herbelin L, McVey A, Kissel J, Walsh R, Amato A, **Mozaffar T**, Hungs M, Chui L, Goldstein J, Novella S, Burns T, Phillips L, Claussen G, Oh S. Clinical findings in MuSK-antibody positive myasthenia gravis. Presented at the 17<sup>th</sup> International Meeting of the Myasthenia Gravis Foundation of America, May 2007, Chicago, IL.
88. **Mozaffar T**, Strandberg EJ, Abe K, Cahill K, Hilgenberg LG, Smith MA, Gupta R. Atrogin-1 levels and axonal integrity and maintained after chronic nerve compression-induced sprouting. *NEUROLOGY* 2007 68:A251.
89. **Mozaffar T**, Andrews BS. Rituximab reduces anti-Jo1-antibody titers and improves clinical symptoms in anti-Jo1-antibody associated myositis. *NEUROLOGY* 2007;68:A243.
90. Pasnoor M, Wolfe G, Nations S, Trivedi J, Barohn R, Herbelin L, McVey A, Kissel J, Walsh R, Amato A, **Mozaffar T**, Hungs M, Chui L, Goldstein J, Novella S, Burns T, Phillips L, Claussen G, Oh S. Clinical findings in MuSK-antibody positive myasthenia gravis. *NEUROLOGY* 2007; 68:A299.
91. Florence JM, Moore D, Spitalny GM, Miller RG, Gordon PH and **the Minocycline Trial Investigators**. Performance of in-person vs. phone ALSFRS-R in a randomized controlled phase III clinical trial of minocycline in ALS. 17<sup>th</sup> International Symposium on ALS/MND 2006, Yokohama, Japan.
92. Cudkovicz ME, Shefner J, Brown R, Schoenfeld D, Zhang H, Simpson E, Grasso D, Weiland S, Barber J, and **the Northeast ALS Consortium**. A multicenter, dose-ranging safety and pharmacokinetics study of Arimoclomol in amyotrophic lateral sclerosis (ALS). 17<sup>th</sup> International Symposium on ALS/MND 2006, Yokohama, Japan.
93. Duncleley T, Craig DW, Huentelman MJ, Hesterlee SE, Pestronk A, Levine T, Bertorini T, Graves MC, **Mozaffar T**, Jackson CE, Bosch P, Barohn R, Lomen-Hoerth C, Mitsumoto H, Bowser R, Miller RG, Appel SH, Stephan DA. Whole-Genome association analysis of sporadic ALS: new insight into the pathogenesis of disease. 17<sup>th</sup> International Symposium on ALS/MND 2006, Yokohama, Japan.
94. Cudkovicz ME, Shefner J, Brown R, Schoenfeld D, Zhang H, Simpson E, Grasso D, Weiland S, Barber J, and **the Northeast ALS Consortium**. A multicenter, dose-ranging safety and pharmacokinetics study of Arimoclomol in amyotrophic lateral sclerosis (ALS). American Neurological Association Annual Meeting, October 8, 2006, Chicago, IL.
95. Bear D, Rummler LS, Chao T, **Mozaffar T**, Gupta R. Localized ion channel migration after neural injury induces pain. Transactions of the Orthopaedic Research Society 31. [http://www.ors.org/Documents/ORS\\_06\\_Program\\_Book.pdf](http://www.ors.org/Documents/ORS_06_Program_Book.pdf) (2006).
96. **Mozaffar T**, Lee K. Myasthenia gravis as a manifestation of the immune reconstitution inflammatory syndrome. Myasthenia Gravis Foundation of America Annual Meeting, September 24, 2005, San Diego, CA.
97. **Mozaffar T**, Haddad F, Zhang LY, Adams GR, Baldwin KM. Molecular Markers of Myogenesis are Upregulated in Acute Quadriplegic Myopathy (AQM). *NEUROLOGY* 64 (6): A339-A339 Suppl. 1 MAR 22 2005

98. Berger B L, **Mozaffar T**, Gupta R. Chronic nerve compression alters the occurrence of Schmidt-Lanterman incisures. Transactions of the Orthopedic Research Society 30, 2005.  
<http://www.ors.org/Transactions/51/0548.PDF>
99. Channal J C, **Mozaffar T**, Steward O, Gupta R. The temporal pattern of macrophage recruitment in a model for chronic nerve compression injury. Transactions of the Orthopedic Research Society 30, 2005. <http://www.ors.org/Transactions/51/0538.PDF>
100. Chao T, **Mozaffar T**, Steward O, Gupta R. Chronic nerve compression preferentially induces sprouting from smaller caliber axonal fibers. Transactions of the Orthopedic Research Society 30, 2005.  
<http://www.ors.org/Transactions/51/0536.PDF>
101. Pawling J, Gao G, **Mozaffar T**, Dennis J, Demetriou M. Negative regulation of spontaneous demyelinating disease by Mgat5 N-glycosylation. *J Neuroimmunol* 154 (1-2): 229-229 757 Sp. Iss. SI, SEP 2004
102. Gray M, Modafferi E, Chao T, Bear D, Rummmler LS, **Mozaffar T**, Steward O, Gupta R. Schwann Cell Production of Vascular Endothelial Growth Factor (VEGF) in a Model for Carpal Tunnel Syndrome. Transactions of the Orthopaedic Research Society 29:915, 2004  
<http://www.ors.org/Transactions/50/0915.PDF>.
103. Rowshan K, Chao T, Bui P, **Mozaffar T**, Steward O, Gupta R. Altered Schwann Cell Function with a Model for Carpal Tunnel Syndrome. Transactions of the International Symposium on Ligaments & Tendons 4:41, 2004.
104. Gray M, Modafferi E, Chao T, Jones NF, **Mozaffar T**, Steward O, Gupta R. Angiogenesis and Carpal Tunnel Syndrome. Transactions of the American Association for Hand Surgery 34:141, 2004.
105. Rowshan K, Chao T, **Mozaffar T**, Gupta R. Myelin Changes During Chronic Nerve Compression. Transactions of the American Society for Peripheral Nerve 14:57, 2004.
106. Rose-Gottron C, Nemet D, **Mozaffar T**, Caiozzo VJ, Cooper DM. Feasibility of Integrated Human Performance Testing in a Patient with Lambert-Eaton Myasthenia Gravis Syndrome (LEMS). *MEDICINE AND SCIENCE IN SPORTS AND EXERCISE* 36 (5): S306-S306 2099 Suppl. S, MAY 2004
107. **Mozaffar T**, Haddad F, Zhang LY, Baldwin GR. A Molecular Profile of Markers of Muscle Protein Degradation in Acute Quadriplegic Myopathy (AQM). Presented at the American Academy of Neurology 55<sup>th</sup> Annual Meeting, Honolulu, HI, April 2, 2003 (Presentation # P04.136).
108. **Mozaffar T**, Haddad F, Zhang LY, Adams GR, Baldwin KM. Molecular Markers of Myogenesis are Upregulated in Acute Quadriplegic Myopathy (AQM). *Exp Biol* (FASEB) 2003, San Diego, CA April 15-19, 2003.
109. Rowshan K, Chao T, **Mozaffar T**, Jones NF, Gupta R. The Lost Art of Nerve Teasing. Transaction of American Society for Surgery of the Hand Residents & Fellows Conference 21:21, 2003.
110. Chao T, Bui P, Gray M, Rummmler L, Jones NF, **Mozaffar T**, Gupta R. Chronic nerve compression induces aberrant axonal sprouting. Transactions of the Plastic Surgery Research Council 48: 194, April 2003.
111. Bui P, Chao T, Gray M, Jones NF, **Mozaffar T**, Gupta R. How are macrophages involved with carpal tunnel syndrome? Transactions of the Plastic Surgery Research Council 48: 201, April 2003.
112. Gray M, Modafferi E, Chao T, Rummmler L, Jones NF, **Mozaffar T**, Steward O, Gupta R. The role of vascular endothelial growth factor and its receptors in carpal tunnel syndrome. Transactions of the Plastic Surgery Research Council 48: 137, April 2003.
113. Bui P, Lin YM, **Mozaffar T**, Gupta R. Macrophage Recruitment Follows the Pattern of Inducible Nitric Oxide Synthetase Expression in a Model for Carpel Tunnel Syndrome. Transactions of the Orthopedic Research Society, New Orleans, LA February 2-5, 2003 (Poster # 1205)  
<http://www.ors.org/Transactions/49/1205.PDF>
114. Rowshan K, Chao T, Bui P, **Mozaffar T**, Gupta R. Aberrant Axonal Sprouting with the Absence of Wallerian Degeneration in a Model for Carpel Tunnel Syndrome. Transactions of the Orthopedic Research Society, New Orleans, LA, February 2-5, 2003 (Paper # 64)  
<http://www.ors.org/Transactions/49/0064.PDF>
115. Leung MK, Dyck PJB, **Mozaffar T**. Peripheral Nerve Pathology in Acquired Neuro-Myotonia (Isaac's syndrome). *Muscle Nerve* 2002; 26:582.
116. **Mozaffar T**, Haddad F, Qin L, Zeng M, Baldwin KM. Pre-Translational Events Involving the MyHC Genes may contribute to the selective Myosin depletion in Acute Quadriplegic Myopathy. Transaction of the American Neurological Association, New York, NY, October 2002 (Program # WIP 7).

117. Chen YW, Masny P, Flanigan K, Martin J, **Mozaffar T**, Qian H, Winokur S. Disease-specific changes in Facioscapulohumeral muscular dystrophy by expression profiling. Transactions of the American Society for Human Genetics, Baltimore, MD, October 2002 (Program # 2195).
118. Bui P, **Mozaffar T**, Steward O, Gupta R. Chronic nerve compression induces Schwann cell proliferation. American Society for Surgery of the Hand, Boston, MA (November 2001)
119. Rowshan K, Bear David, **Mozaffar T**, Steward O, Gupta R. Early preservation of axonal integrity with chronic nerve compression. American Society for Surgery of the Hand. Boston, MA (November 2001)
120. Qureshi HU, Habib AA, Siddiqui A, Sarwari AR, **Mozaffar T**. Predictors of Mortality in Brain Abscess. *Neurology* 1999; 52: A42
121. **Mozaffar T**, Levin MI, Al-Lozi MT, Pestronk A. Paraneoplastic Necrotizing Myopathy. *Muscle Nerve* 1998; 21 (supplement 7): S14
122. **Mozaffar T**, Lopate G, Pestronk A. Clinical Correlates of Granulomas in Muscle. *Neurology* 1997; 48: A321

## Invited Seminar and Professional Meeting Presentations

Neurology Grand Rounds The Ohio State University Wexner College of Medicine Columbus, OH	Inclusion Body Myositis: The Unmet Clinical and Research Needs	March 2022
Professor Muhammad Tariq Memorial Lecture 28 <sup>th</sup> Annual National Neurology Meeting of the Pakistan Neurological Society (PNS) Lahore, Pakistan (Virtual presentation)	Gene Therapy in Spinal Muscular Atrophy	March 2022
Annual Meeting of the Brazilian Academy of Neurology Virtual	Pompe Disease and Update on Potential Treatment Options	November 2021
Annual Meeting American Association of Electrodiagnostic and Neuromuscular Medicine (AANEM) Biomarkers in Muscle Course Aurora, CO	Primary Inflammatory Myopathies: Advances in Our Understanding of Diagnosis and Pathogenesis of Dermatomyositis and Anti- Synthetase Syndrome	September 2021
Annual Scientific Meeting The Myositis Association Virtual	INSPIRE-IBM, a multicenter, observational study in Inclusion Body Myositis	September 2021
Muscle Study Group (MSG) Annual Meeting Virtual	INSPIRE-IBM, a multicenter, observational study in Inclusion Body Myositis	October 2021
1 <sup>st</sup> Annual Neuromuscular Course National University of Singapore (Virtual)	Immune Myopathies with Perimysial Pathology	October 2021
Annual UCLA FSHD Conference UCLA Los Angeles, CA	Facioscapulohumeral Muscular Dystrophies (FSHD): Symptoms, Variability, and Genetics	September 2021
Saudi Arabian Neuromuscular and Electrodiagnostic Medicine Association Annual Virtual Meeting	Sporadic Inclusion Body Myositis: An Autoimmune vs. Myodegenerative Disease?	April 2021
Rheumatology Grand Rounds Division of Rheumatology Department of Medicine UC Irvine	Immune Myopathies and Clinical Trial Update	June 2020
Treat-NMD Master Class of Limb-Girdle Muscular Dystrophies (Virtual)	Frequency and Distribution of LGMDs across the World	June 2020
Jinnah Medical University Karachi, Pakistan Web-based Lecture Series	Myasthenia Gravis: Disease of the Neuromuscular Junction	Mar 2020

Muscle Study Group (MSG) Annual Meeting Virtual	“Influence of NT5c1A antibodies on disease progression, clinical phenotype and blood and muscle biomarkers in sporadic Inclusion Body Myositis - A prospective evaluation”	Sep 2020
Agrim Institute of Neurosciences, Gurgaon, India Virtual Seminar	Unicorns, Dragons, Polymyositis, and other Mythological Beasts: The truth about polymyositis	Sep 2020
Treat-NMD Master Class on Limb-Girdle Muscular Dystrophies Virtual Seminar Series	Frequency and Distribution of LGMDs across the World	Jun 2020
The Myositis Association Webinar Alexandria, VA	Telemedicine: Is it right for the Myositis Community	May 2020
The Muscular Dystrophy Association Chicago, IL	MDA Engage IBM Virtual Symposium Inclusion Body Myositis	April 2020
The Muscular Dystrophy Association Chicago, IL	Ask the Experts: Telemedicine Best Practices	April 2020
California Neurological Society Annual Meeting Pasadena, CA	#myositisantibodiesmatter The Evolving Classification of Idiopathic Inflammatory Myopathies	Mar 2020
Jinnah-Sindh Medical University Web-Based Lecture Series Karachi, Pakistan	Myasthenia Gravis: Disease of the Neuromuscular Junction	Mar 2020
UCI Neuroscience Symposium 2019 Costa Mesa, CA	Update on Therapeutics in Neuromuscular Disorders	September 2019
Muscle Study Group (MSG): Annual Meeting Snowbird, UT	“Influence of NT5c1A antibodies on disease progression, clinical phenotype and blood and muscle biomarkers in sporadic Inclusion Body Myositis - A prospective evaluation”	September 2019
Muscle Study Group (MSG): Annual Meeting Snowbird, UT	IPANEMA: Final Results from the 4 years long Study	September 2019
Invited Lecture National Center for Neurology and Psychiatry Tokyo, Japan	#myositisantibodiesmatter The Evolving Classification of Idiopathic Inflammatory Myopathies	August 2019
Invited Lecture, Patient Association for Distal Myopathies (PADM), Japan Annual Meeting, Tokyo, Japan	Updates on Muscular Dystrophies: GNE Myopathy, OPME, and Miyoshi Myopathy/LGMD2B	August 2019

Muscular Dystrophy Association Annual Scientific Conference Orlando, FL	Genetics for Healthcare Providers: Testing Options Available	April 2019
Muscular Dystrophy Association Annual Scientific Conference Orlando, FL	Changing Landscape in Pompe Disease: Update on Diagnostics and Emerging Therapies	April 2019
Keynote Speaker University of Toronto Neuromuscular Day Toronto, ON, Canada	#myositisantibodiesmatter The Evolving Classification of Idiopathic Inflammatory Myopathies	March 2019
Sue and Bill Gross Stem Cell Center Irvine, CA	ALS: Current Understanding of Biology and Treatment	February 2019
Neurosciences in the Clinic American Academy of Neurology Fall Meeting Las Vegas, NV	ALS: Current Understanding of Biology and Treatment	October 2018
2 <sup>nd</sup> Annual Eastern Canada Neuromuscular Review Course Montreal Neurological Institute Montreal, CA	Therapeutic Advances in Myasthenia Gravis	October 2018
Immunoglobulin Nursing Society (IgNS) Annual Meeting Dallas, TX	Update on Idiopathic Inflammatory Myopathies: Diagnosis and Treatment	October 2018
Teaching Course, International Congress of Neuromuscular Disorders (ICNMD), 2018 Vienna, Austria	Utility of Genetic Testing in Neuromuscular Disorders	July 2018
C89: Clinical Approaches to Muscle Disorder American Academy of Neurology Annual Meeting Los Angeles, CA	The Evolving Classification of Idiopathic Inflammatory Myopathies: Myopathologic and Serologic Advances	April 2018
Neurology Grand Rounds Kansas University School of Medicine Kansas City, KS	The Evolving Classification of Idiopathic Inflammatory Myopathies: Myopathologic and Serologic Advances	March 2018
Rheumatology Grand Rounds (The Myositis Association Professorship) Mount Sinai School of Medicine New York, NY	The Evolving Classification of Idiopathic Inflammatory Myopathies: Myopathologic and Serologic Advances	March 2018
Stem Cell Winter Seminar Series Sue and Bill Gross Stem Cell Center University of California, Irvine	Of Mice and Men: Lessons Learned from the Muscle Atrophy Inhibition Trials in Neurological Disorders	March 2018
2 <sup>st</sup> Annual Neuromuscular Colloquium Oregon Health Sciences University Portland, OR	Update on Myopathy Therapy	February 2018

Amicus Investigator Meeting STRIDE Trial (POM-003 Trial) New Orleans, LA	Respiratory Functions in Pompe Disease: Utility in Diagnosis and Monitoring of Treatment Response	January 2018
Neurology Grand Rounds University of Washington Seattle, WA	The Evolving Classification of Idiopathic Inflammatory Myopathies: Myopathologic and Serologic Advances	November 2017
Neurology Grand Rounds Seattle Science Foundation/Swedish Medical Center, Cherry Hill Campus Seattle, WA	The Evolving Classification of Idiopathic Inflammatory Myopathies: Myopathologic and Serologic Advances	November 2017
T. Evans Wyckoff Lecture Virginia Mason Medical Center Seattle, WA	Of Mice and Men: Lessons Learned from the Muscle Atrophy Inhibition Trials in Neurological Disorders	October 2017
Annual Meeting of the American Association of Neuromuscular and Electrodiagnostic Medicine Phoenix, AZ	Crossfire Session: Con: needle muscle biopsy is equally sufficient as open muscle biopsy	September 2017
Special Seminar Department of Pathology and Laboratory Medicine University of California, Irvine	The Evolving Classification of Idiopathic Inflammatory Myopathies: Myopathologic and Serologic Advances	August 2017
16 <sup>th</sup> Annual Meeting Asian and Oceanic Myology Center Singapore	VCP Associated Multisystem Proteinopathy	August 2017
16 <sup>th</sup> Annual Meeting Asian and Oceanic Myology Center Singapore	Antibody Testing in Inflammatory Myositides	August 2017
Neurology Grand Rounds Stony Brook University Stony Brook, NY	Polymyositis: Fact or Fiction	June 2017
Clinical Approaches to Muscle Disorder American Academy of Neurology Annual Meeting Boston, MA	Unicorns, Dragons, Polymyositis, and Other Mythical Beasts: The Truth About Polymyositis	April 2017
1 <sup>st</sup> Year Medical Student Lecture and Demonstration University of California, Riverside Riverside, CA	Introduction to Electrodiagnostic Studies	March 2017
2 <sup>nd</sup> Neuro-Rheumatology Symposium California Neurological Society Northridge, CA	Unicorns, Dragons, Polymyositis, and Other Mythical Beasts: The Truth About Polymyositis	March 2017
1 <sup>st</sup> Annual Neuromuscular Colloquium	Neuromuscular Research Update	March 2017

Oregon Health Sciences University  
Portland, OR

UC Irvine Myositis Patient Conference Orange, CA	Clinical Research Studies in Myositis at UC Irvine	February 2017
Rheumatology Grand Rounds Northwell University Great Neck, NY	Sporadic Inclusion Body Myositis: An Autoimmune vs. Myodegenerative Disease?	January 2017
National Health Symposium: Neurosciences The Aga Khan University Karachi, Pakistan	Update on Treatment of Common Hereditary Neuromuscular Disorders	November 2016
National Health Symposium: Neurosciences The Aga Khan University Karachi, Pakistan	Competency Based Neurology Residency Training: Opportunities and Way Forward	November 2016
7 <sup>th</sup> Annual Myasthenia Gravis Patient Education Conference Houston, TX	Myasthenia Gravis: What is New in Research and What is on the Horizon?	October 2016
Neurology Grand Rounds Methodist Neurological Institute Houston, TX	Unicorns, Dragons, Polymyositis, and Other Mythical Beasts: The Truth About Polymyositis	October 2016
224 <sup>th</sup> ENMC International Workshop on IBMPFD Zandvoort, Netherlands	Conventional Treatment of Immune Mediated Necrotizing Myopathies	October 2016
Muscular Dystrophy Association Annual Clinical Conference Arlington, VA	Pompe Disease: Day 0 through Day 30000	March 2016
Workshop titled “Newborn Screening for Neuromuscular Diseases: Improving Patient Outcomes and Evaluating Public Health” St. Louis, MO	Monitoring for Disease Manifestation in Late-Onset Pompe Disease: Challenges from the Newborn Screening Program	March 2016
Harbor-UCLA Medical Center Department of Neurology Grand Rounds Torrance, CA	Sporadic Inclusion Body Myositis: An Autoimmune vs. Myodegenerative Disease?	January 2016
215 <sup>th</sup> ENMC International Workshop on IBMPFD Heemskerk, Netherlands	Natural History and Management of VCP Disease	November 2015
University of Buffalo Neurology Grand Rounds Buffalo, NY	Peripheral Nerve Injuries: Current and Future Treatment Strategies	November 2015
Muscular Dystrophy Association Meeting Hershey, PA	Pompe Disease Update	August 2015
Special Seminar Hennepin County Medical Center	Pompe Disease: When Limb-Girdle Muscle	July 2015

Minneapolis, MN	Weakness Means Something Out of the Ordinary	
Desert Valley Medical Center Neurology Special Talk Neurology Residency Program Las Vegas, NV	Pompe Disease: When Limb-Girdle Muscle Weakness Means Something Out of the Ordinary	May 2015
California Neurological Society NeuroRheumatology Seminar Santa Barbara, CA	Unicorns, Dragons, Polymyositis, and Other Mythical Beasts: The Truth About Polymyositis	May 2015
CHI-Baylor-St. Luke's Medical Center Neuromuscular Disorders Seminar Houston, TX	Utility of Genetic Testing in Neuromuscular Disorders	April 2015
Cedar Sinai Medical Center Neurology Grand Rounds Los Angeles, CA	Peripheral Nerve Injuries: Current and Future Treatment Strategies	March 2015
University of Toledo Neurology Grand Rounds Toledo, OH	Peripheral Nerve Injuries: Current and Future Treatment Strategies	February 2015
San Diego Neurological Society Invited Lecture San Diego, CA	Chronic Inflammatory Demyelinating Polyradiculoneuropathy	May 2014
University of California, Irvine Department of Neurology Grand Rounds Orange, CA	Sporadic Inclusion Body Myositis: An Autoimmune vs. Myodegenerative Disease?	May 2014
University of California, San Diego Department of Neurology Grand Rounds La Jolla, CA	Peripheral Nerve Injuries: Current and Future Treatment Strategies	December 2013
The Mayo Clinic Department of Neurology Grand Rounds Rochester, MN	Peripheral Nerve Injuries: Current and Future Treatment Strategies	November 2013
Kansas University Department of Neurology Grand Rounds Kansas City, KS	Peripheral Nerve Injuries: Current and Future Treatment Strategies	August 2013
Invited Talk Canadian Neurological Societies Federation Annual Meeting Montreal, QC, Canada	Treatable Myopathies: State of the Art in Diagnosis and Management	June 2013
Harbor-UCLA Medical Center Department of Neurology Grand Rounds Torrance, CA	Peripheral Nerve Injuries: Current and Future Treatment Strategies	November 2012
Southern California Kaiser Permanente Neurology Conference, Costa Mesa, CA	A Tale of Five Demyelinating Neuropathies	November 2012

San Francisco Rheumatological Society Monthly Meeting San Francisco, CA	Unicorns, Dragons, Polymyositis, and Other Mythical Beasts: The Truth About Inflammatory Myopathies	October 2012
The Myositis Association Medical/Scientific Advisory Board Seminar Orlando, FL	Myositis Specific Autoantibodies: Should we be measuring titers?	October 2012
Inaugural Conference of the Immunoglobulin Nursing Society (IgNS) Orlando, FL	Unicorns, Dragons, Polymyositis, and Other Mythical Beasts: The Truth About Inflammatory Myopathies	August, 2012
Association of American Physicians of Indian Origin (AAPI) Annual CME conference Long Beach, CA	A Tale of Immune Neuropathies	July 2012
Oregon Health Sciences University Department of Neurology Grand Rounds Portland, OR	Peripheral Nerve Injuries: Current and Future Treatment Strategies	June 2012
Invited Lecture: HSS Neurological Directions 2012 Hospital for Special Surgery New York, NY	Peripheral Nerve Injuries: Current and Future Treatment Strategies	March 2012
Invited Lecture: HSS Neurological Directions 2012 Hospital for Special Surgery New York, NY	Neuraltus NP001 Trial in ALS	March 2012
Department of Neurology Research Social University of California, Irvine	Current Research in Amyotrophic Lateral Sclerosis (ALS)	February 2012
Special Seminar: Pompe Disease Children's Hospital of Orange County Orange, CA	Late Onset Pompe Disease: Clinical Management	February 2012
Invited Platform Talk International ALS MND Meeting Sydney, Australia	A late onset ALS-like disease in transgenic mice with a mutation in the valosin-containing protein (VCP) gene	December 2011
Invited Lecture ALS Seminar Muscular Dystrophy Association Phoenix, AZ	Stem Cell Treatments in ALS: Why is it taking so long?	May 2011
Rheumatology Grand Rounds Department of Medicine University of California, Irvine	Unicorns, Dragons, Polymyositis, and Other Mythical Beasts: The Truth About Inflammatory Myopathies	March 2011

Annual Meeting of the North East ALS Consortium Bethesda, MD	Motor Neuron Replacement Strategies in Human Motor Neuron Disorders: The UC Irvine Approach	October 2010
California ALS Research Summit San Francisco, CA	The Challenge of Diagnosis in Amyotrophic Lateral Sclerosis	July 2010
University of California, Irvine Department of Neurology Grand Rounds Orange, CA	Neuromuscular Disorders	July 2010
Invited Lecture ALS Seminar Muscular Dystrophy Association Salt Lake City, UT	ALS: Current Understanding of Biology and Treatment	May 2010
University of Arizona Neurology Grand Rounds Tucson, AZ	Unicorns, Dragons, Polymyositis, and Other Mythical Beasts: The Truth About Inflammatory Myopathies	March 2010
University of California, Irvine Department of Neurology Grand Rounds Orange, CA	ALS: Current Understanding of Biology and Treatment	January 2010
Invited Lecture Northern California ALS Conference Dublin, CA	Stem Cell Trials in ALS: Why is it taking so long?	November 2009
University of California, Irvine Department of Neurosurgery Grand Rounds Orange, CA	Neuromuscular Disorders	July 2009
Samueli Center for Complementary and Alternative Medicine Colloquium	Complementary and Alternative Methods of Treatments in Amyotrophic Lateral Sclerosis	June 2009
Southern California ALS Seminar	Clinical Trials in Southern California	May 2009
Seminar titled "Recent Advances in Treatment of Neuromuscular Disorders with Subcutaneous Administration of Immunoglobulins" Seattle, WA	Safety and Efficacy of Immunoglobulin Therapy in a Home-Based Setting	April 2009
Neurology Grand Rounds Harbor-UCLA Medical Center Torrance, CA	Neurologic Emergencies: Myasthenia Gravis	October 2008
Current Concepts in Biological Therapy in Immune-Mediated Diseases	Uses of IVIG in Neurological Diseases	September 2008
ALS Association (Orange County Chapter) ALS Conference 2007 Laguna Hills, CA	Clinical Research in ALS: A Status Report	September 2008

Invited Speaker Seminar titled: "Myasthenia Gravis and other autoimmune neuromuscular disorders" Dana Point, CA	Inflammatory Immune Myositides	February 2008
"The changing face of muscular dystrophies" Neurology Grand Rounds Harbor-UCLA Medical Center Torrance, CA	Two decades after dystrophin: An update on inherited muscular dystrophies	December 2007
"The changing face of muscular dystrophies" California State University, Northridge Genetic Counseling Program Northridge, CA	Two decades after dystrophin: An update on inherited muscular dystrophies	September 2007
"The changing face of muscular dystrophies" California State University, Northridge Genetic Counseling Program Northridge, CA	Inherited muscular dystrophies: Historical aspects	September 2007
The Myositis Association Annual Meeting 2007 Seattle, WA	Understanding IVIG, Autoimmunity and Myositis	September 2007
The Aga Khan University Department of Medicine, Grand Rounds Karachi, Pakistan	Charcot's ALS: A mighty beast still unleashed	August 2007
University of California, Irvine Department of Medicine Grand Rounds Orange, CA	Update on Inherited Muscular Dystrophies	June 2007
Muscular Dystrophy Association, Southern California Region ALS 2007	So What is New in ALS?	May 2007
Loma Linda University Dermatology-Rheumatology Grand Rounds Loma Linda, CA	"Unicorns, Dragons, Polymyositis, and Other Mythological Beasts": The truth about inflammatory myopathies	December 2006
Los Angeles Neurological Society Los Angeles, CA	So What is New in ALS?	November 2006
University of Arizona Neurology Grand Rounds Tucson, AZ	Schwann cell dysfunction in Compressive Neuropathies: Lessons from an animal model	October 2006
ALS Association (Orange County Chapter) ALS Conference 2007 Laguna Hills, CA	So What is New in ALS?	September 2006
University of California, Irvine Exercise Physiology Research Retreat and Conference Irvine, CA	So What's New in ALS	June 2006

Orthopaedics Research Seminar University of California, Irvine Orange, CA	Nerve Sprouting in CNC is not caused by axonal degeneration	June 2006
Clinical Neurosciences Update Department of Neurology University of California, Irvine Irvine, CA	Neuromuscular Update: So what's new in ALS	March 2006
Southern California Kaiser Permanente Neurology Conference, Anaheim, CA	Neuromuscular Update: So what's new in ALS	March 2006
Southern California Kaiser Permanente Neurology Conference, Anaheim, CA	Neuromuscular Update: Myasthenia Gravis	March 2006
Western ALS Consortium Annual Meeting Phoenix, AZ	A Randomized Phase II clinical trial of Alpha-Lipoic Acid in ALS	January 2006
University of California, Irvine Emergency Medicine Grand Rounds	Myasthenia Gravis and other Neuromuscular Emergencies	November 2005
Department of Medicine Grand Rounds Garden Grove Hospital Garden Grove, CA	Diabetic Neuropathies	September 2005
Department of Neurology Grand Rounds University of California, San Diego La Jolla, CA	Effects of Corticosteroids on Inactive Skeletal Muscles: Lessons from Critical Illness Myopathy	April 2005
Department of Neurology Grand Rounds University of North Carolina, Chapel Hill Chapel Hill, NC	Effects of Corticosteroids on Inactive Skeletal Muscles: Lessons from Critical Illness Myopathy	March 2005
Department of Neurology Special Conference University of California, Los Angeles Westwood, CA	Effects of Corticosteroids on Inactive Skeletal Muscles: Lessons from Critical Illness Myopathy	January 2005
Grand Rounds University of Tennessee Cancer Center Memphis, TN	Cancer related Neuropathies	November 2004
Kaiser Permanente-Muscular Dystrophy Association (LA) Conference on ALS, Woodland Hills, CA	So what's new in ALS	May 2004
Muscular Dystrophy Association Annual ALS Awareness Seminar Orange, CA	Recent Advances in ALS	May 2004
University of California, Irvine Emergency Medicine Grand Rounds	Muscle Disorders and Myasthenia Gravis	April 2004

Washington University in St. Louis Neuromuscular Division Journal Club St. Louis, MO	Effects of Corticosteroids on Inactive Skeletal Muscles: Lessons from Critical Illness Myopathy	March 2004
Children's Hospital of Orange County/Muscular Dystrophy Association Conference on Pediatric Neuromuscular Diseases Orange, CA	Advances in Muscular Dystrophies	November 2003
University of California, Irvine Neurology Grand Rounds	Effects of Corticosteroids on Inactive Skeletal Muscles: Lessons from Critical Illness Myopathy	October 2003
Loma Linda University Medical Center Neurology Department Grand Rounds Loma Linda, CA	A Tale of Two Diseases: Diabetic and Non-Diabetic Lumbosacral Plexopathies	September 2003
ALS Association (Orange County Chapter) ALS Conference 2003 Laguna Hills, CA	So What is New in ALS?	September 2003
Myasthenia Gravis Foundation of California Annual Summer Meeting Commerce, CA	Myasthenia Gravis: State of the Art	June 2003
University of California, Irvine Exercise Physiology Research Retreat and Conference Newport Beach, CA	Effects of Corticosteroids on Inactive Skeletal Muscles: Lessons from Critical Illness Myopathy	May 2003
Muscular Dystrophy Association Annual ALS Awareness Seminar Orange, CA	Recent Advances in ALS	May 2003
ALS Association/Kaiser Permanente San Diego Conference on ALS San Diego, CA	Pharmacologic Options in ALS	May 2003
American Academy of Neurology 55 <sup>th</sup> Annual Meeting Honolulu, HI	Neuromuscular Complications of Malnutrition: Hansen's disease, Osteomalacic myopathy and Neurolathyrism	March 2003
University of California, Irvine Transplant Conference	Neuromuscular Complications after Organ Transplantation	March 2003
The Aga Khan University Annual Course on Neurophysiology Karachi, Pakistan	Clinical Approach in Neurodiagnostic Studies	December 2002
The Aga Khan University Seminar on Advances in Neurology Karachi, Pakistan	Recent Advances in Muscular Dystrophies	December 2002

Loma Linda University Medical Center Neurology Department Grand Rounds Loma Linda, CA	Acute Quadriplegic Myopathies of the Intensive Care: An Emerging Catastrophe	October 2002
Long Beach VAMC Diagnostic and Molecular Medicine Service Grand Rounds Long Beach, CA	A Tale of Two Diseases: Diabetic Amyotrophy and Lumbosacral Plexopathies	October 2002
San Diego Neurological Society La Jolla, CA	A Tale of Two Diseases: Diabetic Amyotrophy and Lumbosacral Plexopathies	September 2002
Muscular Dystrophy Association Myotonic Dystrophy Horizon 2002 Conference Long Beach, CA	Myotonic Dystrophy: A Tale of Two Diseases	August 2002
American Association of Neuroscience Nurses (Orange County Chapter) Bi-Annual Meeting Irvine, CA	Update on Neuromuscular Disorders	May 2002
Muscular Dystrophy Association Annual ALS Seminar Orange, CA	Recent Scientific Advances in ALS	May 2002
University of California, Irvine Neurology Department 3rd Stanley van den Noort Symposium	Neuromuscular Update	March 2002
Orange County Neurological Society Santa Ana, CA	A Tale of Two Diseases: Diabetic Amyotrophy and Lumbosacral Plexopathies	February 2002
University of California, Irvine Emergency Medicine Grand Rounds	Neuromuscular Emergencies	December 2001
University of California, Irvine Neurology Department Grand Rounds	Diabetic Neuropathies	December 2001
Orange County Neurological Society Santa Ana, CA	ALS: State of the Art	August 2001
Muscular Dystrophy Association Myotonic Dystrophy Horizon 2001 Conference Long Beach, CA	Myotonic Dystrophy: Clinical Aspects	August 2001
University of California, Irvine Neurology Department Contemporary Neurology Series	Neuromuscular Emergencies	July 2001
Northridge Hospital Medical Center Noon conference	Recent Advances in ALS	June 2001

Northridge, CA

University of California, Irvine Otolaryngology Department Grand Rounds	Role of Electrodiagnostics in Disorders of the Facial and Cranial Nerves	June 2001
Huntington Beach Hospital Noon conference Huntington Beach, CA	Diabetic Neuropathies	June 2001
Muscular Dystrophy Association Annual ALS Seminar Orange, CA	Recent Scientific Advances in ALS	May 2001
University of California, Irvine Pathology Department Seminar	Pathogenetic Mechanisms in Immune-mediated and Toxic Myopathies	May 2001
University of California, Irvine Pediatrics Department (Chief Rounds)	Myasthenia Gravis	March 2001
University of California, Irvine Neurology Department 2 <sup>nd</sup> Stanley van den Noort Symposium	Neuromuscular Update	March 2001
University of California, Irvine GCRC Muscle Biology Research Conference	Myopathies with loss of Myosin- heavy filament	February 2001
University of California, Irvine Neurology Department Grand Rounds	Radiation-induced CNS Damage	February 2001
South Coast Medical Center Noon conference Laguna Beach, CA	Immune Demyelinating Polyneuropathy	February 2001
University of California, Irvine Center for Occupational and Environmental Medicine Grand Rounds Irvine, CA	Toxic Neuromuscular Disorders	November 2000
ALS Association Orange County Annual Scientific Session Irvine, CA	Scientific Update and the Current State of the Art in Management of Patients with ALS	November 2000
University of California, Irvine Neurology Department Contemporary Neurology Series	Current Concepts in Immune- Mediated Myopathies	October 2000
University of California, Irvine Neurology Department Contemporary Neurology Series	Neuromuscular Emergencies	July 2000
Medical University of South Carolina Neurology Department Grand Rounds Charleston, SC	Unusual (unconventional) Immune- Mediated Myopathies	June 2000
University of California, Irvine	Neuromuscular Update	April 2000

Neurology Department  
1<sup>st</sup> Stanley van den Noort Symposium

The Aga Khan University (Karachi, Pakistan) Medicine Department Grand Rounds	Current Concepts in Immune-Mediated Myopathies	February 2000
College of Physicians and Surgeons, (Karachi, Pakistan) 2 <sup>nd</sup> Annual Course on Orthopedic Surgery	Role of Electrodiagnostic Medicine in Orthopedics	August 1999
University of California, Irvine Neurology Department Grand Rounds	Unusual (unconventional) Immune Mediated Myopathies	April 1999
Pakistan Academy of Neurological Sciences (Peshawar, Pakistan)	Immune Mediated Neuropathies	March 1999
IXth International Congress on Neuromuscular Disease (Adelaide, Australia) Seminar on Paraneoplastic Disorders	Paraneoplastic Necrotizing Myopathies	August 1998
College of Physicians and Surgeons, (Karachi, Pakistan) 1 <sup>st</sup> Annual Course on Orthopedic Surgery	Role of Electrodiagnostic Medicine in Orthopedics	August 1998